



(11) **EP 1 054 064 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
22.11.2000 Bulletin 2000/47

(51) Int. Cl.⁷: **C12N 15/86**, C12N 15/34,
C12N 5/10, A61K 48/00

(21) Application number: **00201738.2**

(22) Date of filing: **16.05.2000**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **17.05.1999 EP 99201545**

(71) Applicant: **Introgene B.V.**
2333 AL Leiden (NL)

(72) Inventors:
• **Bout, Abraham**
2751 AR Moerkapelle (NL)
• **Vogels, Ronald**
3461 HW Linschoten (NL)

• **Havenga, Menzo Jans Emco**
2401 BV Alphen aan den Rijn (NL)

(74) Representative:
Prins, Adrianus Willem et al
Vereenigde,
Nieuwe Parklaan 97
2587 BN Den Haag (NL)

Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35**

(57) The serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described above, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins

EP 1 054 064 A1

Description

[0001] The present invention relates to the field of gene therapy, in particular gene therapy involving elements derived from viruses, more in particular elements of adenoviruses. Adenoviruses have been proposed as suitable vehicles to deliver genes to the host.

[0002] There are a number of features of adenoviruses that make them particularly useful for the development of gene-transfer vectors for human gene therapy:

The adenovirus genome is well characterized. It consists of a linear double-stranded DNA molecule of approximately 36000 base pairs. The adenovirus DNA contains identical Inverted Terminal Repeats (ITR) of approximately 90-140 base pairs with the exact length depending on the serotype. The viral origins of replication are within the ITRs exactly at the genome ends;

The biology of the adenoviruses is characterized in detail; the adenovirus is not associated with severe human pathology in immuno-competent individuals

The virus is extremely efficient in introducing its DNA into the host cell; the virus can infect a wide variety of cells and has a broad host-range;

The virus can be produced at high virus titers in large quantities;

The virus can be rendered replication defective by deletion of the early-region 1 (E1) of the viral genome (Brody et al, 1994). Most adenoviral vectors currently used in gene therapy have a deletion in the E1 region, where desired genetic information can be introduced.

[0003] Based on these features, preferred methods for *in vivo* gene transfer into human target cells, make use of adenoviral vectors as gene delivery vehicles.

[0004] However, there are still drawbacks associated with the therapeutic use of adenoviral vectors in humans. A major drawback is the existence of widespread pre-existing immunity among the population against adenoviruses. Exposure to wild-type adenoviruses is very common in humans, as has been documented extensively [reviewed in Wadell, 1984]. This exposure has resulted in immune responses against most types of adenoviruses, not alone against adenoviruses to which individuals have actually been exposed, but also against adenoviruses which have similar (neutralizing) epitopes.

[0005] This phenomenon of pre-existing antibodies in humans, in combination with a strong secondary humoral and cellular immune response against the virus, can seriously affect gene transfer using recombinant adenoviral vectors.

[0006] To date, six different subgroups of human adenoviruses have been proposed which in total encompasses 51 distinct adenovirus serotypes (see table 1). A serotype is defined on the basis of its immunological distinctiveness as determined by quantitative neutralization with animal antisera (horse, rabbit). If neutralization shows a certain degree of cross-reaction between two viruses, distinctiveness of serotype is assumed if A) the hemagglutinins are unrelated, as shown by lack of cross-reaction on hemagglutination-inhibition, or B) substantial biophysical/ biochemical differences in DNA exist (Francki et al, 1991). The nine serotypes identified last (42-51) were isolated for the first time from HIV-infected patients (Hierholzer et al 1988; Schnurr et al 1993;). For reasons not well understood, most of such immune-compromised patients shed adenoviruses that were rarely or never isolated from immune-competent individuals (Hierholzer et al 1988, 1992; Khoo et al, 1995, De Jong et al, 1998).

[0007] The vast majority of individuals have had previous exposure to adenoviruses, especially the well investigated adenovirus serotypes 5 and type 2 (Ad5 and Ad2) or immunologically related serotypes. Importantly, these two serotypes are also the most extensively studied for use in human gene therapy. from other (adeno) viruses, as long as one replaces an element which could lead to immunity against such a gene delivery vehicle by an element of adenovirus 35 or a functional homologue thereof, which has less of such a drawback and which preferably avoids such a drawback. In the present invention a gene delivery vehicle is any vehicle that is capable of delivering a nucleic acid of interest to a host cell. It must, according to the invention comprise an element of adenovirus 35 or a functional equivalent of such an element, which must have a beneficial effect regarding the immune response against such a vehicle. Basically all other elements making up the vehicle can be any elements known in the art or developed in the art, as long as together they are capable of delivering said nucleic acid of interest. In principle the person skilled in the art can use and/or produce any adenoviral products or production systems that can or have been applied in the adenoviral field.

[0008] Typically the products of the invention can be made in the packaging cells useable for e.g. adenovirus 5, typically the vectors based on adenovirus 35 can be produced and/or used in the same manner as those of other adenoviruses e.g. adenovirus 2 and/or 5. A good overview of the possibilities of minimal vectors, packaging systems, intracellular amplification, vector and plasmid based systems can be found in applicant's copending applications (PCT/NL99/00235 and PCT/NL96/00244) incorporated herein by reference. Non-viral delivery systems can also be provided with elements according to the invention as can viral delivery systems.

[0009] Both kinds of systems are well known in the art in many different set-ups and do therefor not need any further elaboration here. A review on the many different systems and their properties can be found in Robbins and Ghivizani (1998) and in Prince (1998) incorporated herein by reference.

[0010] Gene delivery vehicles typically contain a nucleic acid of interest. A nucleic acid of interest can be a gene or a functional part of a gene (wherein a gene is any nucleic acid which can be expressed) or a precursor of a gene or a transcribed gene on any nucleic acid level (DNA and/or RNA: double or single stranded). Genes of interest are well known in the art and typically include those encoding therapeutic proteins such as TPA, EPO, cytokines, antibodies or derivatives thereof, etc. An overview of therapeutic proteins to be applied in gene therapy are listed below.

Immune-stimulatory factors like tumor-specific antigens, cytokines, etc.;

Anti-angiogenic factors non-limiting examples endostatin, angiostatin, ATF-BPTI CDT-6, dominant negative VEGF-mutants, etc.;

Angiogenic factors non-limiting example VEGF, Fibroblast growth factors, Nitric oxide synthases, C-type natriuretic peptide, etc.;

Inflammation inhibiting proteins like soluble CD40, FasL, IL-12, IL-10, IL-4, IL-13 and excreted single chain antibodies to CD4, CD5, CD7, CD52, IL-2, IL-1, IL-6, TNF, etc. or excreted single chain antibodies to the T-cell receptor on the auto-reactive T-cells. Also, dominant negative mutants of PML may be used to inhibit the immune response.

[0011] Furthermore, antagonists of inflammation promoting cytokines may be used, for example IL-1RA (receptor antagonist) and soluble receptors like sIL-1RI, sIL-1RII, sTNFRI and sTNFRII. Growth and/or immune response inhibiting genes such as cēNOS, Bcl3, cactus and IκBα, β or γ and apoptosis inducing proteins like the VP3 protein of chicken anemia virus may also be used. Furthermore, suicide genes like HSV-TK, cytosine deaminase, nitroreductase and linamerase may be used.

[0012] A nucleic acid of interest may also be a nucleic acid which can hybridise with a nucleic acid sequence present in the host cell thereby inhibiting expression or transcription or translation of said nucleic acid. It may also block through cosuppression. In short a nucleic acid of interest is any nucleic acid that one may wish to provide a cell with in order to induce a response by that cell, which response may be production of a protein, inhibition of such production, apoptosis, necrosis, proliferation, differentiation etc.

[0013] The present invention is the first to disclose adenovirus 35 or a functional homologue thereof for therapeutic use, therefor the invention also provides an adenovirus serotype 35 or a functional homologue thereof or a chimaeric virus derived therefrom, or a gene delivery vehicle based on said virus its homologue or its chimaera for use as a pharmaceutical. The serotype of the present invention, adenovirus type 35, is in itself known in the art. It is an uncommon group B adenovirus that was isolated from patients with acquired immunodeficiency syndrome and other immunodeficiency disorders (Flomenberg *et al.*, 1987; De Jong *et al.*, 1983). Ad 35 has been shown to differ from the more fully characterized subgroup C (including Ad2 and Ad5) with respect to pathogenic properties (Basler *et al.*, 1996). It has been suggested that this difference may be correlated with differences in the E3 region of the Ad35 genome (Basler *et al.*, 1996). The DNA of Ad35 has been partially cloned and mapped (Kang *et al.*, 1989a and b; Valderrama-Leon *et al.*, 1985).

[0014] B type adenovirus serotypes such as 34 and 35 have a different E3 region than other serotypes. Typically this region is involved in suppressing immune response to adenoviral products. Thus the invention provides a gene delivery vehicle according to the invention whereby said elements involved in avoiding or diminishing immune response comprise adenovirus 35 E3 expression products or the genes encoding them or functional equivalents of either or both.

[0015] Another part of adenoviruses involved in immune responses is the capsid, in particular the penton and/or the hexon proteins. Thus the invention also provides a gene delivery vehicle according to the invention whereby the elements comprise at least one adenovirus 35 capsid protein or functional part thereof, such as fiber, penton and/or hexon proteins or a gene encoding at least one of them. It is not necessary that a whole protein relevant for immune response is of adenovirus 35 (or a functional homologue thereof) origin. It is very well possible to insert a part of an adenovirus fiber, penton or hexon protein into another fiber, penton or hexon. Thus chimaeric proteins are obtained.

[0016] It is also possible to have a penton of a certain adenovirus, a hexon from another and a fiber or an E3 region from yet another adenovirus. According to the invention at least one of the proteins or genes encoding them should comprise an element from adenovirus 35 or a functional homologue thereof, whereby said element has an effect on the immune response of the host. Thus the invention provides a gene delivery according to the invention, which is a chimaera of adenovirus 35 with at least one other adenovirus. In this way one can also modify the resulting virus in other aspects than the immune response alone. One can enhance its efficiency of infection with elements responsible therefor; one can enhance its replication on a packaging cell, or one can change its tropism.

[0017] Thus the invention e.g. provides a gene delivery vehicle according to the invention which has a different tropism than adenovirus 35. Of course the tropism should be altered preferably such that the gene delivery vehicle is delivered preferentially to a subset of the host's cells, i.e. the target cells. Changes in tropism and other changes which can

also be applied in the present invention of adenoviral or other gene delivery vehicles are disclosed in applicant's copending applications (nos. 98204482.8, 99200624.7 and 98202297.2) incorporated herein by reference. Of course the present application also provides any and all building blocks necessary and/or useful to get to the gene delivery vehicles and/or the chimaeras, etc. of the present invention. This includes packaging cells such as PER.C6 (ECACC deposit number 96022940) or cells based thereon, but adapted for Ad35 or a functional homologue thereof; it also includes any nucleic acids encoding functional parts of adenovirus 35 or a functional homologue thereof, such as helper constructs and packaging constructs, as well as vectors comprising genes of interest and e.g. an ITR, etc.

[0018] Typically applicant's application (PCT/NL96/00244) incorporated herein by reference, discloses elements necessary and useful for arriving at the invented gene delivery vehicles. Thus the invention also provides a nucleic acid encoding at least a functional part of a gene delivery vehicle according to the invention, or a virus, homologue or chimaera thereof according to the invention.

[0019] According to the invention, such elements, which encode functions that will end up in the resulting gene delivery vehicle must comprise or be encoded by a nucleic acid encoding at least one of the adenovirus serotype 35 elements or a functional equivalent thereof, responsible for avoiding or deminishing neutralising activity against adenoviral elements by the host to which the gene is to be delivered.

[0020] Typically the gene of interest would be present on the same nucleic acid which means that such a nucleic acid has such a gene or that it has a site for introducing a gene of interest therein.

[0021] Typically such a nucleic acid also comprises at least one ITR and if it is a nucleic acid to be packaged also a packaging signal. However, as mentioned before all necessary and useful elements and/or building blocks for the present invention can be found in applicant's application (PCT/NL96/00244). A set of further improvements in the field of producing adenoviral gene delivery vehicles is applicant's plasmid system disclosed in PCT/NL99/00235 mentioned herein before. This system works in one embodiment as a homologous recombination of an adapter plasmid and a longer plasmid, together comprising all elements of the nucleic acid to be incorporated in the gene delivery vehicle. These methods can also be applied to the presently invented gene delivery vehicles and their building elements.

[0022] Thus the invention also provides a nucleic acid according to the invention further comprising a region of nucleotides designed or useable for homologous recombination, preferably as part of at least one set of two nucleic acids comprising a nucleic acid according to the invention, whereby said set of nucleic acids is capable of a single homologous recombination event with each other, which leads to a nucleic acid encoding a functional gene delivery vehicle.

[0023] Both empty packaging cells (in which the vector to be packaged to make a gene delivery vehicle according to the invention still has to be introduced or produced) as well as cells comprising a vector according to the invention to be packaged are provided. Thus the invention also encompasses a cell comprising a nucleic acid according to the invention or a set of nucleic acids according to the invention, preferably a cell which complements the necessary elements for adenoviral replication which are absent from the nucleic acid according to be packaged, or from a set of nucleic acids according to the invention. In the present invention it has been found that E1-deleted adenovirus 35 vectors, are not capable of replication on cells that provide adenovirus 5 proteins *in trans*. The invention therefore further provides a cell capable of providing adenovirus 35 E1 proteins *in trans*. Such a cell is typically a human cell derived from the retina or the kidney. Embryonal cells such as amniocytes, have been shown to be particularly suited for the generation of an E1 complementing cell line. Such cells are therefor preferred in the present invention. Serotype specific complementation by E1 proteins can be due to one or more protein(s) encoded by the E1 region. It is therefor essential that at least the serotype specific protein is provided *in trans* in the complementing cell line. The non-serotype specific E1 proteins essential for effective complementation of an E1-deleted adenovirus can be derived from other adenovirus serotypes. Preferably, at least an E1 protein from the E1B region of adenovirus 35 is provided *in trans* to complement E1-deleted adenovirus 35 based vectors.

[0024] In one embodiment nucleic acid encoding the one or more serotype specific E1-proteins is introduced into the PER.C6 cell or a cell originating from a PER.C6 cell (ECACC deposit number 96022940), or a similar packaging cell complementing with elements from Ad 35 or a functional homologue thereof.

[0025] As already alluded to the invention also encompasses a method for producing a gene delivery vehicle according to the invention, comprising expressing a nucleic acid according to the invention in a cell according to the invention and harvesting the resulting gene delivery vehicle. The above refers to the filling of the empty packaging cell with the relevant nucleic acids. The format of the filled cell is of course also part of the present invention, which provides a method for producing a gene delivery vehicle according to the invention, comprising culturing a filled packaging cell (producer cell) according to the invention in a suitable culture medium and harvesting the resulting gene delivery vehicle.

[0026] The resulting gene delivery vehicles obtainable by any method according to the invention are of course also part of the present invention, particularly also a gene delivery vehicle according to the invention, which is derived from a chimaera of an adenovirus and an integrating virus.

[0027] It is well known that adenoviral gene delivery vehicles do not integrate into the host genome normally. For

long term expression of genes in a host cell it is therefor preferred to prepare chimaeras which do have that capability. Such chimaeras have been disclosed in our copending application PCT/NL98/00731 incorporated herein by reference. A very good example of such a chimaera of an adenovirus and an integrating virus wherein said integrating virus is an adeno associated virus. As discussed hereinbefore other useful chimaeras, which can also be combined with the above are chimaeras (be it in swapping whole proteins or parts thereof or both) which have altered tropism. A very good exam-
 5 ple thereof is a chimaera of Ad 35 and Ad 16, possibly with elements from for instance Ad 2 or Ad 5, wherein the tropism determining part of Ad 16 or a functional equivalent thereof is used to direct the gene delivery vehicle to synoviocytes and/or smooth muscle cells (see our copending applications nos. 98204482.8 and 99200624.7) incorporated herein by reference). Dendritic cells (DC) and hemopoietic stem cells (HSC) are not easily transduced with Ad2 or Ad5 derived
 10 gene delivery vehicles. The present invention provides gene delivery vehicles that posses increased transduction capacity of DC and HSC cells. Such gene delivery vehicles at least comprises the tissue tropism determining part of an Ad35 adenovirus. The invention therefore further provides the use of a tissue tropism determining part of an adenovirus 35 capsid for transducing dendritic cells and/or hemopoietic stem cells. Other B-type adenoviruses are also suited. A tissue tropism determining part comprises at least the knob and/or the shaft of a fiber protein. Of course it is very well
 15 possible for a person skilled in the art to determine the amino acid sequences responsible for the tissue tropism in the fiber protein. Such knowledge can be used to devise chimaeric proteins comprising such amino acid sequences. Such chimaeric proteins are therefor also part of the invention. DC cells are very efficient antigen presenting cells. By introducing the gene delivery vehicle into such cells the immune system of the host can be triggered to toward specific anti-
 20 gens. Such antigens can be encoded by nucleic acid delivered to the DC or by the proteins of the gene delivery vehicle it self. The present invention therefor also provides a gene delivery vehicle with the capacity to evade to host immune system as a vaccine. The vector being capable to evade the immune system long enough to efficiently find it target cells and at the same time capable of delivering specific antigens to antigen presenting cells thereby allowing the induction and/or stimulation of an efficient immune responses toward the specific antigen(s). To further modulate the immune
 25 response, the gene delivery vehicle may comprise proteins and/or nucleic encoding such proteins capable of modulat- ing an immune response. Non-limiting examples of such proteins are found among the interleukins, the adhesion mol-
 30 ecules, the co-stimulatory proteins, the interferons etc. The invention therefore further provides a vaccine comprising a gene delivery vehicle of the invention. The invention further provides an adenovirus vector with the capacity to efficiently transduce DC and/or HSC, the vehicle comprising at least a tissue tropism determing part of serotype 35 adenovirus. The invention further provides the use of such delivery vehicles for the transduction of HSC and/or DC cells. Similar tis-
 35 sue tropisms are found among other adenoviruses of serotype B, particularly in serotype 11 and are also part of the invention. Of course it is also possible to provide other gene delivery vehicles with the tissue tropism determining part thereby providing such delivery vehicles with an enhanced DC and/or HSC transduction capacity. Such gene delivery vehicles are therefor also part of the invention.

[0028] The gene delivery vehicles according to the invention can be used to deliver genes or nucleic acids of inter-
 35 est to host cells. This will typically be a pharmaceutical use. Such a use is included in the present invention. Composi-
 40 tions suitable for such a use are also part of the present invention. The amount of gene delivery vehicle that needs to be present per dose or per infection (m.o.i) will depend on the condition to be treated, the route of administration (typi-
 45 cally parenteral) the subject and the efficiency of infection, etc. Dose finding studies are well known in the art and those already performed with other (adenoviral) gene delivery vehicles can typically be used as guides to find suitable doses
 50 of the gene delivery vehicles according to the invention. Typically this is also where one can find suitable excipients, suitable means of administration, suitable means of preventing infection with the vehicle where it is not desired, etc. Thus the invention also provides a pharmaceutical formulation comprising a gene delivery vehicle according to the invention and a suitable excipient, as well as a pharmaceutical formulation comprising an adenovirus, a chimaera thereof, or a functional homologue thereof according to the invention and a suitable excipient.

Detailed description

[0029] As described above, the most extensively studied serotypes of adenovirus are not ideally suitable for deliv-
 50 ering additional genetic material to host cells. This is partly due to the pre-existing immunity among the population against these serotypes. This presence of pre-existing antibodies in humans, in combination with a strong secondary humoral and cellular immune response against the virus will affect adenoviral gene therapy.

[0030] The present invention provides the use of at least elements of a serotype and functional homologues thereof of adenovirus which are very suitable as gene therapy vectors.

[0031] The present invention also discloses an automated high-throughput screening of all known adenovirus sero-
 55 types against sera from many individuals. Surprisingly, no neutralizing ability was found in any of the sera that were evaluated against one particular serotype, adenovirus 35 (Ad35). This makes the serotype of the present invention extremely useful as a vector system for gene therapy in man.

[0032] Such vector system is capable of efficiently transferring genetic material to a human cell without the inherent

problem of pre-existing immunity.

[0033] Typically, a virus is produced using an adenoviral vector (typically a plasmid, a cosmid or baculovirus vector). Such vectors are of course also part of the present invention. The invention also provides adenovirus derived vectors that have been rendered replication defective by deletion or inactivation of the E1 region. Of course, also a gene of interest can be inserted at for instance the site of E1 of the original adenovirus from which the vector is derived.

[0034] In all aspects of the invention the adenoviruses may contain deletions in the E1 region and insertions of heterologous genes linked either or not to a promoter. Furthermore, the adenoviruses may contain deletions in the E2, E3 or E4 regions and insertions of heterologous genes linked to a promoter. In these cases, E2 and/or E4 complementing cell lines are required to generate recombinant adenoviruses.

[0035] One may choose to use the Ad35 serotype itself for the preparation of recombinant adenoviruses to be used in gene therapy. Alternatively, one may choose to use elements derived from the serotype of the present invention in such recombinant adenoviruses. One may for instance develop a chimaeric adenovirus that combines desirable properties from different serotypes. Some serotypes have a somewhat limited host range, but have the benefit of being less immunogenic, some are the other way round. Some have a problem of being of a limited virulence, but have a broad host range and/or a reduced immunogenicity. Such chimaeric adenoviruses are known in the art, and they are intended to be within the scope of the present invention. Thus in one embodiment the invention provides a chimaeric adenovirus comprising at least a part of the adenovirus genome of the present serotype, providing it with absence of pre-existing immunity, and at least a part of the adenovirus genome from another adenovirus serotype resulting in a chimaeric adenovirus. In this manner the chimaeric adenovirus produced is such that it combines the absence of pre-existing immunity of the serotype of the present invention, to other characteristics of another serotype. Such characteristics may be temperature stability, assembly, anchoring, redirected infection, production yield, redirected or improved infection, stability of the DNA in the target cell, etc.

[0036] A packaging cell will generally be needed in order to produce sufficient amount of adenoviruses. For the production of recombinant adenoviruses for gene therapy purposes, several cell lines are available. These include but are not limited to the known cell lines PER.C6 (ECACC deposit number 96022940), 911, 293, and E1 A549.

[0037] An important feature of the present invention is the means to produce the adenovirus. Typically, one does not want an adenovirus batch for clinical applications to contain replication competent adenovirus. In general therefore, it is desired to omit a number of genes (but at least one) from the adenoviral genome on the adenoviral vector and to supply these genes in the genome of the cell in which the vector is brought to produce chimaeric adenovirus. Such a cell is usually called a packaging cell. The invention thus also provides a packaging cell for producing an adenovirus (a gene delivery vehicle) according to the invention, comprising in trans all elements necessary for adenovirus production not present on the adenoviral vector according to the invention. Typically vector and packaging cell have to be adapted to one another in that they have all the necessary elements, but that they do not have overlapping elements which lead to replication competent virus by recombination.

[0038] Thus the invention also provides a kit of parts comprising a packaging cell according to the invention and a recombinant vector according to the invention whereby there is essentially no sequence overlap leading to recombination resulting in the production of replication competent adenovirus between said cell and said vector.

[0039] Thus the invention provides methods for producing adenovirus, which upon application will escape pre-existing humoral immunity, comprising providing a vector with elements derived from an adenovirus serotype against which virtually no natural immunity exists and transfecting said vector in a packaging cell according to the invention and allowing for production of viral particles.

[0040] In one aspect this invention describes the use of the adenovirus serotype of the present invention to overcome natural existing or induced, neutralising host activity towards adenoviruses administered in vivo for therapeutic applications. The need for a new serotype is stressed by observations that 1) repeated systemic delivery of recombinant adenovirus serotype 5 is unsuccessful due to formation of high titers of neutralising antibodies against the recombinant adenovirus serotype 5 (Schulick et al, 1997), and 2) pre-existing or humoral immunity is widespread in the population.

[0041] In another aspect this invention provides the use of gene delivery vehicles of the invention or the use of adenovirus serotype 35 for vaccination purposes. Such use prevents at least in part undesired immune responses of the host. Non-limiting examples of undesired immune responses are evoking an immune response against the gene delivery vehicle or adenovirus serotype 35 and/or boosting of an immune response against the gene delivery vehicle or adenovirus serotype 35.

[0042] In another aspect of the invention, alternating use is made of Ad vectors belonging to different subgroups. This aspect of the invention therefore circumvents the inability to repeat the administration of an adenovirus for gene therapy purposes.

EP 1 054 064 A1

Example 1

A high throughput assay for the detection of neutralising activity in human serum

- 5 [0043] To enable screening of a large amount of human sera for the presence of neutralising antibodies against all adenovirus serotypes, an automated 96-wells assay was developed.

Human sera

- 10 [0044] A panel of 100 individuals was selected. Volunteers (50% male, 50% female) were healthy individuals between 20 and 60 years old with no restriction for race. All volunteers signed an informed consent form. People professionally involved in adenovirus research were excluded.
- [0045] Approximately 60 ml blood was drawn in dry tubes. Within two hours after sampling, the blood was centrifuged at 2500 rpm for 10 minutes. Approximately 30 ml serum was transferred to polypropylene tubes and stored frozen at -20°C until further use.
- 15 [0046] Serum was thawed and heat-inactivated at 56°C for 10 minutes and then aliquotted to prevent repeated cycles of freeze/thawing. Part was used to make five steps of twofold dilutions in medium (DMEM, Gibco BRL) in a quantity enough to fill out approximately 70 96-well plates. Aliquots of undiluted and diluted sera were pipetted in deep well plates (96-well format) and using a programmed platemate dispensed in 100 µl aliquots into 96-well plates. This way the plates were loaded with eight different sera in duplo (100 µl/well) according to the scheme below:

25

S1/ 2	S1/ 4	S1/ 8	S1/ 16	S1/ 32	S5/ 2	S5/ 4	S5/ 8	S5/ 16	S5/ 32	-	-
S1/ 2	S1/ 4	S1/ 8	S1/ 16	S1/ 32	S5/ 2	S5/ 4	S5/ 8	S5/ 16	S5/ 32	-	-
S2/ 2	S2/ 4	S2/ 8	S2/ 16	S2/ 32	S6/ 2	S6/ 4	S6/ 8	S6/ 16	S6/ 32	-	-
S2/ 2	S2/ 4	S2/ 8	S2/ 16	S2/ 32	S6/ 2	S6/ 4	S6/ 8	S6/ 16	S6/ 32	-	-
30 S3/ 2	S3/ 4	S3/ 8	S3/ 16	S3/ 32	S7/ 2	S7/ 4	S7/ 8	S7/ 16	S7/ 32	-	-
S3/ 2	S3/ 4	S3/ 8	S3/ 16	S3/ 32	S7/ 2	S7/ 4	S7/ 8	S7/ 16	S7/ 32	-	-
S4/ 2	S4/ 4	S3/ 8	S3/ 16	S3/ 32	S8/ 2	S8/ 4	S8/ 8	S8/ 16	S8/ 32	-	-
35 S4/ 2	S4/ 4	S3/ 8	S3/ 16	S3/ 32	S8/ 2	S8/ 4	S8/ 8	S8/ 16	S8/ 32	-	-

- [0047] Where S1/2 to S8/2 in columns 1 and 6 represent 1x diluted sera and Sx/4, Sx/8, Sx/16 and Sx/32 the two-fold serial dilutions. The last plates also contained four wells filled with 100µl foetal calf serum as a negative control. Plates were kept at -20°C until further use.

40

Preparation of human adenovirus stocks

- [0048] Prototypes of all known human adenoviruses were inoculated on T25 flasks seeded with PER.C6 cells (ECACC deposit number 96022940) (Fallaux *et al.*, 1998) and harvested upon full CPE. After freeze/thawing 1-2 ml of the crude lysates was used to inoculate a T80 flask with PER.C6 cells (ECACC deposit number 96022940) and virus was harvested at full CPE. The timeframe between inoculation and occurrence of CPE as well as the amount of virus needed to re-infect a new culture, differed between serotypes. Adenovirus stocks were prepared by freeze/thawing and used to inoculate 3-4 T175 cm² three-layer flasks with PER.C6 cells (ECACC deposit number 96022940). Upon occurrence of CPE, cells were harvested by tapping the flask, pelleted and virus was isolated and purified by a two step CsCl gradient as follows. Cell pellets were dissolved in 50 ml 10 mM NaPO₄ buffer (pH 7.2) and frozen at -20°C. After thawing at 37°C, 5.6 ml sodium deoxycholate (5% w/v) was added. The solution was mixed gently and incubated for 5-15 minutes at 37°C to completely lyse the cells. After homogenizing the solution, 1875 µl 1M MgCl₂ was added. After the addition of 375 µl DNase (10 mg/ml) the solution was incubated for 30 minutes at 37°C. Cell debris was removed by centrifugation at 1880xg for 30 minutes at PT without brake. The supernatant was subsequently purified from proteins by extraction with freon (3x). The cleared supernatant was loaded on a 1M Tris/HCl buffered cesiumchloride blockgradient (range: 1.2/1.4 gr/ml) and centrifugated at 21000 rpm for 2.5 hours at 10°C. The virus band is isolated after which a second purification using a 1M Tris/HCl buffered continuous gradient of 1.33 gr/ml of cesiumchloride was performed. The virus was then centrifuged for 17 hours at 55000 rpm at 10°C. The virus band is isolated and sucrose (50 % w/v)

EP 1 054 064 A1

is added to a final concentration of 1%. Excess cesiumchloride is removed by dialysis (three times 1 hr at RT) in dialysis slides (Slide-a-lizer, cut off 10000 kDa, Pierce, USA) against 1.5 ltr PBS supplemented with CaCl_2 (0.9 mM), MgCl_2 (0.5mM) and an increasing concentration of sucrose (1, 2, 5%). After dialysis, the virus is removed from the slide-a-lizer after which it is aliquoted in portions of 25 and 100 μl upon which the virus is stored at -85°C .

5 [0049] To determine the number of virus particles per milliliter, 50 μl of the virus batch is run on a high-pressure liquid chromatograph (HPLC) as described by Shabram et al (1997).

[0050] Viruses were eluted using an NaCl gradient ranging from 0 to 600 mM. As depicted in table I, the NaCl concentration by which the viruses were eluted differed significantly among serotypes.

10 [0051] Most human adenoviruses replicated well on PER.C6 cells (ECACC deposit number 96022940) with a few exceptions. Adenovirus type 8 and 40 were grown on 911-E4 cells (He *et al.*, 1998). Purified stocks contained between 5×10^{10} and 5×10^{12} virus particles/ml (VP/ml; see table I).

Titration of purified human adenovirus stocks

15 [0052] Adenoviruses were titrated on PER.C6 cells (ECACC deposit number 96022940) to determine the amount of virus necessary to obtain full CPE in five days, the length of the neutralisation assay. Hereto, 100 μl medium was dispensed into each well of 96-well plates. 25 μl of adenovirus stocks prediluted 10^4 , 10^5 , 10^6 or 10^7 times were added to column 2 of a 96-well plate and mixed by pipetting up and down 10 times. Then 25 μl was brought from column 2 to column 3 and again mixed. This was repeated until column 11 after which 25 μl from column 11 was discarded. This way serial dilutions in steps of 5 were obtained starting off from a prediluted stock. Then 3×10^4 PER.C6 cells (ECACC deposit number 96022940) were added in a 100 μl volume and the plates were incubated at 37°C , 5% CO_2 for five or six days. CPE was monitored microscopically. The method of Reed and Muensch was used to calculate the cell culture inhibiting dose 50% (CCID50).

20 [0053] In parallel identical plates were set up that were analysed using the MTT assay (Promega). In this assay living cells are quantified by colorimetric staining. Hereto, 20 μl MTT (7.5 mgr/ml in PBS) was added to the wells and incubated at 37°C , 5% CO_2 for two hours. The supernatant was removed and 100 μl of a 20:1 isopropanol/triton-X100 solution was added to the wells. The plates were put on a 96-wells shaker for 3-5 minutes to solubilise precipitated staining.

25 [0054] Absorbance was measured at 540 nm and at 690 nm (background). By this assay wells with proceeding CPE or full CPE can be distinguished.

Neutralisation assay

35 [0055] 96-well plates with diluted human serum samples were thawed at 37°C , 5% CO_2 . Adenovirus stocks diluted to 200 CCID50 per 50 μl were prepared and 50 μl aliquots were added to columns 1-11 of the plates with serum. Plates were incubated for 1 hour at 37°C , 5% CO_2 . Then 50 μl PER.C6 cells (ECACC deposit number 96022940) at $6 \times 10^5/\text{ml}$ were dispensed in all wells and incubated for 1 day at 37°C , 5% CO_2 . Supernatant was removed using fresh pipet tips for each row and 200 μl fresh medium was added to all wells to avoid toxic effects of the serum. Plates were incubated for another 4 days at 37°C , 5% CO_2 . In addition, parallel control plates were set up in duplo with diluted positive control sera generated in rabbits and specific for each serotype to be tested in rows A and B and with negative control serum (FCS) in rows C and D. Also, in each of the rows E-H a titration was performed as described above with steps of five times dilutions starting with 200 CCID50 of each virus to be tested. On day 5 one of the control plates was analysed microscopically and with the MTT assay. The experimental titer was calculated from the control titration plate observed microscopically.

45 [0056] If CPE was found to be complete, i.e. the first dilution in the control titration experiment analysed by MTT shows clear cell death, all assay plates were processed. If not, the assay was allowed to proceed for one or more days until full CPE was apparent after which all plates were processed. In most cases the assay was terminated at day 5. For Ad1, 5, 33, 39, 42 and 43 the assay was left for six days and for Ad2 for eight days.

50 [0057] A serum sample is regarded to be non-neutralising when at the highest serum concentration a maximum protection is seen of 40% compared to the controls without serum.

[0058] The results of the analysis of 44 prototype adenoviruses against serum from 100 healthy volunteers is shown in figure 1. As expected the percentage of serum samples that contained neutralising antibodies to Ad2 and Ad5 was very high. This was also true for most of the lower numbered adenoviruses. Surprisingly, none of the serum samples contained neutralising antibodies to adenovirus serotype 35.

55 [0059] Also, the number of individuals with neutralising antibody titers to the serotypes 26, 34 and 48 was very low.

[0060] Therefore, recombinant E1-deleted adenoviruses based on Ad35 or one of the other above mentioned serotypes have an important advantage compared to recombinant vectors based on Ad5 with respect to clearance of the viruses by neutralising antibodies.

[0061] Also, Ad5-based vectors that have (parts of) the capsid proteins involved in immunogenic response of the host replaced by the corresponding (parts of) the capsid proteins of Ad35 or one of the other serotypes will be less, or even not, neutralised by the vast majority of human sera.

[0062] As can be seen in table I the VP/CCID50 ratio calculated from the virus particles per ml and the CCID50 obtained for each virus in the experiments was highly variable and ranged from 0.4 to 5 log. This is probably caused by different infection efficiencies of PER.C6 cells (ECACC deposit number 96022940) and by differences in replication efficiency of the viruses. Furthermore, differences in batch qualities may play a role. A high VP/CCID50 ratio means that more virus was put in the wells to obtain CPE in 5 days. As a consequence the outcome of the neutralisation study might be biased since more (inactive) virus particles could shield the antibodies. To check whether this phenomenon had taken place, the VP/CCID50 ratio was plotted against the percentage of serum samples found positive in the assay (Figure 2). The graph clearly shows that there is no negative correlation between the amount of viruses in the assay and neutralisation in serum.

Example 2

15 Generation of Ad5 plasmid vectors for the production of recombinant viruses and easy manipulation of adenoviral genes

pBr/Ad.Bam-rITR (ECACC deposit P97082122)

20 [0063] In order to facilitate blunt end cloning of the ITR sequences, wild-type human adenovirus type 5 (Ad5) DNA was treated with Klenow enzyme in the presence of excess dNTPs. After inactivation of the Klenow enzyme and purification by phenol/chloroform extraction followed by ethanol precipitation, the DNA was digested with BamHI. This DNA preparation was used without further purification in a ligation reaction with pBr322 derived vector DNA prepared as follows: pBr322 DNA was digested with EcoRV and BamHI, dephosphorylated by treatment with TSAP enzyme (Life Technologies) and purified on LMP agarose gel (SeaPlaque GTG). After transformation into competent *E. coli* DH5 α (Life Techn.) and analysis of ampicillin resistant colonies, one clone was selected that showed a digestion pattern as expected for an insert extending from the BamHI site in Ad5 to the right ITR.

25 [0064] Sequence analysis of the cloning border at the right ITR revealed that the most 3' G residue of the ITR was missing, the remainder of the ITR was found to be correct. Said missing G residue is complemented by the other ITR during replication.

pBr/Ad.Sal-rITR (ECACC deposit P97082119)

35 [0065] pBr/Ad.Bam-rITR was digested with BamHI and Sall. The vector fragment including the adenovirus insert was isolated in LMP agarose (SeaPlaque GTG) and ligated to a 4.8 kb Sall-BamHI fragment obtained from wt Ad5 DNA and purified with the GeneClean II kit (Bio 101, Inc.). One clone was chosen and the integrity of the Ad5 sequences was determined by restriction enzyme analysis. Clone pBr/Ad.Sal-rITR contains adeno type 5 sequences from the Sall site at bp 16746 up to and including the rITR (missing the most 3' G residue).

40 *pBr/Ad.Cla-Bam (ECACC deposit P97082117)*

[0066] wt Adeno type 5 DNA was digested with ClaI and BamHI, and the 20.6 kb fragment was isolated from gel by electro-elution. pBr322 was digested with the same enzymes and purified from agarose gel by GeneClean. Both fragments were ligated and transformed into competent DH5 α . The resulting clone pBr/Ad.Cla-Bam was analysed by restriction enzyme digestion and shown to contain an insert with adenovirus sequences from bp 919 to 21566.

pBr/Ad.AflII-Bam (ECACC deposit P97082114)

50 [0067] Clone pBr/Ad.Cla-Bam was linearized with EcoRI (in pBr322) and partially digested with AflII. After heat inactivation of AflII for 20' at 65°C the fragment ends were filled in with Klenow enzyme. The DNA was then ligated to a blunt double stranded oligo linker containing a PacI site (5'-AATTGTCCTAATTAAACCGCTTAA-3'). This linker was made by annealing the following two oligonucleotides: 5'-AATTGTCCTAATTAAACCGC-3' and 5'-AATTGCGGTAAATTAAGAC-3', followed by blunting with Klenow enzyme. After precipitation of the ligated DNA to change buffer, the ligations were digested with an excess PacI enzyme to remove concatamers of the oligo. The 22016 bp partial fragment containing Ad5 sequences from bp 3534 up to 21566 and the vector sequences, was isolated in LMP agarose (SeaPlaque GTG), religated and transformed into competent DH5 α . One clone that was found to contain the PacI site and that had retained the large adeno fragment was selected and sequenced at the 5' end to verify correct insertion of the PacI linker

in the (lost) AflII site.

pBr/Ad.Bam-r.ITRpac#2 (ECACC deposit P97082120) and *pBr/Ad.Bam-r.ITRpac#8* (ECACC deposit P97082121)

5 **[0068]** To allow insertion of a PacI site near the ITR of Ad5 in clone *pBr/Ad.Bam-r.ITR* about 190 nucleotides were removed between the ClaI site in the pBr322 backbone and the start of the ITR sequences. This was done as follows: *pBr/Ad.Bam-r.ITR* was digested with ClaI and treated with nuclease Bal31 for varying lengths of time (2', 5', 10' and 15'). The extend of nucleotide removal was followed by separate reactions on pBr322 DNA (also digested at the ClaI site), using identical buffers and conditions. Bal31 enzyme was inactivated by incubation at 75 °C for 10', the DNA was pre-
10 cipitated and resuspended in a smaller volume TE buffer.

[0069] To ensure blunt ends, DNAs were further treated with T4 DNA polymerase in the presence of excess dNTPs. After digestion of the (control) pBr322 DNA with Sall, satisfactory degradation (~150 bp) was observed in the samples created for 10' or 15'. The 10' or 15' treated *pBr/Ad.Bam-r.ITR* samples were then ligated to the above described blunted PacI linkers (See *pBr/Ad.AflII-Bam*). Ligations were purified by precipitation, digested with excess PacI and separated
15 from the linkers on an LMP agarose gel. After religation, DNAs were transformed into competent DH5α and colonies analyzed. Ten clones were selected that showed a deletion of approximately the desired length and these were further analyzed by T-track sequencing (T7 sequencing kit, Pharmacia Biotech). Two clones were found with the PacI linker inserted just downstream of the r.ITR. After digestion with PacI, clone #2 has 28 bp and clone #8 has 27 bp attached to the ITR.

20 *pWE/Ad.AflII-r.ITR* (ECACC deposit P97082116)

[0070] Cosmid vector pWE15 (Clontech) was used to clone larger Ad5 inserts. First, a linker containing a unique PacI site was inserted in the EcoRI sites of pWE15 creating pWE.pac. To this end, the double stranded PacI oligo as
25 described for *pBr/Ad.AflII-BamHI* was used but now with its EcoRI protruding ends. The following fragments were then isolated by electro-elution from agarose gel: pWE.pac digested with PacI, *pBr/AflII-Bam* digested with PacI and BamHI and *pBr/Ad.Bam-r.ITR#2* digested with BamHI and PacI. These fragments were ligated together and packaged using λ phage packaging extracts (Stratagene) according to the manufacturer's protocol. After infection into host bacteria, colonies were grown on plates and analyzed for presence of the complete insert. *pWE/Ad.AflII-r.ITR* contains all adenovi-
30 rus type 5 sequences from bp 3534 (AflII site) up to and including the right ITR (missing the most 3' G residue).

pBr/Ad.I.ITR-Sal(9.4) (ECACC deposit P97082115)

[0071] Adeno 5 wt DNA was treated with Klenow enzyme in the presence of excess dNTPs and subsequently
35 digested with Sall. Two of the resulting fragments, designated left ITR-Sal(9.4) and Sal(16.7)-right ITR, respectively, were isolated in LMP agarose (Seaplaque GTG). pBr322 DNA was digested with EcoRV and Sall and treated with phosphatase (Life Technologies). The vector fragment was isolated using the GeneClean method (BIO 101, Inc.) and ligated to the Ad5 Sall fragments. Only the ligation with the 9.4 kb fragment gave colonies with an insert. After analysis and sequencing of the cloning border a clone was chosen that contained the full ITR sequence and extended to the Sall
40 site at bp 9462.

pBr/Ad.I.ITR-Sal(16.7) (ECACC deposit P97082118) *pBr/Ad.I.ITR-Sal(9.4)* is digested with Sall and dephosphorylated (TSAP, Life Technologies). To extend this clone upto the third Sall site in Ad5, *pBr/Ad.Cla-Bam* was linearized with BamHI and partially digested with Sall. A 7.3 kb Sall fragment containing adenovirus sequences from 9462-16746 was
45 isolated in LMP agarose gel and ligated to the Sall-digested *pBr/Ad.I.ITR-Sal(9.4)* vector fragment.

pWE/Ad.AflII-EcoRI

[0072] pWE.pac was digested with ClaI and 5' protruding ends were filled using Klenow enzyme. The DNA was
50 then digested with PacI and isolated from agarose gel. *pWE/AflII-r.ITR* was digested with EcoRI and after treatment with Klenow enzyme digested with PacI. The large 24 kb fragment containing the adenoviral sequences was isolated from agarose gel and ligated to the ClaI-digested and blunted pWE.pac vector using the Ligation Express™ kit from Clontech. After transformation of Ultracompetent XL10-Gold cells from Stratagene, clones were identified that contained the expected insert. *pWE/AflII-EcoRI* contains Ad5 sequences from bp 3534-27336.

55 Generation of *pWE/Ad.AflII-r.ITRsp*

[0073] The 3' ITR an the vector *pWE/Ad.AflII-r.ITR* does not include the terminal G-nucleotide. Furthermore, the

EP 1 054 064 A1

PacI site is located almost 30 bp from the right ITR. Both these characteristics may decrease the efficiency of virus generation due to inefficient initiation of replication at the 3' ITR. Note that during virus generation the left ITR in the adapter plasmid is intact and enables replication of the virus DNA after homologous recombination.

[0074] To improve the efficiency of initiation of replication at the 3' ITR, the pWE/Ad.AfIII-rITR was modified as follows: construct pBr/Ad.Bam-rITRpac#2 was first digested with PacI and then partially digested with AvrII and the 17.8 kb vector containing fragment was isolated and dephosphorylated using SAP enzyme (Boehringer Mannheim). This fragment lacks the adenosequences from nucleotide 35464 to the 3'ITR. Using DNA from pWE/Ad.AfIII-rITR as template and the primers ITR-EPH:

10 5'-CGG AAT TCT TAA TTA AGT TAA CAT CAT CAA TAA TAT ACC-3'
and
Ad101: 5'-TGA TTC ACA TCG GTC AGT GC-3'

a 630 bp PCR fragment was generated corresponding to the 3' Ad5 sequences. This PCR fragment was subsequently cloned in the vector pCR2.1 (Invitrogen) and clones containing the PCR fragment were isolated and sequenced to check correct amplification of the DNA. The PCR clone was then digested with PacI and AvrII and the 0.5 kb adeno insert was ligated to the PacI/ partial AvrII digested pBr/Ad.Bam-rITRpac#2 fragment generating pBr/Ad.Bam-rITRsp. Next this construct was used to generate a cosmid clone (as described above) that has an insert corresponding to the adenosequences 3534 to 35938. This clone was named pWE/AfIII-rITRsp.

20 Generation of pWE/Ad.AfIII-rITRΔE2A:

[0075] Deletion of the E2A coding sequences from pWE/Ad.AfIII-rITR (ECACC deposit P97082116) has been accomplished as follows.

25 [0076] The adenoviral sequences flanking the E2A coding region at the left and the right site were amplified from the plasmid pBr/Ad.Sal.rITR (ECACC deposit P97082119) in a PCR reaction with the Expand PCR system (Boehringer) according to the manufacturers protocol. The following primers were used: Right flanking sequences (corresponding Ad5 nucleotides 24033 to 25180):

30 ΔE2A.SnaBI: 5'-GGC GTA CGT AGC CCT GTC GAA AG-3'
ΔE2A.DBP-start: 5'-CCA ATG CAT TCG AAG TAC TTC CTT CTC CTA TAG GC-3'

[0077] The amplified DNA fragment was digested with SnaBI and NsiI (NsiI site is generated in the primer ΔE2A.DBP-start, underlined).

35 [0078] Left flanking sequences (corresponding Ad5 nucleotides 21557 to 22442):

ΔE2A.DBP-stop: 5'-CCA ATG CAT ACG GCG CAG ACG G-3'
ΔE2A.BamHI: 5'-GAG GTG GAT CCC ATG GAC GAG-3'

40 [0079] The amplified DNA was digested with BamHI and NsiI (NsiI site is generated in the primer ΔE2A.DBP-stop, underlined).

[0080] Subsequently, the digested DNA fragments were ligated into SnaBI/BamHI digested pBr/Ad.Sal-rITR. Sequencing confirmed the exact replacement of the DBP coding region with a unique NsiI site in plasmid pBr/Ad.Sal-rITRΔE2A. The unique NsiI site can be used to introduce an expression cassette for a gene to be transduced by the recombinant vector.

45 [0081] The deletion of the E2A coding sequences was performed such that the splice acceptor sites of the 100K encoding L4-gene at position 24048 in the top strand was left intact. In addition, the poly adenylation signals of the original E2A-RNA and L3-RNAs at the left hand site of the E2A coding sequences were left intact. This ensures proper expression of the L3-genes and the gene encoding the 100K L4-protein during the adenovirus life cycle.

50 [0082] Next, the plasmid pWE/Ad.AfIII-rITRΔE2A was generated. The plasmid pBr/Ad.Sal-rITRΔE2A was digested with BamHI and SpeI. The 3.9-Kb fragment in which the E2A coding region was replaced by the unique NsiI site was isolated. The pWE/Ad.AfIII-rITR was digested with BamHI and SpeI. The 35 Kb DNA fragment, from which the BamHI/SpeI fragment containing the E2A coding sequence was removed, was isolated. The fragments were ligated and packaged using λ phage-packaging extracts according to the manufacturer protocol (Stratagene), yielding the plasmid pWE/Ad.AfIII-rITRΔE2A.

55 [0083] This cosmid clone can be used to generate adenoviral vectors that are deleted for E2A by cotransfection of PacI digested DNA together with digested adapter plasmids onto packaging cells that express functional E2A gene product.

Construction of adapter plasmids

[0084] The absence of sequence overlap between the recombinant adenovirus and E1 sequences in the packaging cell line is essential for safe, RCA-free generation and propagation of new recombinant viruses. The adapter plasmid pMLP1.TK (described in PCT/NL96/00244) is an example of an adapter plasmid designed for use according to the invention in combination with the improved packaging cell lines of the invention. This plasmid was used as the starting material to make a new vector in which nucleic acid molecules comprising specific promoter and gene sequences can be easily exchanged.

[0085] First, a PCR fragment was generated from pZipΔMo+PyF101(N') template DNA (described in PCT/NL96/00195) with the following primers: LTR-1: 5'-CTG TAC GTA CCA GTG CAC TGG CCT AGG CAT GGA AAA ATA CAT AAC TG-3' and LTR-2: 5'-GCG GAT CCT TCG AAC CAT GGT AAG CTT GGT ACC GCT AGC GTT AAC CGG GCG ACT CAG TCA ATC G-3'. Pwo DNA polymerase (Boehringer Mannheim) was used according to manufacturers protocol with the following temperature cycles: once 5' at 95°C; 3' at 55°C; and 1' at 72°C, and 30 cycles of 1' at 95°C, 1' at 60°C, 1' at 72°C, followed by once 10' at 72°C. The PCR product was then digested with BamHI and ligated into pMLP10 (Levrero *et al.*, 1991) vector digested with PvuII and BamHI, thereby generating vector pLTR10. This vector contains adenoviral sequences from bp 1 up to bp 454 followed by a promoter consisting of a part of the Mo-MuLV LTR having its wild-type enhancer sequences replaced by the enhancer from a mutant polyoma virus (PyF101). The promoter fragment was designated L420. Next, the coding region of the murine HSA gene was inserted. pLTR10 was digested with BstBI followed by Klenow treatment and digestion with NcoI. The HSA gene was obtained by PCR amplification on pUC18-HSA (Kay *et al.*, 1990) using the following primers: HSA1, 5'-GCG CCA CCA TGG GCA GAG CGA TGG TGG C-3' and HSA2, 5'-GTT AGA TCT AAG CTT GTC GAC ATC GAT CTA CTA ACA GTA GAG ATG TAG AA-3'. The 269 bp amplified fragment was subcloned in a shuttle vector using the NcoI and BglII sites. Sequencing confirmed incorporation of the correct coding sequence of the HSA gene, but with an extra TAG insertion directly following the TAG stop codon. The coding region of the HSA gene, including the TAG duplication was then excised as a NcoI(sticky)-Sall(blunt) fragment and cloned into the 3.5 kb NcoI(sticky)/BstBI(blunt) fragment from pLTR10, resulting in pLTR-HSA10.

[0086] Finally, pLTR-HSA10 was digested with EcoRI and BamHI after which the fragment containing the left ITR, packaging signal, L420 promoter and HSA gene was inserted into vector pMLP1.TK digested with the same enzymes and thereby replacing the promoter and gene sequences. This resulted in the new adapter plasmid pAd/L420-HSA that contains convenient recognition sites for various restriction enzymes around the promoter and gene sequences. SnaBI and AvrII can be combined with HpaI, NheI, KpnI, HindIII to exchange promoter sequences, while the latter sites can be combined with the ClaI or BamHI sites 3' from HSA coding region to replace genes in this construct.

[0087] Another adapter plasmid that was designed to allow easy exchange of nucleic acid molecules was made by replacing the promoter, gene and poly A sequences in pAd/L420-HSA with the CMV promoter, a multiple cloning site, an intron and a poly-A signal. For this purpose, pAd/L420-HSA was digested with AvrII and BglII followed by treatment with Klenow to obtain blunt ends. The 5.1 kb fragment with pBr322 vector and adenoviral sequences was isolated and ligated to a blunt 1570 bp fragment from pcDNA1/amp (Invitrogen) obtained by digestion with HhaI and AvrII followed by treatment with T4 DNA polymerase. This adapter plasmid was named pAd5/CLIP. To enable removal of vector sequences from the left ITR in pAd5/Clip, this plasmid was partially digested with EcoRI and the linear fragment was isolated. An oligo of the sequence 5' TTAAGTCGAC-3' was annealed to itself resulting in a linker with a Sall site and EcoRI overhang. The linker was ligated to the partially digested pAd5/Clip vector and clones were selected that had the linker inserted in the EcoRI site 23 bp upstream of the left adenovirus ITR in pAd5/Clip resulting in pAd5/Clipsal. Likewise, the EcoRI site in pAd5/Clip has been changed to a PacI site by insertion of a linker of the sequence 5'-AATTGTCTTAATTAACCGCAATT-3'. The pAd5/Clip vector was partially digested with EcoRI, dephosphorylated and ligated to the PacI linker with EcoRI overhang. The ligation mixture was digested with PacI to remove concatamers, isolated from agarose gel and religated. The resulting vector was named pAd5/Clippac. These changes enable more flexibility to liberate the left ITR from the plasmid vector sequences.

[0088] The vector pAd5/L420-HSA was also modified to create a Sall or PacI site upstream of the left ITR. Hereto pAd5/L420-HSA was digested with EcoRI and ligated to the above described PacI linker. The ligation mixture was digested with PacI and religated after isolation of the linear DNA from agarose gel to remove concatamerised linkers. This resulted in adapter plasmid pAd5/L420-HSApac. This construct was used to generate pAd5/L420-HSAsal as follows: pAd5/L420-HSApac was digested with ScaI and BsrGI and the vector fragment was ligated to the 0.3 kb fragment isolated after digestion of pAd5/Clipsal with the same enzymes.

55 *Generation of adapter plasmids pAdMire and pAdApt*

[0089] To create an adapter plasmid that only contains a polylinker sequence and no promoter or polyA sequences, pAd5/L420-HSApac was digested with AvrII and BglII. The vector fragment was ligated to a linker oligonucleotide

EP 1 054 064 A1

digested with the same restriction enzymes. The linker was made by annealing oligos of the following sequence:

PLL-1: 5'- GCC ATC CCT AGG AAG CTT GGT ACC GGT GAA TTC GCT AGC GTT AAC GGA TCC TCT AGA
CGA GAT CTG G-3' and
PLL-2: 5'- CCA GAT CTC GTC TAG AGG ATC CGT TAA CGC TAG CGA ATT CAC CGG TAC CAA GCT TCC TAG
GGA TGG C-3'.

[0090] The annealed linkers were digested with AvrII and BglII and separated from small ends by column purification (Qiaquick nucleotide removal kit) according to manufacturers recommendations. The linker was then ligated to the AvrII/BglII digested pAd5/L420-HSApac fragment. A clone, named AdMire, was selected that had the linker incorporated and was sequenced to check the integrity of the insert.

[0091] Adapter plasmid AdMire enables easy insertion of complete expression cassettes.

[0092] An adapter plasmid containing the human CMV promoter that mediates high expression levels in human cells was constructed as follows: pAd5/L420-HSApac was digested with AvrII and 5' protruding ends were filled in using Klenow enzyme. A second digestion with HindIII resulted in removal of the L420 promoter sequences. The vector fragment was isolated and ligated to a PCR fragment containing the CMV promoter sequence. This PCR fragment was obtained after amplification of CMV sequences from pCMVLacI (Stratagene) with the following primers:

CMVplus: 5'-GATCGGTACCACTGCACTGGTCAATATTGGCCATTAGCC-3' and
CMVminA: 5'-GATCAAGCTTCCAATGCACCGTCCCGGC-3'.

[0093] The PCR fragment was first digested with PstI (underlined in CMVplus) after which the 3'-protruding ends were removed by treatment with T4 DNA polymerase. Then the DNA was digested with HindIII (underlined in CMVminA) and ligated into the above described pAd5/L420-HSApac vector fragment digested with AvrII and HindIII. The resulting plasmid was named pAd5/CMV-HSApac. This plasmid was then digested with HindIII and BamHI and the vector fragment was isolated and ligated to the polylinker sequence obtained after digestion of AdMire with HindIII and BglII. The resulting plasmid was named pAdApt. Adapter plasmid pAdApt contains nucleotides - 735 to +95 of the human CMV promoter (Boshart et al., 1985). A second version of this adapter plasmid containing a SalI site in place of the PacI site upstream of the left ITR was made by inserting the 0.7 kb Scal-BsrGI fragment from pAd5/Clipsal into pAdApt digested with Scal and partially digested with BsrGI. This clone was named pAdApt.sal.

Generation of recombinant adenoviruses based on Ad5

[0094] RCA free recombinant adenoviruses can be generated very efficiently using the above described adapter plasmids and the pWe/Ad.AfIII-rITR or pWe/Ad.AfIII-rITRsp constructs.

[0095] Generally, the adapter plasmid containing the desired transgene in the desired expression cassette is digested with suitable enzymes to liberate the insert from vector sequences at the 3' and/or at the 5' end. The adenoviral complementation plasmids pWe/Ad.AfIII-rITR or pWe/Ad.AfIII-rITRsp are digested with PacI to liberate the adeno sequences from the vector plasmids. As a non-limiting example the generation of AdApt-LacZ is described. Adapter plasmid pAdApt-LacZ was generated as follows. The E.coli LacZ gene was amplified from the plasmid pMLP.nlsLacZ (EP 95-202 213) by PCR with the primers 5'-GGGGTGGCCAGGGTACCTCTAGGCTTTTGCAA-3' and 5'-GGGGGGATCCATAAACAAGTTCAGAATCC-3'. The PCR reaction was performed with Ex Tag (Takara) according to the suppliers protocol at the following amplification program: 5 minutes 94°C, 1 cycle; 45 seconds 94°C and 30 seconds 60°C and 2 minutes 72°C, 5 cycles; 45 seconds 94°C and 30 seconds 65°C and 2 minutes 72°C, 25 cycles; 10 minutes 72; 45 seconds 94°C and 30 seconds 60°C and 2 minutes 72°C, 5 cycles, 1 cycle. The PCR product was subsequently digested with KpnI and BamHI and the digested DNA fragment was ligated into KpnI/BamHI digested pcDNA3 (Invitrogen), giving rise to pcDNA3.nlsLacZ. Construct pcDNA3.nlsLacZ was then digested with KpnI and BamHI and the 3 kb LacZ fragment was isolated from gel using the gene clean spin kit (Bio 101, Inc.).

[0096] pAdApt was also digested with KpnI and BamHI and the linear vector fragment was isolated from gel as above. Both isolated fragments were ligated and one clone containing the LacZ insert was selected. Construct pAdApt-LacZ was digested with SalI, purified by the gene clean spin kit and subsequently digested with PacI. pWe/Ad.AfIII-rITRsp was digested with PacI. Both digestion mixtures were treated for 30' by 65 °C to inactivate the enzymes. Samples were put on gel to estimate the concentration. 2.5×10^6 PER.C6 cells (ECACC deposit number 96022940) were seeded in T25 flasks in DMEM with 10% FCS and 10mM MgCl. The next day four microgram of each plasmid was transfected into PER.C6 cells (ECACC deposit number 96022940) using lipofectamine transfection reagent (Life Technologies Inc.) according to instructions of the manufacturer. The next day the medium was replaced by fresh culture medium and cells were further cultured at 37° C, 10% CO₂. Again 24 hrs. later cells were trypsinised, seeded into T80 flasks and cultured at 37°C, 10% CO₂. Full CPE was obtained 6 days after seeding in the T80 flask. Cells were har-

vested in the medium and subjected to one freeze/thaw cycle. The crude lysate obtained this way was used to plaque purify the mixture of viruses. Ten plaques were picked, expanded in a 24 well plate and tested for LacZ expression following infection of A549 cells. Viruses from all ten plaques expressed LacZ.

5 Example 3

Generation of chimeric recombinant adenoviruses

Generation of hexon chimeric Ad5-based adenoviruses

10

[0097] Neutralising antibodies in human serum are mainly directed to the hexon protein and to a lesser extent to the penton protein. Hexon proteins from different serotypes show highly variable regions present in loops that are predicted to be exposed at the outside of the virus (Athappilly et al., 1994; J. Mol. Biol. 242, 430-455). Most type specific epitopes have been mapped to these highly variable regions (Toogood et al., 1989; J. Gen Virol. 70, 3203-3214). Thus replacement of (part of) the hexon sequences with corresponding sequences from a different serotype is an effective strategy to circumvent (pre-existing) neutralising antibodies to Ad5. Hexon coding sequences of adenovirus serotype 5 are located between nucleotides 18841 and 21697.

15

[0098] To facilitate easy exchange of hexon coding sequences from alternative adenovirus serotypes into the adenovirus serotype 5 backbone, first a shuttle vector was generated.

20

[0099] This subclone, coded pBr/Ad.Eco-PmeI, was generated by first digesting plasmid pBr322 with EcoRI and EcoRV and inserting the 14 kb PmeI-EcoRI fragment from pWE/Ad.AflII-Eco. In this shuttle vector a deletion was made of a 1430 bp SmaDI fragment by digestion with SmaDI and religation to give pBr/Ad.Eco-PmeI ΔSmaDI. The removed fragment contains unique SpeI and MunI sites. From pBr/Ad.Eco-PmeIΔSmaDI the adenovirus serotype 5 DNA encoding hexon was deleted.

25

[0100] Hereto, the hexon flanking sequences were PCR amplified and linked together thereby generating unique restriction sites replacing the hexon coding region. For these PCR reactions four different oligonucleotides were required: Δhex1-Δhex4.

30

Δhex1: 5'- CCT GGT GCT CCC AAC AGC-3'

Δhex2: 5'- CCG GAT CCA CTA GTG GAA AGC GGG CGC GCG-3'

Δhex3: 5'- CCG GAT CCA ATT GAG NAG CAA GCA ACA TCA ACA AC-3'

Δhex4: 5'- GAG AAG GGC ATG GAG GCT G-3'

35

[0101] The amplified DNA product of ± 1100 bp obtained with oligonucleotides Δhex1 and Δhex2 was digested with BamHI and FseI. The amplified DNA product of ± 1600 bp obtained with oligonucleotides Δhex3 and Δhex4 was digested with BamHI and SbfI. These digested PCR fragments were subsequently purified from agarose gel and in a tri-part ligation reaction using T4 ligase enzyme linked to pBr/Ad.Eco-PmeI ΔSmaDI digested with FseI and SbfI. The resulting construct was coded pBr/Ad.Eco-PmeIΔHexon. This construct was sequenced in part to confirm the correct nucleotide sequence and the presence of unique restriction sites MunI and SpeI.

40

[0102] pBr/Ad.Eco-PmeIΔHexon serves as a shuttle vector to introduce heterologous hexon sequences amplified from virus DNA from different serotypes using primers that introduce the unique restriction sites MunI and SpeI at the 5' and 3' ends of the hexon sequences respectively. To generate Ad5-based vectors that contain hexon sequences from the serotypes to which healthy individuals have no, or very low, titers of NAB the hexon sequences of Ad35, Ad34, Ad26 and Ad48 were amplified using the following primers:

45

Hex-up2: 5'-GACTAGTCAAGATGGCYACCCCHTCGATGATG-3' and

Hex-do2: 5'-GCTGGCCAATTGTTATGKTGKGCGTTRCCGGC-3'.

50

[0103] These primers were designed using the sequences of published hexon coding regions (for example hexon sequences of Ad2, Ad3, Ad4, Ad5, Ad7, Ad16, Ad40 and Ad41 can be obtained at Genbank). Degenerated nucleotides were incorporated at positions that show variation between serotypes.

[0104] PCR products were digested with SpeI and MunI and cloned into the pBr/Ad.Eco-PmeIΔHexon construct digested with the same enzymes.

55

[0105] The hexon modified sequences were subsequently introduced in the construct pWE/Ad.AflII-rTR by exchange of the AscI fragment generating pWE/Ad.AflII-rTRHexXX where XX stands for the serotype used to amplify hexon sequences.

[0106] The pWE/Ad.AflII-rTRHexXX constructs are then used to make viruses in the same manner as described above for Ad5 recombinant viruses.

EP 1 054 064 A1

Generation of penton chimeric Ad5-based recombinant viruses

5 [0107] The adenovirus type 5 penton gene is located between sequences 14156 and 15869. Penton base is the adenovirus capsid protein that mediates internalisation of the virus into the target cell. At least some serotypes (type C and B) have been shown to achieve this by interaction of an RGD sequence in penton with integrins on the cell surface.

[0108] However, type F adenoviruses do not have an RGD sequence and for most viruses of the A and D group the penton sequence is not known. Therefore, penton may be involved in target cell specificity. Furthermore, as a capsid protein, the penton protein is involved in the immunogenicity of the adenovirus (Gahery-Segard *et al.*, 1998). Therefore, replacement of Ad5 penton sequences with penton sequences from serotypes to which no or low titers of NAB exist in addition to replacement of the hexon sequences will prevent clearance of the adenoviral vector more efficiently than replacement of hexon alone. Replacement of penton sequences may also affect infection specificity.

10 [0109] To be able to introduce heterologous penton sequences in Ad5 we made use of the plasmid-based system described above.

[0110] First a shuttle vector for penton sequences was made by insertion of the 7.2 kb *NheI*-*EcoRV* fragment from construct pWE/Ad.AfIII-*EcoRI* into pBr322 digested with the same enzymes. The resulting vector was named pBr/XN. From this plasmid Ad5 penton sequences were deleted and replaced by unique restriction sites that are then used to introduce new penton sequences from other serotypes. Hereto, the left flanking sequences of penton in pBr/XN were PCR amplified using the following primers:

20 DP5-F: 5'- CTG TTG CTG CTG CTA ATA GC-3' and
DP5-R: 5'- CGC GGA TCC TGT **ACA** ACT AAG GGG AAT ACA AG-3'

[0111] DP5-R has an *Bam*HI site (underlined) for ligation to the right flanking sequence and also introduces a unique *Bsr*GI site (bold face) at the 5'-end of the former Ad5 penton region.

25 [0112] The right flanking sequence was amplified using:

DP3-F: 5'-CGC GGA TCC CTT **AAG** GCA AGC ATG TCC ATC CTT-3' and
DP3-3R: 5'- AAA ACA CGT TTT ACG CGT CGA CCT TTC-3'

30 [0113] DP3-F has an *Bam*HI site (underlined) for ligation to the left flanking sequence and also introduces a unique *Afl*III site (bold face) at the 3'-end of the former Ad5 penton region.

[0114] The two resulting PCR fragments were digested with *Bam*HI and ligated together. Then this ligation mixture was digested with *Avr*II and *Bgl*II. pBr/XN was also digested with *Avr*II and *Bgl*II and the vector fragment was ligated to the digested ligated PCR fragments. The resulting clone was named pBr/Ad.Δpenton. Penton coding sequences from Ad35, Ad34, Ad26 and Ad48 were PCR amplified such that the 5' and 3' ends contained the *Bsr*GI and *Afl*III sites respectively. Hereto, the following primers were used:

For Ad34 and Ad35:

40 P3-for: 5'-GCT CGA TGT ACA ATG AGG AGA CGA GCC GTG CTA-3'
P3-rev: 5'-GCT CGA CTT AAG TTA GAA AGT GCG GCT TGA AAG-3'

For Ad26 and Ad48:

45 P17F: 5'-GCT CGA TGT ACA ATG AGG CGT GCG GTG GTG TCT TC-3'
P17R: 5'-GCT CGA CTT AAG TTA GAA GGT GCG ACT GGA AAG C-3'

[0115] Amplified pcr products were digested with *Bfr*I and *Bsr*GI and cloned into pBr/Ad.Δpenton digested with the same enzymes.

50 [0116] Introduction of these heterologous penton sequences in pBr/Ad.Δpenton generated constructs named pBr/Ad.pentonXX where XX represents the number of the serotype corresponding to the serotype used to amplify the inserted penton sequences. Subsequently the new penton sequences were introduced in the a pWE/Ad.AfIII-rITR vector having a modified hexon. For example penton sequences from Ad35 were introduced in the construct pWE/Ad.AfIII-rITR-Hex35 by exchange of the common *Fse*I fragment. Other combinations of penton and hexon sequences were also made. Viruses with modified hexon and penton sequences were made as described above using cotransfection with an adapter plasmid on PER.C6 cells (ECACC deposit number 96022940). In addition, penton sequences were introduced in the pWE/Ad.AfIII-rITR construct. The latter constructs contain only a modified penton and viruses generated from these constructs will be used to study the contribution of penton sequences to the neutralisation of adenoviruses and

also for analysis of possible changes in infection efficiency and specificity.

Generation of fiber chimeric Ad5-based viruses

5 [0117] Adenovirus infection is mediated by two capsid proteins fiber and penton. Binding of the virus to the cells is achieved by interaction of the protruding fiber protein with a receptor on the cell surface. Internalisation then takes place after interaction of the penton protein with integrins on the cell surface. At least some adenovirus from subgroup C and B have been shown to use a different receptor for cell binding and therefore have different infection efficiencies on different cell types. Thus it is possible to change the infection spectrum of adenoviruses by changing the fiber in the capsid.

10 The fiber coding sequence of adenovirus serotype 5 is located between nucleotides 31042 and 32787. To remove the adenovirus serotype 5 DNA encoding fiber we started with construct pBr/Ad.Bam-riTR. First a NdeI site was removed from this construct. For this purpose, pBr322 plasmid DNA was digested with NdeI after which protruding ends were filled using Klenow enzym. This pBr322 plasmid was then religated, digested with NdeI and transformed into *E.coli* DH5 α . The obtained pBr/ Δ NdeI plasmid was digested with ScaI and Sall and the resulting 3198 bp vector fragment was

15 ligated to the 15349 bp ScaI-Sall fragment derived from pBr/Ad.BamriTR, resulting in plasmid pBr/Ad.Bam-riTR Δ NdeI which hence contained a unique NdeI site. Next a PCR was performed with oligonucleotides

NY-up:

20 5'-CGA CAT ATG TAG ATG CAT TAG TTT GTG TTA TGT TTC AAC GTG-3'

and

NY-down:

25 5'-GGA GAC CAC TGC CAT GTT-3'

[0118] During amplification, both a NdeI (bold face) and a NsiI restriction site (underlined) were introduced to facilitate cloning of the amplified fiber DNAs. Amplification consisted of 25 cycles of each 45 sec. at 94°C, 1 min. at 60°C, and 45 sec. at 72°C. The PCR reaction contained 25 pmol of oligonucleotides NY-up or NY-down, 2mM dNTP, PCR buffer with 1.5 mM MgCl₂, and 1 unit of Elongase heat stable polymerase (Gibco, The Netherlands). One-tenth of the PCR product was run on an agarose gel which demonstrated that the expected DNA fragment of \pm 2200 bp was amplified. This PCR fragment was subsequently purified using GeneClean kit system (Bio101 Inc.). Then, both the construct pBr/Ad.Bam-riTR Δ NdeI as well as the PCR product were digested with restriction enzymes NdeI and SbfI. The PCR fragment was subsequently cloned using T4 ligase enzyme into the NdeI and SbfI digested pBr/Ad.Bam-riTR Δ NdeI,

30 generating pBr/Ad.BamRAFib.

[0119] This plasmid allows insertion of any PCR amplified fiber sequence through the unique NdeI and NsiI sites that are inserted in place of the removed fiber sequence. Viruses can be generated by a double homologous recombination in packaging cells described in patent No. PCT/NL96/00244 using an adapter plasmid, construct pBr/Ad.AfIII-EcoRI digested with PacI and EcoRI and a pBr/Ad.BamRAFib construct in which heterologous fiber sequences have

40 been inserted. To increase the efficiency of virus generation, the construct pBr/Ad.BamRAFib was modified to generate a PacI site flanking the right ITR. Hereto, pBr/Ad.BamRAFib was digested with AvrII and the 5 kb adenofragment was isolated and introduced into the vector pBr/Ad.Bam-riTR.pac#8 described above replacing the corresponding AvrII fragment. The resulting construct was named pBr/Ad.BamRAFib.pac.

[0120] Once a heterologous fiber sequence is introduced in pBr/Ad.BamRAFib.pac, the fiber modified right hand adenovirus clone is introduced into a large cosmid clone as described above for pWE/Ad.AfIII-riTR. Such a large cosmid clone allows generation of adenovirus by only one homologous recombination. Ad5-based viruses with modified fibers have been made and described (nos. 98204482.8 and 99200624.7). In addition, hexon and penton sequences from serotypes from

[0121] this invention are combined with the desired fiber sequences to generate viruses which infect the target cell of choice very efficiently. For example smooth muscle cells, endothelial cells or synoviocytes all from human origin are very well infected with Ad5 based viruses with a fiber from subgroup B viruses especially adenovirus type 16.

50

[0122] The above described examples in which specific sequences can be deleted from the Ad5 backbone in the plasmids and replaced by corresponding sequences from other serotypes clearly show the flexibility of the system. It is evident that by the methods described above any combination of capsid gene from different serotypes can be made.

55 Thus, chimeric recombinant Ad5-based adenoviruses are designed with desired hexon and penton sequences making the virus less sensitive for neutralisation and with desired fiber sequences allowing efficient infection in specific target tissues.

Example 4

Construction of a plasmid-based system to generate Ad35 recombinant viruses

5 [0123] Partial restriction maps of Ad35 have been published previously (Valderrama-Leon *et al.*, 1985; Kang *et al.*, 1989; Li *et al.* 1991). An example of a functional plasmid-based system to generate recombinant adenoviruses based on Ad35 consists of the following elements:

- 10 1. An adapter plasmid comprising a left ITR and packaging sequences derived from Ad35 and at least one restriction site for insertion of an heterologous expression cassette and lacking E1 sequences. Furthermore, the adapter plasmid contains Ad35 sequences 3' from the E1B coding region including the pIX promoter and coding sequences sufficient to mediate homologous recombination of the adapter plasmid with a second nucleotide.
2. A second nucleotide comprising sequences homologous to the adapter plasmid and Ad35 sequences necessary for the replication and packaging of the recombinant virus, that is early, intermediate and late genes that are not
- 15 present in the packaging cell.
3. A packaging cell providing at least functional E1 proteins capable of complementing the E1 function of Ad35.

[0124] Ad35 DNA was isolated from a purified virus batch as follows. To 100 μ l of virus stock (Ad35: 3.26×10^{12} VP/ml) 10 μ l 10x DNase buffer (130 mM Tris-HCl pH7.5; 1,2 M CaCl_2 ; 50mM MgCl_2) was added. After addition of 10 μ l 10mg/ml DNase I (Roche Diagnostics) the mixture was incubated for 1 hr. at 37°C. Following addition of 2.5 μ l 0.5M EDTA, 3.2 μ l 20% SDS and 1.5 μ l ProteinaseK (Roche Diagnostics; 20mg/ml) samples were incubated at 50°C for 1 hr. Next, the viral DNA was isolated using the GeneClean spin kit (Bio101 Inc.) according to the manufacturers instructions. DNA was eluted from the spin column with 25 μ l sterile MilliQ water.

[0125] In the following sizes of DNA fragments and fragment numbering will be used according to Kang *et al.* (1989). Ad35 DNA was digested with EcoRI and the three fragments (approximately 22.3 (A), 7.3 (B) and 6 kb (C)) were isolated from gel using the GeneClean kit (Bio101, Inc.). pBr322 was digested with EcoRI or with EcoRI and EcoRV and digested fragments were isolated from gel and dephosphorylated with Tsap enzyme (Gibco BRL). Next, the 6 kb Ad35 C fragment was ligated to the pBr322xEcoRI fragment and the ITR-containing Ad35 fragment (EcoRI-B) was ligated to the pBr322xEcoRI/EcoRV fragment. Ligations were incubated at 16°C overnight and transformed into DH5 α competent bacteria (Life Techn.). Minipreps of obtained colonies were analysed for correct insertion of the Ad35 fragments by restriction analysis. Both the 6 kb and the 7.3 kb Ad35 fragment were found to be correctly inserted in pBr322. The 6kb fragment was isolated in both orientations pBr/Ad35-Eco6.0⁺ and pBr/Ad35-Eco6.0⁻ whereby the + stands for 5' to 3' orientation relative to pBr322. The clone with the 7.3 kb Ad35 B insert, named pBr/Ad35-Eco7.3 was partially sequenced to check correct ligation of the 3' ITR. It was found that the ITR had the sequence 5'- CATCATCAAT...-3' in the lower strand. Then pBr/Ad35-Eco7.3 was extended to the 5' end by insertion of the 6kb Ad35 fragment. Hereto, pBr/Ad35-Eco7.3 was digested with EcoRI and dephosphorylated. The fragment was isolated from gel and ligated to the 6kb Ad35 EcoRI fragment. After transformation clones were tested for correct orientation of the insert and one clone was selected, named pBr/Ad35-Eco13.3.

[0126] This clone is then extended with the ~5.4 kb Sall D fragment obtained after digestion of wt Ad35 with Sall. Hereto, the Sall site in the pBr322 backbone is removed by partial digestion of pBr/Ad35-Eco13.3 with Sall, filling in of the sticky ends by Klenow treatment and religation. One clone is selected that contains a single Sall site in the adenoviral insert. This clone, named pBr Δ Sall /Ad35-Eco13.3 is then linearised with AatII which is present in the pBr322 backbone and ligated to a Sall linker with AatII complementary ends. The DNA is then digested with excess Sall and the linear fragment is isolated and ligated to the 5.4 kb Sall-D fragment from Ad35. One clone is selected that contains the Sall fragment inserted in the correct orientation in pBr/Ad35-Eco13.3. The resulting clone, pBr/Ad35.Sall2-rITR contains the 3' ~17 kb of Ad35 including the right ITR. To enable liberation of the right ITR from the vector sequences at the time of virus generation, a NotI site flanking the right ITR is introduced by PCR.

[0127] The Ad35 EcoRI-A fragment of 22.3 kb was also cloned in pBr322xEcoRI/EcoRV. One clone, named pBr/Ad35-EcoA3', was selected that apparently had a deletion of approximately 7kb of the 5' end. It did contain the Sall site at 9.4 kb in Ad35 wt DNA and approximately 1.5 kb of sequences upstream. Using this Sall site and the unique NdeI site in the pBr322 backbone this clone is extended to the 5' end by insertion of an approximately 5 kb Ad35 fragment 5' from the first Sall in Ad35 in such a way that a NotI restriction site is created at the 5' end of the Ad35 by insertion of a linker.

[0128] This clone, named pBr/Ad35.pIX-EcoA does not contain the left end sequences (ITR, packaging sequences and E1) and at the 3' end it has approximately 3.5 kb overlap with clone pBr/Ad35.Sall2-rITR.

55 [0129] To create an adapter plasmid, Ad35 was digested with Sall and the left end B fragment of ~9.4 kb was isolated. pBr322 was digested with EcoRV and Sall, isolated from gel and dephosphorylated with Tsap enzyme. Both fragments are ligated and clones with correct insertion and correct sequence of the left ITR are selected. To enable

EP 1 054 064 A1

liberation of the left ITR from the vector sequences at the time of virus generation, a NotI site flanking the left ITR is introduced by PCR. From this clone the E1 sequences are deleted and replaced by a polylinker sequence using PCR. The polylinker sequence is used to introduce an expression cassette for a gene of choice.

5 [0130] Recombinant Ad35 clones are generated by transfection of PER.C6 cells with the adapter plasmid, pBr/Ad35.pIX-EcoA and pBr/Ad35.Sal2-rITR as shown in figure 3. Homologous recombination gives rise to recombinant viruses.

Example 5

10 *The prevalence of neutralizing activity (NA) to Ad35 is low in human sera from different geographic locations*

[0131] In example 1 we have described the analysis of neutralizing activity (NA) in human sera from one location in Belgium. Strikingly, of a panel of 44 adenovirus serotypes tested, one serotype, Ad35, was not neutralized in any of the 100 sera assayed. In addition, a few serotypes, Ad26, Ad34 and Ad48 were found to be neutralized in 8%, or less, of the sera tested. This analysis was further extended to other serotypes of adenovirus not previously tested and, using a selection of serotypes from the first screen, was also extended to sera from different geographic locations.

15 [0132] Hereto, adenoviruses were propagated, purified and tested for neutralization in the CPE-inhibition assay as described in example 1. Using the sera from the same batch as in example 1, adenovirus serotypes 7B, 11, 14, 18 and 44/1876 were tested for neutralization. These viruses were found to be neutralized in respectively 59, 13, 30, 98 and 54 % of the sera. Thus, of this series Ad11 is neutralized with a relatively low frequency.

20 [0133] Since it is known that the frequency of isolation of adenovirus serotypes from human tissue as well as the prevalence of NA to adenovirus serotypes may differ on different geographic locations, we further tested a selection of the adenovirus serotypes against sera from different places. Human sera were obtained from two additional places in Europe (Bristol, UK and Leiden, The Netherlands) and from two places in the United States (Stanford, CA and Great Neck, NY). Adenoviruses that were found to be neutralized in 20% or less of the sera in the first screen, as well as Ad2, Ad5, Ad27, Ad30, Ad38, Ad43, were tested for neutralization in sera from the UK. The results of these experiments are presented in Figure 4.

25 [0134] Adenovirus serotypes 2 and 5 were again neutralized in a high percentage of human sera. Furthermore, some of the serotypes that were neutralized in a low percentage of sera in the first screen are neutralized in a higher percentage of sera from the UK, e.g. Ad26 (7% vs. 30%), Ad28 (13% vs. 50%), Ad34 (5% vs. 27%) and Ad48 (8% vs. 32%). Neutralizing activity against Ad11 and Ad49 that were found in a relatively low percentage of sera in the first screen, are found in an even lower percentage of sera in this second screen (13% vs. 5% and 20% vs. 11% respectively). Serotype Ad35 that was not neutralized in any of the sera in the first screen, was now found to be neutralized in a low percentage (8%) of sera from the UK. The prevalence of NA in human sera from the UK is the lowest to serotypes Ad11 and Ad35.

30 [0135] For further analysis, sera were obtained from two locations in the US (Stanford, CA and Great Neck, NY) and from the Netherlands (Leiden). Figure 5 presents an overview of data obtained with these sera and the previous data. Not all viruses were tested in all sera, except for Ad5, Ad11 and Ad35. The overall conclusion from this comprehensive screen of human sera is that the prevalence of neutralizing activity to Ad35 is the lowest of all serotypes throughout the western countries: on average 7% of the human sera contain neutralizing activity (5 different locations).

35 [0136] Another B-group adenovirus, Ad11 is also neutralized in a low percentage of human sera (average 11% in sera from 5 different locations). Adenovirus type 5 is neutralized in 56% of the human sera obtained from 5 different locations.

40 [0137] Although not tested in all sera, D-group serotype 49 is also neutralized with relatively low frequency in samples from Europe and from one location of the US (average 14%).

[0138] In the above described neutralization experiments a serum is judged non-neutralizing when in the well with the highest serum concentration the maximum protection of CPE is 40% compared to the controls without serum. The protection is calculated as follows:

45
$$\% \text{ protection} = \frac{\text{OD corresponding well} - \text{OD virus control}}{\text{OD non-infected control} - \text{OD virus control}} \times 100\%$$

50 [0139] As described in example 1, the serum is plated in five different dilutions ranging from 4x to 64x diluted.

[0140] Therefore, it is possible to distinguish between low titers (i.e. neutralization only in the highest serum concentrations) and high titers of NA (i.e. also neutralization in wells with the lowest serum concentration). Of the human sera used in our screen that were found to contain neutralizing activity to Ad5, 70% turned out to have high titers whereas of the sera that contained NA to Ad35, only 15% had high titers. Of the sera that were positive for NA to Ad11 only 8% had high titers.

[0141] For Ad49 this was 5%. Therefore, not only is the frequency of NA to Ad35, Ad11 and Ad49 much lower as

compared to Ad5, but of the sera that do contain NA to these viruses, the vast majority has low titers. Adenoviral vectors based on Ad11, Ad35 or Ad49 have therefore a clear advantage over Ad5 based vectors when used as gene therapy vehicles or vaccination vectors *in vivo* or in any application where infection efficiency is hampered by neutralizing activity.

- 5 [0142] In the following examples the construction of a vector system for the generation of safe, RCA-free Ad35-based vectors is described.

Example 6

10 Sequence of the human adenovirus type 35

[0143] Ad35 viruses were propagated on PER.C6 cells and DNA was isolated as described in example 4. The total sequence was generated by Qiagen Sequence Services (Qiagen GmbH, Germany). Total viral DNA was sheared by sonification and the ends of the DNA were made blunt by T4 DNA polymerase.

- 15 [0144] Sheared blunt fragments were size fractionated on agarose gels and gel slices corresponding to DNA fragments of 1.8 to 2.2 kb were obtained. DNA was purified from the gel slices by the QIAquick gel extraction protocol and subcloned into a shotgun library of pUC19 plasmid cloning vectors. An array of clones in 96-wells plates covering the target DNA 8 (+/-2) times was used to generate the total sequence. Sequencing was performed on Perkin-Elmer 9700 thermo cyclers using BigDyeTerminator chemistry and AmpliTaq FS DNA polymerase followed by purification of
20 sequencing reactions using QIAGEN DyeEx 96 technology. Sequencing reaction products were then subjected to automated separation and detection of fragments on ABI 377 XL 96 lane sequencers. Initial sequence contig sequence and gaps were filled in by primer walking reads on the target DNA or by direct sequencing of PCR products. The ends of the virus turned out to be absent in the shotgun library, most probably due to cloning difficulties resulting from the amino acids of pTP that remain bound to the ITR sequences after proteinase K digestion of the viral DNA.

- 25 [0145] Additional sequence runs on viral DNA solved most of the sequence in those regions, however it was difficult to obtain a clear sequence of the most terminal nucleotides. At the 5' end the sequence obtained was 5'-CCAATAATATACCT...-3' while at the 3' end the obtained sequence was 5'-...AGGTATATTATTGATGATGGG-3'. Most human adenoviruses have a terminal sequence 5'-CATCATCAATAATATACC-3'. In addition, a clone representing the 3' end of the Ad35 DNA obtained after cloning the terminal 7 kb Ad35 EcoRI fragment into pBr322 (see example 4) also
30 turned out to have the typical CATCATCAATAAT... sequence. Therefore, Ad35 may have the typical end sequence and the differences obtained in sequencing directly on the viral DNA are due to artefacts correlated with run-off sequence runs and the presence of residual amino acids of pTP.

- [0146] The total sequence of Ad35 with corrected terminal sequences is given in Figure 6. Based sequence homology with Ad5 (genbank # M72360) and Ad7 (partial sequence Genbank # X03000) and on the location of open reading
35 frames, the organization of the virus is identical to the general organization of most human adenoviruses, especially the subgroup B viruses. The total length of the genome is 34794 basepairs.

Example 7

40 Construction of a plasmid-based vector system to generate recombinant Ad35-based viruses.

[0147] A functional plasmid-based vector system to generate recombinant adenoviral vectors comprises the following components:

- 45 1. An adapter plasmid comprising a left ITR and packaging sequences derived from Ad35 and at least one restriction site for insertion of an heterologous expression cassette and lacking E1 sequences. Furthermore, the adapter plasmid contains Ad35 sequences 3' from the E1B coding region including the pIX promoter and coding sequences enough to mediate homologous recombination of the adapter plasmid with a second nucleic acid molecule.
50 2. A second nucleic acid molecule, comprising sequences homologous to the adapter plasmid, and Ad35 sequences necessary for the replication and packaging of the recombinant virus, that is early, intermediate and late genes that are not present in the packaging cell.
3. A packaging cell providing at least functional E1 proteins capable of complementing the E1 function of Ad35.

- 55 [0148] Other methods for the generation of recombinant adenoviruses on complementing packaging cells are known in the art and may be applied to Ad35 viruses without departing from the invention. As an example, the construction of a plasmid based system, as outlined above, is described in detail below.

1) Construction of Ad35 adapter plasmids.

[0149] Hereto, the adapter plasmid pAdApt (Figure 7; described in example 2) was first modified to obtain adapter plasmids that contain extended polylinkers and that have convenient unique restriction sites flanking the left ITR and the adenovirus sequence at the 3' end to enable liberation of the adenovirus insert from plasmid vector sequences. Construction of these plasmids is described below in detail: Adapter plasmid pAdApt (Example 2) was digested with Sall and treated with Shrimp Alkaline Phosphatase to reduce religation. A linker, composed of the following two phosphorylated and annealed oligo's: ExSalPacF 5' - TCG ATG GCA AAC AGC TAT TAT GGG TAT TAT GGG TTC GAA TTA ATT AA- 3'; and ExSalPacR 5' - TCG ATT AAT TAA TTC GAA CCC ATA ATA CCC ATA ATA GCT GTT TGC CA- 3'; was directly ligated into the digested construct, thereby replacing the Sall restriction site by Pi-PspI, SwaI and PacI. This construct was named pADAPT+ExSalPac linker. Furthermore, part of the left ITR of pAdApt was amplified by PCR using the following primers: PCLIPMSF: 5'- CCC CAA TTG GTC GAC CAT CAT CAA TAA TAT ACC TTA TTT TGG -3' and pCLIPBSRG1: 5'- GCG AAA ATT GTC ACT TCC TGT G - 3'. The amplified fragment was digested with MunI and BsrGI and cloned into pAd5/Clip (see Example 2), which was partially digested with EcoRI and after purification digested with BsrGI, thereby re-inserting the left ITR and packaging signal. After restriction enzyme analysis, the construct was digested with Scal and SgrAI and an 800 bp fragment was isolated from gel and ligated into Scal/SgrAI digested pADAPT+ExSalPac linker. The resulting construct, named pIPspSalAdapt, was digested with Sall, dephosphorylated, and ligated to the phosphorylated ExSalPacF/ExSalPacR doublestranded linker mentioned above. A clone in which the PacI site was closest to the ITR was identified by restriction analysis and sequences were confirmed by sequence analysis. This novel pAdApt construct, termed pIPspAdapt (Figure 8) thus harbors two ExSalPac linkers containing recognition sequences for PacI, PI-PspI and BstBI, which surround the adenoviral part of the adenoviral adapter construct, and which can be used to linearize the plasmid DNA prior to cotransfection with adenoviral helper fragments.

[0150] In order to further increase transgene cloning permutations a number of polylinker variants were constructed based on pIPspAdapt. For this purpose pIPspAdapt was first digested with EcoRI and dephosphorylated. A linker composed of the following two phosphorylated and annealed oligo's:

Ecolinker+: 5' -AAT TCG GCG CGC CGT CGA CGA TAT CGA TAG CGG CCG C -3' and Ecolinker-: 5' -AAT TGC GGC CGC TAT CGA TAT CGT CGA CGG CGC GCC G -3' was ligated into this construct, thereby creating restriction sites for AscI, Sall, EcoRV, ClaI and NotI. Both orientations of this linker were obtained and sequences were confirmed by restriction analysis and sequence analysis. The plasmid containing the polylinker in the order 5' HindIII, KpnI, AgeI, EcoRI, AscI, Sall, EcoRV, ClaI, NotI, NheI, HpaI, BamHI and XbaI was termed pIPspAdapt1 (Figure 9) while the plasmid containing the polylinker in the order HindIII, KpnI, AgeI, NotI, ClaI, EcoRV, Sall, AscI, EcoRI, NheI, HpaI, BamHI and XbaI was termed pIPspAdapt2.

[0151] To facilitate the cloning of other sense or antisense constructs, a linker composed of the following two oligonucleotides was designed, to reverse the polylinker of pIPspAdapt: HindXba+ 5'-AGC TCT AGA GGA TCC GTT AAC GCT AGC GAA TTC ACC GGT ACC AAG CTT A-3'; HindXba- 5'-CTA GTA AGC TTG GTA CCG GTG AAT TCG CTA GCG TTA ACG GAT CCT CTA G-3'.

[0152] This linker was ligated into HindIII/XbaI digested pIPspAdapt and the correct construct was isolated.

[0153] Confirmation was done by restriction enzyme analysis and sequencing. This new construct, pIPspAdaptA, was digested with EcoRI and the above mentioned Ecolinker was ligated into this construct. Both orientations of this linker were obtained, resulting in pIPspAdapt3 (Figure 10), which contains the polylinker in the order XbaI, BamHI, HpaI, NheI, EcoRI, AscI, Sall, EcoRV, ClaI, NotI, AgeI, KpnI and HindIII. All sequences were confirmed by restriction enzyme analysis and sequencing.

[0154] Adapter plasmids based on Ad35 were then constructed as follows:

[0155] The left ITR and packaging sequence corresponding to Ad35 wt sequences nucleotides 1 to 464 (Figure 6) were amplified by PCR on wtAd35 DNA using the following primers:

Primer 35F1:

5'-CGG AAT TCT TAA TTA ATC GAC ATC ATC AAT AAT ATA CCT TAT AG-3'

Primer 35R2:

5'-GGT GGT CCT AGG CTG ACA CCT ACG TAA AAA CAG-3'

[0156] Amplification introduces a PacI site at the 5' end and an AvrII site at the 3' end of the sequence.

[0157] For the amplification Platinum Pfx DNA polymerase enzyme (LTI) was used according to manufacturers instructions but with primers at 0.6 μ M and with DMSO added to a final concentration of 3%. Amplification program was as follows: 2 min. at 94°C, (30 sec. 94°C, 30 sec. at 56°C, 1 min. at 68°C) for 30 cycles, followed by 10 min. at 68°C.

EP 1 054 064 A1

[0158] The PCR product was purified using a PCR purification kit (LTI) according to the manufacturer's instructions and digested with *PacI* and *AvrII*. The digested fragment was then purified from gel using the GeneClean kit (Bio 101, Inc.).

[0159] The Ad5-based adapter plasmid pIPspAdApt-3 (Figure 10) was digested with *AvrII* and then partially with *PacI* and the 5762 bp fragment was isolated in an LMP agarose gel slice and ligated with the abovementioned PCR fragment digested with the same enzymes and transformed into electrocompetent DH10B cells (LTI). The resulting clone is named pIPspAdApt3-Ad35lTR.

[0160] In parallel, a second piece of Ad35 DNA was amplified using the following primers:

35F3: 5'- TGG TGG AGA TCT GGT GAG TAT TGG GAA AAC-3'
35R4: 5'- CGG AAT TCT TAA TTA AGG GAA ATG CAA ATC TGT GAG G-3'

[0161] The sequence of this fragment corresponds to nucl. 3401 to 4669 of wtAd35 (Figure 6) and contains 1.3 kb of sequences starting directly 3' from the E1B 55k coding sequence.

[0162] Amplification and purification was done as described above for the fragment containing the left ITR and packaging sequence. The PCR fragment was then digested with *PacI* and subcloned into pNEB193 vector (New England Biolabs) digested with *SmaI* and *PacI*. The integrity of the sequence of the resulting clone was checked by sequence analysis.

[0163] pNEB/Ad35pF3R4 was then digested with *BglII* and *PacI* and the Ad35 insert was isolated from gel using the QIAexII kit (Qiagen). pIPspAdApt3-Ad35lTR was digested with *BglII* and then partially with *PacI*. The 3624 bp fragment (containing vector sequences, the Ad35 ITR and packaging sequences as well as the CMV promoter, multiple cloning region and polyA signal), was also isolated using the QIAexII kit (Qiagen).

[0164] Both fragments were ligated and transformed into competent DH10B cells (LTI). The resulting clone, pAdApt35IP3 (Figure 11), has the expression cassette from pIPspAdApt3 but contains the Ad35 left ITR and packaging sequences and a second fragment corresponding to nucl. 3401 to 4669 from Ad35. A second version of the Ad35 adapter plasmid having the multiple cloning site in the opposite orientation was made as follows:

pIPspAdapt1 (Figure 9) was digested with *NdeI* and *BglII* and the 0.7 kbp band containing part of the CMV promoter, the MCS and SV40 polyA was isolated and inserted in the corresponding sites of pAdApt35IP3 generating pAdApt35IP1 (Figure 12).

pAdApt35.LacZ and pAdApt35.Luc adapter plasmids were then generated by inserting the transgenes from pcDNA.LacZ (digested with *KpnI* and *BamHI*) and pAdApt.Luc (digested with *HindIII* and *BamHI*) into the corresponding sites in pAdApt35IP1. The generation of pcDNA.LacZ and pAdApt.Luc is described in WO99/55132.

2) Construction of cosmid pWE.Ad35.pXI-rTR

[0165] Figure 13 presents the various steps undertaken to construct the cosmid clone containing Ad35 sequences from bp 3401 to 34794 (end of the right ITR) that are described in detail below.

[0166] A first PCR fragment (pIX-NdeI) was generated using the following primer set:

35F5: 5'-CGG AAT TCG CGG CCG CGG TGA GTA TTG GGA AAA C -3'
35R6: 5'-CGC CAG ATC GTC TAC AGA ACA G-3'

[0167] DNA polymerase Pwo (Roche) was used according to manufacturer's instructions, however, with an endconcentration of 0.6 μ M of both primers and using 50 ngr wt Ad35 DNA as template.

[0168] Amplification was done as follows: 2 min. at 94 °C, 30 cycles of 30 sec. at 94 °C, 30 sec. at 65 °C and 1 min. 45 sec. at 72 °C, followed by 8 min. at 68 °C. To enable cloning in the TA cloning vector PCR2.1, a last incubation with 1 unit superTaq polymerase (HT Biotechnology LTD) for 10 min. at 72 °C was performed.

[0169] The 3370 bp amplified fragment contains Ad35 sequences from bp 3401 to 6772 with a *NotI* site added to the 5' end.

[0170] Fragments were purified using the PCR purification kit (LTI).

[0171] A second PCR fragment (*NdeI*-rTR) was generated using the following primers:

35F7: 5'-GAA TGC TGG CTT CAG TTG TAA TC -3'
35R8: 5'- CGG AAT TCG CGG CCG CAT TTA AAT CAT CAT CAA TAA TAT ACC-3'

[0172] Amplification was done with pfx DNA polymerase (LTI) according to manufacturer's instructions but with 0.6 μ M of both primers and 3% DMSO using 10 ngr. of wtAd35 DNA as template. The program was as follows:

EP 1 054 064 A1

3 min. at 94 °C and 5 cycles of 30 sec. at 94 °C, 45 sec. at 40 °C, 2 min.45 sec. at 68 °C followed by 25 cycles of 30 sec. at 94 °C, 30 sec. at 60 °C, 2 min.45 sec. at 68 °C. To enable cloning in the TA-cloning vector PCR2.1, a last incubation with 1 unit superTag polymerase for 10 min. at 72 °C was performed. The 1.6 kb amplified fragment ranging from nucl. 33178 to the end of the right ITR of Ad35, was purified using the PCR purification kit (LTI).

5 [0173] Both purified PCR fragments were ligated into the PCR2.1 vector of the TA-cloning kit (Invitrogen) and transformed into STBL-2 competent cells (LTI). Clones containing the expected insert were sequenced to confirm correct amplification. Next, both fragments were excised from the vector by digestion with NotI and NdeI and purified from gel using the geneClean kit (BIO 101, Inc.). Cosmid vector pWE15 (Clontech) was digested with NotI, dephosphorylated and also purified from gel. These three fragments were ligated and transformed into STBL2 competent cells (LTI). One of the correct clones that contained both PCR fragments was then digested with NdeI and the linear fragment was purified from gel using the geneClean kit. Ad35 wtDNA was digested with NdeI and the 26.6 kb fragment was purified from LMP gel using agarase enzyme (Roche) according to the manufacturers instructions. These fragments were ligated together and packaged using λ phage packaging extracts (Stratagene) according to the manufacturer's protocol. After infection into STBL-2 cells, colonies were grown on plates and analyzed for presence of the complete insert. One clone with the large fragment inserted in the correct orientation and having the correct restriction patterns after independent digestions with three enzymes (NcoI, PvuII and ScaI) was selected. This clone is named pWE.Ad35.pIX-rITR. It contains the Ad35 sequences from bp 3401 to the end and is flanked by NotI sites (Figure 14).

3) Generation of Ad35 based recombinant viruses on PER.C6.

20 [0174] Wild type Ad35 virus can be grown on PER.C6 packaging cells to very high titers. However, whether the Ad5-E1 region that is present in PER.C6 is able to complement E1-deleted Ad35 recombinant viruses is unknown. To test this, PER.C6 cells were cotransfected with the above described adapter plasmid pAdApt35.LacZ and the large backbone fragment pWE.Ad35.pIX-rITR. First, pAdApt35.LacZ was digested with PacI and pWE.Ad35.pIX-rITR was digested with NotI. Without further purification 4 μ g of each construct was mixed with DMEM (LTI) and transfected into PER.C6 cells, seeded at a density of 5×10^6 cells in a T25 flask the day before, using Lipofectamin (LTI) according to the manufacturers instructions. As a positive control, 6 μ g of PacI digested pWE.Ad35.pIX-rITR DNA was cotransfected with a 6.7 kb NheI fragment isolated from Ad35 wt DNA containing the left end of the viral genome including the E1 region.

30 [0175] The next day medium (DMEM with 10% FBS and 10mM $MgCl_2$) was refreshed and cells were further incubated. At day 2 following the transfection, cells were trypsinized and transferred to T80 flasks. The positive control flask showed CPE at five days following the transfection, showing that the pWE.Ad35.pIX-rITR construct is functional at least in the presence of Ad35-E1 proteins. The transfection with the Ad35 LacZ adapter plasmid and pWE.Ad35.pIX-rITR did not give rise to CPE. These cells were harvested in the medium at day 10 and freeze/thawed once to release virus from the cells. 4 ml of the harvested material was added to a T80 flask with PER.C6 cells (at 80% confluency) and incubated for another five days. This harvest/re-infection was repeated for two times but there was no evidence for virus associated CPE.

40 [0176] From this experiment it seems that the Ad5-E1 proteins are not, or not well enough, capable of complementing Ad35 recombinant viruses, however, it may be that the sequence overlap of the adapter plasmid and the pWE.Ad35.pIX-rITR backbone plasmid is not large enough to efficiently recombine and give rise to a recombinant virus genome. The positive control transfection was done with a 6.7 kb left end fragment and therefore the sequence overlap was about 3.5 kb. The adapter plasmid and the pWE.Ad35.pIX-rITR fragment have a sequence overlap of 1.3 kb. To check whether the sequence overlap of 1.3 kb is too small for efficient homologous recombination, a cotransfection was done with PacI digested pWE.Ad35.pIX-rITR and a PCR fragment of Ad35 wtDNA generated with the above mentioned 35F1 and 35R4 using the same procedures as described before. The PCR fragment thus contains left end sequences up to bp 4669 and therefore has the same overlap sequences with pWE.Ad35.pIX-rITR as the adapter plasmid pAdApt35.LacZ but has Ad35 E1 sequences.

50 [0177] Following PCR column purification, the DNA was digested with Sall to remove possible intact template sequences. A transfection with the digested PCR product alone served as a negative control. Four days after the transfection, CPE occurred in the cells transfected with the PCR product and the Ad35 pIX-rITR fragment, and not in the negative control.

[0178] This shows that 1.3 kb overlapping sequences is sufficient to generate viruses in the presence of Ad35 E1 proteins.

55 [0179] From these experiments we conclude that the presence of at least one of the Ad35.E1 proteins is necessary to generate recombinant Ad35 based vectors from plasmid DNA on Ad5 complementing cell lines.

Example 8

1) Construction of Ad35.E1 expression plasmids

5 [0180] Since Ad5-E1 proteins in PER.C6 are not capable of complementing Ad35 recombinant viruses efficiently, Ad35 E1 proteins have to be expressed in Ad5 complementing cells (e.g. PER.C6) or a new packaging cell line expressing Ad35 E1 proteins has to be made, starting from either diploid primary human cells or established cell lines not expressing adenovirus E1 proteins. To address the first possibility, the Ad35 E1 region was cloned in expression plasmids as described below.

10 [0181] First, the Ad35 E1 region from bp 468 to bp 3400 was amplified from wtAd35 DNA using the following primer set:

35F11: 5'-GGG GTA CCG AAT TCT CGC TAG GGT ATT TAT ACC-3'
35F10: 5'-GCT CTA GAC CTG CAG GTT AGT CAG TTT CTT CTC CAC TG-3'

15 [0182] This PCR introduces a KpnI and EcoRI site at the 5' end and a SbfI and XbaI site at the 3' end.
[0183] Amplification on 5 ngr. template DNA was done with Pwo DNA polymerase (Roche) using manufacturers instructions, however, with both primers at a final concentration of 0.6 µM. The program was as follows: 2 min. at 94 °C, 5 cycles of 30 sec. at 94 °C, 30 sec. at 56 °C and 2 min. at 72 °C, followed by 25 cycles of 30 sec. at 94 °C, 30 sec. at 20 60 °C and 2 min. at 72 °C, followed by 10 min. at 72 °C. PCR product was purified by a PCR purification kit (LTI) and digested with KpnI and XbaI. The digested PCR fragment was then ligated to the expression vector pRSVhvbvNeo (see below), also digested with KpnI and XbaI. Ligations were transformed into competent STBL-2 cells (LTI) according to manufacturers instructions and colonies were analysed for the correct insertion of Ad35E1 sequences into the polylinker in between the RSV promoter and HBV polyA.

25 [0184] The resulting clone was named pRSV.Ad35-E1 (Figure 15). The Ad35 sequences in pRSV.Ad35-E1 were checked by sequence analysis.

[0185] pRSVhvbvNeo was generated as follows: pRc-RSV (Invitrogen) was digested with PvuII, dephosphorylated with TSAP enzyme (LTI) and the 3 kb vector fragment was isolated in low melting point agarose (LMP). Plasma pPG-KneopA (Figure 16; described in WO96/35798, was digested with SspI completely to linearise the plasmid and facilitate partial digestion with PvuII. Following the partial digestion with PvuII, the resulting fragments were separated on a LMP 30 agarose gel and the 2245 bp PvuII fragment, containing the PGK promoter, neomycine resistance gene and HBVpolyA, was isolated. Both isolated fragments were ligated to give the expression vector pRSV-pNeo that now has the original SV40prom-neo-SV40polyA expression cassette replaced by a PGKprom-neo-HBVpolyA cassette (Figure 17). This plasmid was further modified to replace the BGHpA with the HBVpA as follows: pRSVpNeo was linearised with Scal 35 and further digested with XbaI. The 1145 bp fragment, containing part of the Amp gene and the RSV promoter sequences and polylinker sequence, was isolated from gel using the GeneClean kit (Bio Inc. 101).

[0186] Next pRSVpNeo was linearised with Scal and further digested with EcoRI partially and the 3704 bp fragment containing the PGKneo cassette and the vector sequences were isolated from gel as above. A third fragment, containing the HBV polyA sequence flanked by XbaI and EcoRI at the 5' and 3' end respectively, was then generated 40 by PCR amplification on pRSVpNeo using the following primer set:

HBV-F: 5'- GGC TCT AGA GAT CCT TCG CGG GAC GTC -3' and
HBV-R: 5'- GGC GAA TTC ACT GCC TTC CAC CAA GC -3'.

45 [0187] Amplification was done with Elongase enzyme (LTI) according to the manufacturers instructions with the following conditions: 30 seconds at 94°C, then 5 cycles of 45 seconds at 94 °C, 1 minute at 42 °C and 1 minute 68 °C, followed by 30 cycles of 45 seconds at 94 °C, 1 minute at 65 °C and 1 minute at 68 °C, followed by 10 minutes at 68 °C. The 625 bp PCR fragment was then purified using the Qiaquick PCR purification kit, digested with EcoRI and XbaI and purified from gel using the GeneClean kit. The three isolated fragments were ligated and transformed into DH5α competent cells (LTI) to give the construct pRSVhvbvNeo (Figure 18). In this construct the transcription regulatory regions of 50 the RSV expression cassette and the neomycine selection marker are modified to reduce overlap with adenoviral vectors that often contain CMV and SV40 transcription regulatory sequences.

2) Generation of Ad35 recombinant viruses on PER.C6 cells cotransfected with an Ad35-E1 expression construct.

55 [0188] PER.C6 cells were seeded at a density of 5×10^6 cells in a T25 flask and the next day transfected with a DNA mixture containing:

- 1 µg pAdApt35.LacZ digested with PacI
- 5 µg pRSV.Ad35E1 undigested
- 2 µg pWE.Ad35.pIX-rITR digested with NotI

5 [0189] Transfection was done using Lipofectamine according to the manufacturers instructions. Five hours after addition of the transfection mixture to the cells, medium was removed and replaced by fresh medium. After two days cells were transferred to T80 flasks and further cultured. One week post-transfection 1 ml of the medium was added to A549 cells and the following day cells were stained for LacZ expression. Blue cells were clearly visible after two hours of staining indicating that recombinant LacZ expressing viruses were produced. The cells were further cultured but no clear appearance of CPE was noted. However, after 12 days clumps of cells appeared in the monolayer and 18 days following transfection cells were detached. Cells and medium were then harvested, freeze-thawed once and 1 ml of the crude lysate was used to infect PER.C6 cells in a 6-well plate. Two days after infection cells were stained for LacZ activity. After two hours 15% of the cells were stained blue. To test for the presence of wt and / or replicating competent viruses, A549 cells were infected with these viruses and further cultured. No signs of CPE were found indicating the absence of replication competent viruses.

15 [0190] These experiments show that recombinant AdApt35.LacZ viruses were made on PER.C6 cells cotransfected with an Ad35-E1 expression construct.

3) Ad35 recombinant viruses escape neutralization in human serum containing neutralizing activity to Ad5 viruses.

20 [0191] The AdApt35.LacZ viruses were then used to investigate infection in the presence of serum that contains neutralizing activity to Ad5 viruses. Purified Ad5-based LacZ virus served as a positive control for NA. Hereto, PER.C6 cells were seeded in a 24-wells plate at a density of 2×10^5 cells/well. The next day a human serum sample with high neutralizing activity to Ad5 was diluted in culture medium in five steps of five times dilutions. 0.5 ml of diluted serum was then mixed with 4×10^6 virus particles AdApt5.LacZ virus in 0.5 ml medium and after 30 minutes of incubation at 37 °C, 0.5 ml of the mixture was added to PER.C6 cells in duplicate. For the AdApt35.LacZ viruses, 0.5 ml of the diluted serum samples were mixed with 0.5 ml crude lysate containing AdApt35.LacZ virus and after incubation 0.5 ml of this mixture was added to PER.C6 cells in duplo.

30 [0192] Virus samples incubated in medium without serum was used as a positive control for infection. After two hours of infection at 37 °C, medium was added to reach a final volume of 1 ml and cells were further incubated. Two days after infection cells were stained for LacZ activity. The results are shown in Table II. From these results it is clear that whereas AdApt5.LacZ viruses are efficiently neutralized, AdApt35.LacZ viruses remain infectious irrespective of the presence of human serum. This proves that recombinant Ad35-based viruses escape neutralization in human sera that contain NA to Ad5-based viruses.

Example 9:

An Ad5/fiber35 chimeric vector with cell type specificity for hemopoietic CD34 Lin stem cells

40 [0193] In example 3 we have described the generation of a library of Ad5 based adenoviruses harboring fiber proteins of other serotypes. As a non-limiting example for the use of this library we here describe the identification of fiber-modified adenoviruses that show improved infection of hemopoietic stem cells.

45 [0194] Cells isolated from human bone marrow, umbilical cord blood, or mobilized peripheral blood carrying the flow cytometric phenotype of being positive for the CD34 antigen and negative for the early differentiation markers CD33, CD38, and CD71 (lin) are commonly referred to as hemopoietic stem cells (HSC). Genetic modification of these cells is of major interest since all hemopoietic lineages are derived from these cells and therefore the HSC is a target cell for the treatment of many acquired or congenital human hemopoietic disorders. Examples of diseases that are amendable for genetic modification of HSC, but not limited to, include Hurlers disease, Hunters disease, Sanfilippo disease, Morquio disease, Gaucher disease, Farbers disease, Niemann-Pick disease, Krabbe disease, Metachromatic Leucodystrophy, I-cell disease, severe immunodeficiency syndrome, Jak-3 deficiency, Fucosidose deficiency, thalassemia, and erythropoietic porphyria. Besides these hemopoietic disorders also strategies to prevent or treat acquired immunodeficiency syndrome (AIDS) and hemopoietic cancers are based on the genetic modification of HSCs or cells derived from the HSCs such as CD4 positive T lymphocytes in case of AIDS. The examples listed above thus aim at introducing DNA into the HSC in order to complement on a genetic level for a gene and protein deficiency. In case of strategies for AIDS or cancer, the DNA to be introduced into the HSC can be anti-viral genes or suicide genes.

55 [0195] Besides the examples listed above, there are several other areas in which efficient transduction of HSCs using adenoviral vectors plays an important role. For instance in the field of tissue engineering. In this area it is important to drive differentiation of HSCs to specific lineages. Some, non-limiting, examples are *ex vivo* bone formation, car-

tilage formation, skin formation, as well as the generation of T-cell precursors or endothelial cell precursors. The generation of bone, cartilage or skin in bioreactors can be used for transplantation after bone fractures or spinal cord lesions or severe burn injuries.

[0196] Naturally, transduced cells can also directly be re-infused into a patient. The formation of large numbers of endothelial cell precursor from HSCs is of interest since these endothelial precursors cells can home, after re-infusion, to sites of cardiovascular injury such as ischemia. Likewise, the formation of large numbers of T-cells from HSCs is of interest since these T-cell precursors can be primed, *ex vivo*, to eradicate certain targets in the human body after reinfusion of the primed T-cells. Preferred targets in the human body can be tumours or virus infected cells.

[0197] From the examples described above, it can be concluded that efficient gene delivery to HSCs is a major interest for the field of gene therapy. Therefore, alteration of the adenovirus serotype 5 host cell range to be able to target HSCs *in vitro* as well as *in vivo* is a major interest of the invention. To identify a chimeric adenovirus with preferred infection characteristics for human HSCs, we generated a library of Ad5 based viruses carrying the fiber molecule from alternative serotypes (serotypes 8, 9, 13, 16, 17, 32, 35, 45, 40-L, 51). The generation of this fiber modified library is described in example 3. Ad5 was taken along as a reference. A small panel of this library was tested on human TF-1 (erythroidleukemia, ATCC CRL-2003) whereas all chimaeric viruses generated were tested on human primary stroma cells and human HSCs. Human TF-1 cell were routinely maintained in DMEM supplemented with 10% FCS and 50 ng/ml IL-3 (Sandoz, Basel, Switzerland). Human primary fibroblast-like stroma, isolated from a bone marrow aspirate, is routinely maintained in DMEM/ 10% FCS. Stroma was seeded at a concentration of 1×10^5 cells per well of 24-well plates. 24 hours after seeding cells were exposed for 2 hours to 1000 virus particles per cell of Ad5, Ad5.Fib16, Ad5.Fib17, Ad5.Fib35, Ad5.Fib40-L, or Ad5.Fib51 all carrying the green fluorescent protein (GFP) as a marker. After 2 hours cells were washed with PBS and reseeded in medium without addition of virus. TF-1 cells were seeded at a concentration of 2×10^5 cells per well of 24-well plates and were also exposed for 2 hours to 1000 virus particles of the different chimeric adenoviruses. Virus was removed by washing the cells after the 2 hours exposure. Both cell types were harvested 48 hours after virus exposure and analysed for GFP expression using a flow cytometer. The results on TF-1 cells, shown in figure 19, demonstrates that chimeric adenoviruses carrying a fiber from serotypes 16, 35, or 51 (all derived from adenovirus subgroup B) have preferred infection characteristics as compared to Ad5 (subgroup C), Ad5.Fib17 (subgroup D), or Ad5.Fib40-L (subgroup F). Primary human stroma was tested since these cells are commonly used as a "feeder" cell to allow proliferation and maintenance of HSCs under *ex vivo* culture conditions. In contrast to the transduction of TF-1 cells, none of the fiber chimeric adenoviruses were able to efficiently transduce human primary stroma (Figure 20). Reasonable infection of human fibroblast-like primary stroma was observed only with Ad5 despite the observation that none of the known receptor molecules are expressed on these cells (see table III). The absence of infection of human stroma using the chimeric viruses is advantageous since in a co-culture setting, the chimeric adenovirus will not be absorbed primarily by the stroma "feeder" cells.

[0198] To test the transduction capacity of the fiber chimaeric viruses, a pool of umbilical cord blood (3 individuals) was used for the isolation of stem cells. CD34⁺ cells were isolated from mononuclear cell preparation using a MACS laboratory separation system (Miltenyi Biotec) using the protocol supplied by the manufacturer. Of the CD34⁺ cells, 2×10^5 were seeded in a volume of 150 μ l DMEM (no serum; Gibco, Gaithersburg, MD) and 10 μ l of chimeric adenovirus (to give a final virus particles/cell ratio of 1000) was added. The chimeric adenoviruses tested were Ad5, Ad5.Fib16, Ad5.Fib35, Ad5.Fib17, Ad5.Fib51 all containing Green fluorescent protein (GFP) as a marker. Cells were incubated for 2 hours in a humidified atmosphere of 10% CO₂ at 37°C.

[0199] Thereafter, cells were washed once with 500 μ l DMEM and resuspended in 500 μ l of StemPro-34 SF medium (Life Technologies, Grand Island, NY).

[0200] Cells were then cultured for 5 days in 24-well plates (Greiner, Frickenhausen, Germany) on irradiated (20 Gy) pre-established human bone marrow stroma (ref 1), in a humidified atmosphere of 10% CO₂ at 37°C. After 5 days, the entire cell population was collected by trypsinization with 100 μ l 0.25% Trypsin-EDTA (Gibco). The number of cells before and after 5 days of culture was determined using a hemacytometer. The number of CD34⁺ and CD34⁺CD33,38,71 cells in each sample was calculated from the total number of cells recovered and the frequency of the CD34⁺CD33,38,71 cells in the whole population as determined by FACS analysis. The transduction efficiency was determined by FACS analysis while monitoring in distinct sub populations the frequency of GFP expressing cells as well as the intensity of GFP per individual cell. The results of this experiment, shown in figure 21, demonstrates that adenovirus serotype 5 or the chimeric adenovirus Ad5.Fib17 does not infect CD34⁺Lin⁻ cells as witnessed by the absence of GFP expression. In contrast, with the chimeric viruses carrying the fiber molecule of serotypes 16, 51, or 35 high percentages of GFP positive cells are scored in this cell population. Specificity for CD34⁺Lin⁻ is demonstrated since little GFP expression is observed in CD34⁺ cells that are also expressing CD33, CD38, and CD71. Subfractioning of the CD34⁺Lin⁻ cells (Figure 22) showed that the percentage of cells positive for GFP declines using Ad5.Fib16, Ad5.Fib35, or Ad5.Fib51 when the cells become more and more positive for the early differentiation markers CD33 (myeloid), CD71 (erythroid), and CD38 (common early differentiation marker).

[0201] These results thus demonstrate the specificity of the chimeric adenoviruses Ad5.Fib16, Ad5.Fib35, and

Ad5.Fib51 for HSCs. Figure 23 shows an alignment of the Ad5 fiber with the chimeric B-group fiber proteins derived from Ad16, 35 and 51. By determining the number of cells recovered after the transduction procedure the toxicity of adenovirus can be determined. The recovery of the amount of CD34⁺ cells as well as the amount of CD34⁺Lin⁻ (Figure 24) demonstrates that a 2 hour exposure to 1000 adenovirus particles did not have an effect on the number of cells recovered.

Example 10

An Ad5/fiber35 chimeric vector with cell type specificity for Dendritic cells

[0202] Dendritic cells are antigen presenting cells (APC), specialized to initiate a primary immune response and able to boost a memory type of immune response. Dependent on their stage of development, DC display different functions: immature DC are very efficient in the uptake and processing of antigens for presentation by Major Histocompatibility Complex (MHC) class I and class II molecules, whereas mature DC, being less effective in antigen capture and processing, perform much better at stimulating naive and memory CD4⁺ and CD8⁺ T cells, due to the high expression of MHC molecules and co-stimulatory molecules at their cell surface. The immature DCs mature *in vivo* after uptake of antigen, travel to the T-cell areas in the lymphoid organs, and prime T-cell activation.

[0203] Since DCs are the cells responsible for triggering an immune response there has been a long standing interest in loading DCs with immunostimulatory proteins, peptides or the genes encoding these proteins to trigger the immune system. The applications for this strategy are in the field of cancer treatment as well as in the field of vaccination. So far, anti-cancer strategies have focussed primarily on *ex vivo* loading of DCs with antigen (protein or peptide). These studies have revealed that this procedure resulted in induction of cytotoxic T cell activity. The antigens used to load the cells are generally identified as being tumor specific. Some, non-limiting, examples of such antigens are GP100, mage, or Mart-1 for melanoma.

[0204] Besides treatment of cancer many other potential human diseases are currently being prevented through vaccination. In the vaccination strategy, a "crippled" pathogen is presented to the immune system via the action of the antigen presenting cells, i.e. the immature DCs. Well-known examples of disease prevention via vaccination strategies include Hepatitis A, B, and C, influenza, rabies, yellow fever, measles. Besides these well-known vaccination programs, research programs for treatment of malaria, ebola, river blindness, HIV and many other diseases are being developed.

[0205] Many of the above mentioned pathogens are considered to dangerous for the generation of a "crippled" pathogen vaccine. This latter thus calls for the isolation and characterization of proteins of each pathogen which is able to mount a "full blown" immune response thus resulting in complete protection upon challenge with wild type pathogen.

[0206] For this strategy of loading DCs with immunostimulatory proteins or peptides to become therapeutically feasible

[0207] At least two distinct criteria have to be met 1) the isolation of large numbers of DCs which can be isolated, manipulated, and reinfused into a patient, making the procedure autologous. To date, it is possible to obtain such large quantities of immature DCs from cultured peripheral blood monocytes from any given donor. 2) a vector which can transduce DCs efficiently such that the DNA encoding for an immunostimulatory protein can be delivered. The latter is extremely important since it has become clear that the time required for DCs to travel to the lymphoid organs is such that most proteins or peptides are already released from the DCs resulting in incomplete immune priming. Because DCs are terminally differentiated and thus non-dividing cells, recombinant adenoviral vectors are being considered for delivering the DNA encoding for antigens to DCs. Ideally this adenovirus should have a high affinity for dendritic cells but also should not be recognized by neutralizing antibodies of the host such that *in vivo* transduction of DCs can be accomplished. This latter would omit the need for *ex vivo* manipulations of DCs but would result in a medical procedure identical to the vaccination programs which are currently in place, i.e. intramuscular or subcutaneous injection predominantly. Thus, DC transduced by adenoviral vectors encoding an immunogenic protein may be ideally suited to serve as natural adjuvants for immunotherapy and vaccination.

[0208] From the above described examples, it can be concluded that efficient gene delivery to DCs is a major interest for the field of gene therapy. Therefore, alteration of the adenovirus serotype 5 host cell range to be able to target DCs *in vitro* as well as *in vivo* is a major interest of the invention. To identify a chimeric adenovirus with preferred infection characteristics for human DCs, we generated a library of Ad5 based viruses carrying the fiber molecule from alternative serotypes (serotypes 8, 9, 13, 16, 17, 32, 35, 45, 40-L, 51). Ad5 was taken along as a reference.

[0209] We evaluated the susceptibility of human monocyte derived immature and mature DC to recombinant chimeric adenoviruses expressing different fibers.

[0210] Human PBMC from healthy donors were isolated through Ficoll-Hypaque density centrifugation. Monocytes were isolated from PBMC by enrichment for CD14⁺ cells using staining with FITC labeled anti-human CD 14 monoclonal antibody (Becton Dickinson), anti FITC microbeads and MACS separation columns (Miltenyi Biotec).

[0211] This procedure usually results in a population of cells that are < 90 % CD14⁺ as analysed by FACS. Cells

were placed in culture using RPMI-1640 medium (Gibco) containing 10% Foetal Bovine Serum (Gibco), 200 ng/ml rhu GM-CSF (R&D/ITK diagnostics, 100 ng/ml rhu IL-4 (R&D/ITK diagnostics) and cultured for 7 days with feeding of the cultures with fresh medium containing cytokines on alternate days. The immature DC resulting from this procedure after 7 days express a phenotype CD83⁺, CD14^{low} or CD14⁺, HLA-DR⁺, as was demonstrated by FACS analysis. Immature DC are matured by culturing the cells in medium containing 100 ng/ml TNF- α for 3 days, where after they expressed CD83 on their cell surface.

[0212] In a pilot experiment $5 \cdot 10^5$ immature DCs were seeded in wells of 24-well plates and exposed for 24 hours to 100 and 1000 virus particles per cell of each fiber recombinant virus. Virus tested was adenovirus serotype 5 (Ad5), and the fiber chimeric viruses based on Ad5: Ad5.Fib12, Ad5.Fib16, Ad5.Fib28, Ad5.Fib32, Ad5.Fib40-L (long fiber of serotype 40), Ad5.Fib49, and Ad5.Fib51 (where Fibxx stands for the serotype of which the fiber molecule is derived). These viruses are derived from subgroup C, A, B, D, D, F, D, and B respectively. After 24-hours cells were lysed (1% Triton X-100/ PBS) and luciferase activity was determined using a protocol supplied by the manufacturer (Promega, Madison, WI, USA). The results of this experiment, shown in figure 25, demonstrates that Ad5 poorly infects immature DCs as witnessed by one low level of transgene expression. In contrast, Ad5.Fib16 and Ad5.Fib51 (both a B-group fiber chimeric virus) and also Ad5.Fib40-L (Subgroup F) show efficient infection of immature DCs based on luciferase transgene expression.

[0213] In a second experiment, $5 \cdot 10^5$ immature and mature DC were infected with 10000 virus particles per cell of Ad5, Ad5.Fib16, Ad5.Fib40-L, and Ad5.Fib51 all carrying the LacZ gene as a marker. LacZ expression was monitored by flow cytometric analysis using a CM-FDG kit system and the instructions supplied by the manufacturer (Molecular probes, Leiden, The Netherlands). The results of this experiment, shown in figure 26, correlates with the previous experiment in that Ad5.Fib16 and Ad5.Fib51 are superior to Ad5 in transducing mature and immature human DCs. Also, this experiment shows that Ad5.Fib40-L is not as good as Ad5.Fib16 and Ad5.Fib51 but better than Ad5.

[0214] Based on these results we tested other chimeric adenoviruses containing fibers of B group viruses e.g. Ad5.Fib11 and Ad5.Fib35 for their capacity to infect DCs. We focussed on immature DCs since these are the cells that process an expressed transgene product into MHC class I and II presentable peptides. Immature DC's were seeded at a cell density of $5 \cdot 10^5$ cells/well in 24 well plates (Costar) and infected with 1000 and 5000 virus particles per cell after which the cells were cultured for 48 hours under conditions for immature DCs prior to cell lysis and Luciferase activity measurements. The result of this experiment, shown in figure 27, demonstrate that Ad5 based chimeric adenoviruses containing fibers of group-B viruses efficiently infect immature DCs. In a fourth experiment we again infected immature DCs identically as described in the former experiments but this time Ad5, Ad5.Fib16, and Ad5.Fib35 were used carrying green fluorescent protein (GFP) as a marker gene. The results on GFP expression measured with a flow cytometer 48 hours after virus exposure is shown in figure 28 and correlates with the data obtained so far.

[0215] Thus, the results so far are consistent in that Ad5 based vectors carrying a fiber from a alternative adenovirus derived from subgroup B predominantly fiber of 35, 51, 16, and 11 are superior to Ad5 for transducing human DCs.

[0216] The adenoviruses disclosed herein are also very suitable in vaccination of animals. To illustrate this, we tested DCs derived from mouse and chimpanzee to identify whether these viruses can be used in these animal models. This latter in particular since the receptor for human adenovirus derived from subgroup B is unknown to date and therefore it is unknown whether this protein is conserved among species. For both species immature DCs were seeded at a density of 10^5 cells per well of 24-well plates. Cells were subsequently exposed for 48 hours to 1000 virus particles per cell of Ad5, Ad5.Fib16, and Ad5.Fib51 in case of mouse DC and Ad5, and Ad5.Fib35 in case of chimpanzee DCs (see figure 29). The mouse experiment was performed with viruses carrying luciferase as a marker and demonstrated approximately 10-50 fold increased luciferase activity as compared to Ad5. The chimpanzee DCs were infected with the GFP viruses and were analysed using a flow cytometer. These results, also shown in figure 29, demonstrate that Ad5 (3%) transduces chimpanzee DCs very poorly as compared to Ad5.Fib35 (66.5%).

Example 11

Construction of a plasmid-based vector system to generate Ad11-based recombinant viruses

[0217] The results of the neutralization experiments described in Example 5 show that Ad11, like Ad35, was also not neutralized in the vast majority of human serum samples.

[0218] Therefore, recombinant adenoviruses based on Ad11 are preferred above the commonly used Ad2 and Ad5-based vectors as vectors for gene therapy treatment and vaccination. Both Ad35 and Ad11 are B-group viruses and are classified as viruses belonging to DNA homology cluster 2 (Wadell, 1984).

[0219] Therefore, the genomes of Ad35 and Ad11 are very similar. To generate a plasmid based system for the production of Ad11-based recombinant viruses the adapter plasmid pAdApt35IP1 generated in Example 7 is modified as follows. Construct pAdApt35IP1 is digested with AvrII and then partially with PacI. The digestion mixture is separated on gel and the 4.4 kb fragment containing the expression cassette and the vector backbone is isolated using the gene-

EP 1 054 064 A1

clean kit (BIO 101, Inc.). Then a PCR amplification is performed on wtAd11 DNA using the primers 35F1 and 35R2 (see Example 7) using Pwo DNA polymerase according to the manufacturers instructions. The obtained PCR fragment of 0.5 kb is purified using the PCR purification kit (LTI) and ligated to the above prepared fragment of pAdApt35IP1. This gives construct pAdApt11-35IP1 in which the 5' adenovirus fragment is exchanged for the corresponding sequence of Ad11. Next, pAdApt11-35IP1 is digested with BglII and partially with PacI. The obtained fragments are separated on gel and the 3.6 kb fragment containing the vector sequences, the 5' adenovirus fragment and the expression cassette is purified from gel as above. Next, a PCR fragment is generated using primers 35F3 and 35R4 (see Example 7) on wtAd11 DNA.

[0220] Amplification is done as above and the obtained 1.3 kb fragment is purified and digested with BglII and PacI. The isolated fragments are then ligated to give construct pAdApt11IP1. This adapter plasmid now contains Ad11 sequences in stead of Ad35 sequences. Correct amplification of PCR amplified Ad11 sequences, is verified by comparison of the sequence in this clone with the corresponding sequence of Ad11 DNA. The latter is obtained by direct sequencing on Ad11 DNA using the indicated PCR primers. The large cosmid clone containing the Ad11 backbone is generated as follows. First, a PCR fragment is amplified on Ad11 DNA using the primers 35F5 and 35R6 with Pwo DNA polymerase as described in Example 7 for Ad35 DNA. The PCR fragment is then purified using the PCR purification kit (LTI) and digested with NotI and NdeI. The resulting 3.1 kb fragment is isolated from gel using the gene clean kit (Bio 101, Inc.). A second PCR fragment is then generated on Ad11 DNA using the primers 35F7 and 35R8 (see Example 7) with Pwo DNA polymerase according to the manufacturers instructions and purified using the PCR purification kit (LTI). This amplified fragment is also digested with NdeI and NotI and the resulting 1.6 kb fragment is purified from gel as above.

[0221] The two digested PCR fragments are then ligated together with cosmid vector pWE15, previously digested with NotI and dephosphorylated using Tsap enzyme (LTI) according to manufacturers instructions. One clone is selected that has one copy of both fragments inserted. Correct clones are selected by analytical NotI digestion that gives a fragment of 4.7 kb. Confirmation is obtained by a PCR reaction using primers 35F5 and 35R8 that gives a fragment of the same size. The correct clone is then linearized with NdeI and isolated from gel. Next, wtAd11 DNA is digested with NdeI and the large 27 kb fragment is isolated from Low melting point agarose gel using agarase enzyme (Roche) according to the manufacturers instructions. Both fragments are then ligated and packaged using λ phage packaging extracts (Stratagene) according to the manufacturers protocol. After infection into STBL-2 cells (LTI) colonies are grown on plates and analysed for the presence of the complete insert.

[0222] The functionality of selected clones is then tested by cotransfection on PER.C6. Hereto, the DNA is digested with NotI and 6 μ g is cotransfected with 2 μ g of a PCR fragment generated on Ad11 DNA with primers 35F1 and 35R4 (see example 7). Correct clones give CPE within one week following transfection. The correct clone is named pWE.Ad11.pIX-rTR.

[0223] Using the above described procedure, a plasmid-based system consisting of an adapter plasmid suitable for insertion of foreign genes and a large helper fragment containing the viral backbone is generated. Recombinant Ad11-based viruses are made using the methods described inhere for Ad35-based recombinant viruses.

Example 12

Neutralization of adenoviruses in samples derived from patients

[0224] In the neutralization experiments described in Examples 1 and 5, all samples were derived from healthy volunteers.

[0225] Since one of the applications of non-neutralized vectors is in the field of gene therapy, it is interesting to investigate whether Ad35 is also neutralized with a low frequency and with low titers in groups of patients that are candidates for treatment with gene therapy.

- Cardio-vascular disease patients

[0226] 26 paired serum and pericardial fluid (PF) samples were obtained from patients with heart failure. These were tested against Ad5 and Ad35 using the neutralization assay described in Example 1. The results confirmed the previous data with samples from healthy volunteers. 70% of the serum samples contained NA to Ad5 and 4% to Ad35. In the pericardial fluid samples the titers were lower resulting in a total of 40% with NA to Ad5 and none to Ad35. There was a good correlation between NA in PF and serum i.e. there were no positive PF samples without NA in the paired serum sample. These results show that non-neutralized vectors based on Ad35 are preferred over Ad5 vectors for treatment of cardio-vascular diseases. As is true for all forms of non-neutralized vectors in this application, the vector may be based on the genome of the non-neutralized serotype or may be based on Ad5 (or another serotype) though displaying at least the major capsid proteins (hexon, penton and optionally fiber) of the non-neutralized serotype.

- Rheumatoid Arthritis patients

[0227] The molecular determinant underlying arthritis is not yet known but both T-cell dysfunction and imbalanced growth factor production in joints is known to cause inflammation and hyperplasia of synovial tissue. The synoviocytes start to proliferate and invade the cartilage and bone which leads to destruction of these tissues. Current treatment starts (when in an early stage) with administration of anti-inflammatory drugs (anti-TNF, IL-1-R α , IL-10) and/or conventional drugs (e.g. MTX, sulfasalazine). In late stage RA synovectomy is performed which is based on surgery, radiation, or chemical intervention. An alternative or additional option is treatment via gene therapy where an adenoviral vector is delivered directly into the joints of patients and expresses an anti-inflammatory drug or a suicide gene. Previous studies performed in rhesus monkeys suffering from collagen-induced arthritis have shown that Ad5-based vectors carrying a marker gene can transduce synoviocytes. Whether in the human situation adenoviral delivery is hampered by the presence of NA is not known. To investigate the presence of NA in synovial fluid (SF) of RA patients, SF samples were obtained from a panel of 53 random selected patients suffering from rheumatoid arthritis (RA).

[0228] These were tested against several wt adenoviruses using the neutralization assay as described in Example 1. Results of this screen are presented in Table III. Adenovirus type 5 was found to be neutralized in 72% of the SF samples. Most of these samples contain high titers of NA as also the highest dilution of the SF sample that was tested (64x) neutralized Ad5 viruses. This means that adenoviral vector delivery to the synoviocytes in the joints of RA patients will be very inefficient. Moreover, since the titers in the SF are so high it is doubtful whether lavage of the joints prior to vector injection will remove enough of the NA. Of the other serotypes that were tested Ad35 was shown to be neutralized in only 4% of the samples. Therefore, these data confirm the results obtained in serum samples from healthy patients and show that for treatment of rheumatoid arthritis Ad35-based vectors or chimeric vectors displaying at least some of the capsid proteins from Ad35 are preferred vectors.

Example 13

Modifications in the backbone of Ad35-based viruses

1) Generation of pBr/Ad35.Pac-rITR and pBr/Ad35.PRN

[0229] Example 4 describes the generation of the Ad35 subclone pBr/Ad35.Eco13.3. This clone contains Ad35 sequences from bp 21943 to the end of the right ITR cloned into the EcoRI and EcoRV sites of pBr322. To extend these sequences to the PacI site located at bp 18137 in Ad35, pBr/Ad35.Eco13.3 (see Example 4) was digested with AatII and SnaBI and the large vector-containing fragment was isolated from gel using the QIAEX II gel extraction kit (QiaGen). Ad35 wt DNA was digested with PacI and SnaBI and the 4.6 kb fragment was isolated as above. This fragment was then ligated to a double-stranded (ds) linker containing a PacI and an AatII overhang. This linker was obtained after annealing the following oligonucleotides:

A-P1: 5'-CTG GTG GTT AAT-3'
A-P2: 5'-TAA CCA CCA GAC GT-3'

[0230] The ligation mix containing the ds linker and the PacI-SnaBI Ad35 fragment was separated from unligated linker on a LMP gel. The 4.6 kb band was cut out the gel, molten at 65 °C, and then ligated to the purified pBr/Ad35.Eco13.3 vector fragment digested with AatII and SnaBI. Ligations were transformed into electrocompetent DH10B cells (Life Technologies Inc.). The resulting clone, pBr/Ad35.Pac-rITR, contained Ad35 sequences from the PacI site at bp 18137 upto the right ITR.

[0231] Next, a unique restriction site was introduced at the 3' end of the right ITR to be able to free the ITR from vector sequences. Hereto, a PCR fragment was used that covers Ad35 sequences from the NdeI site at bp 33165 to the right ITR having the restriction sites SmaI, NotI and EcoRI attached to the rITR. The PCR fragment was generated using primers 35F7 and 35R8 (described in example 7). After purification, the PCR fragment was cloned into the AT cloning vector (Invitrogen) and sequenced to verify correct amplification.

[0232] The correct amplified clone was then digested with EcoRI, blunted with Klenow enzym and subsequently digested with NdeI and the PCR fragment was isolated. In parallel, the NdeI in the pBr vector in pBr/Ad35.Pac-rITR was removed as follows: A pBr322 vector from which the NdeI site was removed by digestion with NdeI, Klenow treatment and religation, was digested with AatII and NheI. The vector fragment was isolated in LMP gel and ligated to the 16.7 kb Ad35 AatII-NheI fragment from pBr/Ad35.Pac-rITR that was also isolated in an LMP gel. This generated pBr/Ad35.Pac-rITR. Δ NdeI. Next pBr/Ad35.Pac-rITR. Δ NdeI was digested with NheI, the ends were filled in using Klenow enzym and the DNA was then digested with NdeI. The large fragment containing the vector and Ad35 sequences was isolated. Ligation of this vector fragment and the PCR fragment resulted in pBr/Ad35.PRN. In this clone specific

EP 1 054 064 A1

sequences coding for fiber, E2A, E3, E4 or hexon can be manipulated. In addition, promoter sequences that drive for instance the E4 proteins or the E2 can be mutated or deleted and exchanged for heterologous promoters.

2) Generation of Ad35-based viruses with fiber proteins from different serotypes.

[0233] Adenoviruses infect human cells with different efficiencies. Infection is accomplished by a two step process involving: 1. the fiber proteins that mediate binding of the virus to specific receptors on the cells, and 2. the penton proteins that mediate internalization by interaction of for example the RGD sequence to integrins present on the cell surface. For subgroup B viruses of which Ad35 is a member, the cellular receptor for the fiber protein is not known. There are striking differences in infection efficiency of human cells of subgroup B viruses compared to subgroup C viruses like Ad5 (see WO 00/03029 and EP 99200624.7). Even within one subgroup infection efficiencies of certain human cells may differ between various serotypes. For example, the fiber of Ad16, when present on an Ad5-based recombinant virus infects primary endothelial cells, smooth muscle cells and synoviocytes of human and rhesus monkey origin better than Ad5 chimeric viruses carrying the fiber of Ad35 or Ad51. Thus, to obtain high infection efficiencies of Ad35-based viruses, it may be necessary to change the fiber protein for a fiber protein of a different serotype. The technology for such fiber chimeras is described for Ad5-based viruses in Example 3, and is below exemplified for Ad35 viruses.

[0234] First, most fiber sequences are deleted from the Ad35 backbone in construct pBr/Ad35.PRN as follows: The left flanking sequences and part of the fiber protein in Ad35 ranging from bp 30225 upstream of a unique MluI site up to bp 30872 (numbers according to wt Ad35 sequence as disclosed in Figure 6) in the tail of fiber are amplified using primers

DF35-1 : 5'-CAC TCA CCA CCT CCA ATT CC-3'

and

DF35-2: 5'-CGG GAT CCC GTA CGG GTA GAC AGG GTT GAA GG-3'

[0235] This PCR amplification introduces a unique BsiWI site in the tail of the fiber gene.

[0236] The right flanking sequences ranging from the end of the fiber protein at bp 31798 to bp 33199 (numbering according to wtAd35 sequence, Figure 6) , 3' from the unique NdeI site is amplified using primers

DF35-3: 5'-CGG GAT CCG CTA GCT GAA ATA AAG TTT AAG TGT TTT TAT TTA AAA TCA C-3'

and

DF35-4: 5'-CCA GTT GCA TTG CTT GGT TGG-3'.

[0237] This PCR introduces a unique NheI site in the place of the fiber sequences. PCR amplification is done with Pwo DNA polymerase (Roche) according to the manufacturers instructions. After amplification the PCR products are purified using a PCR purification kit and the fragments are digested with BamHI and ligated together. The 2 kb ligated fragments are purified from gel and cloned in the PCR Script Amp vector (Stratagene). Correct amplification is checked by sequencing. The PCR fragment is then excised as a MluI/NdeI fragment and cloned in pBr/Ad35.PRN digested with the same enzymes. This generates pBr/Ad35.PRNΔfib, a shuttle vector suitable to introduce fiber sequences of alternative serotypes. This strategy is analogous to the fiber modification strategy for Ad5-based viruses as disclosed in WO00/03029. Primers that are listed in Table I of that application were used to amplify fiber sequences of various subgroups of adenovirus. For amplification of fibers that are cloned in the pBr/Ad35.PRNΔfib the same (degenerate) primer sequences can be used, however, the NdeI site in the forward primers (tail oligonucleotides A to E) should be changed to a BsiWI site and the NsiI site in the reverse oligo (knob oligonucleotide 1 to 8) should be changed in a NheI site. Thus fiber 16 sequences are amplified using the following degenerate primers:

5'- CCK GTS TAC CCG TAC GAA GAT GAA AGC-3' and 5'-CCG GCT AGC TCA GTC ATC TTC TCT GAT ATA-3'. Amplified sequences are then digested with BsiWI and NheI and cloned into pBr/Ad35.PRNΔfib digested with the same enzymes to generate pBr/Ad35.PRNΔfib16. The latter construct is then digested with PacI and SwaI and the insert is isolated from gel. The PacI/SwaI Ad35 fragment with modified fiber is then cloned into the corresponding sites of pWE/Ad35.pIX-rTR to give pWE/Ad35.pIX-rTR.fib16. This cosmid backbone can then be used with an Ad35-based adapter plasmid to generate Ad35 recombinant viruses that display the fiber of Ad16. Other fiber sequences can be amplified with (degenerate) primers as mentioned above. If one of the fibers sequences turns out to have an internal BsiWI or NheI site, the PCR fragment has to be digested partially with that enzyme.

3) Generation of Ad35-based viruses with inducible, E1 independent, E4 expression.

[0238] The adenovirus E4 promoter is activated by expression of E1 proteins. It is not known whether the Ad5 E1 proteins are capable of mediating activation of the Ad35 E4 promoter.

[0239] Therefore, to enable production of Ad35 recombinant viruses on PER.C6 cells, it may be advantageous to make E4 expression independent of E1. This can be achieved by replacing the Ad35-E4 promoter by heterologous promoter sequences like, but not limited to, the 7xTetO promoter.

[0240] Recombinant E1-deleted Ad5-based vectors are shown to have residual expression of viral genes from the vector backbone in target cells, despite the absence of E1 expression. Viral gene expression increases the toxicity and may trigger a host immune response to the infected cell. For most applications of adenoviral vectors in the field of gene therapy and vaccination it is desired to reduce or diminish the expression of viral genes from the backbone. One way to achieve this is to delete all, or as much as possible, sequences from the viral backbone. By deleting E2A, E2B or E4 genes and/or the late gene functions, one has to complement for these functions during production. This complementation can either be by means of a helper virus or through stable addition of these functions, with or without inducible transcription regulation, to the producer cell.

[0241] Methods to achieve this have been described for Ad5 and are known in the art. One specific method is replacement of the E4 promoter by promoter sequences that are not active in the target cells. E4 proteins play a role in for example replication of adenoviruses through activation of the E2 promoter and in late gene expression through regulation of splicing and nuclear export of late gene transcripts. In addition, at least some of the E4 proteins are toxic to cells. Therefore, reduction or elimination of E4 expression in target cells will further improve Ad35-based vectors. One way to achieve this is to replace the E4 promoter by an heterologous promoter that is inactive in the target cells.

[0242] An example of a heterologous promoter/activator system that is inactive in target cells is the tetracyclin inducible TetO system (Gossen and Bujard, 1992). Other prokaryotic or synthetic promoter/activator systems may be used. In this example, the E4 promoter in the backbone of the viral vector is replaced by a DNA fragment containing 7 repeats of the tetracyclin responsive element from the tet operon (7xTetO).

[0243] A strong transactivator for this promoter is a fusion protein containing the DNA binding domain of the tet repressor and the activation domain of VP16 (Tet transactivator protein, Tta). Strong E4 expression, independent of E1 expression, can be accomplished in PER.C6 cells expressing Tta. Tta expressing PER.C6 cells have been generated and described (see Example 15). Ad5 derived E1-deleted viruses with E4 under control of 7xTetO can be generated and propagated on these cells. Following infection in cells of human or animal origin (that do not express the Tta trans-activator), E4 expression was found to be greatly diminished compared to E1 deleted viruses with the normal E4 promoter.

[0244] Below the construction of pWE/Ad35.pIX-rITR.TetO-E4, a cosmid helper vector to produce viruses with the E4 promoter replacement, is described.

[0245] First, a fragment was generated by PCR amplification on pBr/Ad35.PRn DNA using the following primers:

355ITR: 5'- GAT CCC GAG CTC ACA ACG TCA TTT TCC CAC G-3'
and

353ITR: 5'-CGG AAT TCG CGG CCG CAT TTA AAT C-3'

[0246] This fragment contains sequences between bp 34656 (numbering according to wtAd35) and the NotI site 3' or the right ITR in pBr/Ad35.PRn and introduces an SstI site 5' of the right ITR sequence.

[0247] A second PCR fragment was generated on pBr/Ad35.PRn DNA using primers:

35DE4: 5'-CCC AAG CTT GCT TGT GTA TAT ATA TTG TGG-3' and
35F7: See example 7.

[0248] This PCR amplifies Ad35 sequences between bp 33098 and 34500 (numbering according to wtAd35) and introduces a HindIII site upstream of the E4 Tata-box. With these two PCR reactions the right- and left -flanking sequences of the E4 promoter are amplified. For amplification, Pwo DNA polymerase was used according to manufacturers instructions. A third fragment containing the 7xTetO promoter was isolated from construct pAAO-E-TATA-7xTetO by digestion with SstI and HindIII. The generation of pAAO-E-TATA-7xTetO is described below. The first PCR fragment (355/353) was then digested with SstI and NotI and ligated to the 7xTetO fragment. The ligation mixture was then digested with HindIII and NotI and the 0.5 kb fragment is isolated from gel. The second PCR fragment (35DE4/35F7) was digested with NdeI and HindIII and gel purified. These two fragments are then ligated into pBr/Ad35.PRn digested with NdeI and NotI to give pBr/Ad35.PR.TetOE4. The modification of the E4 promoter is then transferred to the Ad35 helper cosmid clone by exchanging the PacI/SwaI fragment of the latter with the one from pBr/Ad35.PR.TetOE4 to give pWE/Ad35.pIX-rITR.TetOE4. pAAO-E-TATA.7xTetO was generated as follows. Two oligonucleotides were synthesized:

TATAplus: 5'-AGC TTT CTT ATA AAT TTT CAG TGT TAG ACT AGT AAA TTG CTT AAG-3' and
TATAmin: 5'-AGC TCT TAA GCA ATT TAC TAG TCT AAC ACT GAA AAT TTA TAA GAA-3'
(The underlined sequences form a modified TATA box).

EP 1 054 064 A1

[0249] The oligonucleotides were annealed to yield a double stranded DNA fragment with 5' overhangs that are compatible with HindIII digested DNA. The product of the annealing reaction was ligated into HindIII digested pGL3-Enhancer Vector (Promega) to yield pAAO-E-TATA. The clone that had the HindIII site at the 5' end of the insert restored was selected for further cloning.

- 5 [0250] Next, the heptamerized tet-operator sequence was amplified from the plasmid pUHC-13-3 (Gossen and Bujard, 1992) in a PCR reaction using the Expand PCR system (Roche) according to the manufacturers protocol. The following primers were used:

10 tet3: 5'- CCG GAG CTC CAT GGC CTA ACT CGA GTT TAC CAC TCC C-3'
tet5: 5'-CCC AAG CTT AGC TCG ACT TTC ACT TTT CTC-3'

[0251] The amplified fragment was digested with SstI and HindIII (these sites are present in tet3 and tet5 respectively) and cloned into SstI/HindIII digested pAAO-E-TATA giving rise to pAAO-E-TATA-7xtetO.

- 15 [0252] To test the functionality of the generated pWE/Ad35.pIX-rITR.TetOE4 cosmid clone, the DNA was digested with NotI. The left end of wtAd35 DNA was then amplified using primers 35F1 and 35R4 (see example 7). Following amplification, the PCR mixture was purified and digested with SalI to remove intact viral DNA. Then 4gr of both the digested pWE/Ad35.pIX-rITR.TetOE4 and the PCR fragment was cotransfected into PER.C6-tTA cells that were seeded in T25 flasks the day before. Transfected cells were transferred to T80 flasks after two days and another two days later CPE was obtained, showing that the cosmid backbone is functional.

20 Example 14

Generation of cell lines capable of complementing E1-deleted Ad35 viruses

25 Generation of pIG135 and pIG270

- [0253] Construct pIG.E1A.E1B contains E1 region sequences of Ad5 corresponding to nucleotides 459 to 3510 of the wt Ad5 sequence (Genbank accession number M72360) operatively linked to the human phosphoglycerate kinase promoter (PGK) and the Hepatitis B Virus polyA sequences. The generation of this construct is described in WO97/00326. The E1 sequences of Ad5 were replaced by corresponding sequences of Ad35 as follows. pRSV.Ad35-E1 (described in example 8) was digested with EcoRI and Sse8387I and the 3 kb fragment corresponding to the Ad35 E1 sequences was isolated from gel. Construct pIG.E1A.E1B was digested with Sse8387I completely and partially with EcoRI. The 4.2 kb fragment corresponding to vector sequences without the Ad5 E1 region but retaining the PGK promoter were separated from other fragments on LMP agarose gel and the correct band was excised from gel. Both obtained fragments were ligated resulting in pIG.Ad35-E1.

- 35 [0254] This vector was further modified to remove the LacZ sequences present in the pUC119 vector backbone. Hereto, the vector was digested with BsaAI and BstXI and the large fragment was isolated from gel. A double stranded oligo was prepared by annealing the following two oligos:

40 BB1: 5'-GTG CCT AGG CCA CGG GG-3' and
BB2: 5'-GTG GCC TAG GCA C-3'

- [0255] Ligation of the oligo and the vector fragment resulted in construct pIG135. Correct insertion of the oligo restores the BsaAI and BstXI sites and introduces a unique AvrII site. Next, we introduced a unique site at the 3' end of the Ad35-E1 expression cassette in pIG135. Hereto, the construct was digested with SapI and the 3' protruding ends were made blunt by treatment with T4 DNA polymerase. The thus treated linear plasmid was further digested with BsrGI and the large vector containing fragment was isolated from gel. To restore the 3' end of the HBVpolyA sequence and to introduce a unique site, a PCR fragment was generated using the following primers:

50 270F: 5'- CAC CTC TGC CTA ATC ATC TC -3' and
270R: 5'- GCT CTA GAA ATT CCA CTG CCT TCC ACC -3'

- 55 [0256] The PCR was performed on pIG.Ad35.E1 DNA using Pwo polymerase (Roche) according to the manufacturers instructions. The obtained PCR product was digested with BsrGI and dephosphorylated using Tsap enzym (LTI), the latter to prevent insert dimerization on the BsrGI site. The PCR fragment and the vector fragment were ligated to yield construct pIG270.

Ad35 E1 sequences are capable of transforming rat primary cells

[0257] New born WAG/RIJ rats were sacrificed at 1 week of gestation and kidneys were isolated. After careful removal of the capsule, kidneys were disintegrated into a single cell suspension by multiple rounds of incubation in trypsin/EDTA (LTI) at 37 °C and collection of floating cells in cold PBS containing 1% FBS. When most of the kidney was trypsinized all cells were resuspended in DMEM supplemented with 10% FBS and filtered through a sterile cheese cloth. Baby Rat Kidney (BRK) cells obtained from one kidney were plated in 5 dishes (Greiner, 6 cm). When a confluency of 70-80% was reached, the cells were transfected with 1 or 5 µgr DNA/dish using the CaPO₄ precipitation kit (LTI) according to the manufacturers instructions. The following constructs were used in separate transfections: pIG.E1A.E1B (expressing the Ad5-E1 region), pRSV.Ad35-E1, pIG.Ad35-E1 and pIG270 (the latter expressing the Ad35-E1). Cells were incubated at 37 °C, 5% CO₂ until foci of transformed cells appeared. Table IV shows the number of foci that resulted from several transfection experiments using circular or linear DNA. As expected, the Ad5-E1 region efficiently transformed BRK cells. Foci also appeared in the Ad35-E1 transfected cell layer although with lower efficiency. The Ad35 transformed foci appeared at a later time point: ~2 weeks post transfection compared with 7-10 days for Ad5-E1. These experiments clearly show that the E1 genes of the B group virus Ad35 are capable of transforming primary rodent cells.

[0258] This proves the functionality of the Ad35-E1 expression constructs and confirms earlier findings of the transforming capacity of the B-group viruses Ad3 and Ad7 (Dijkema, 1979).

[0259] To test whether the cells in the foci were really transformed a few foci were picked and expanded. From the 7 picked foci at least 5 turned out to grow as established cell lines.

Generation of new packaging cells derived from primary human amniocytes

[0260] Amniotic fluid obtained after amniocentesis was centrifugated and cells were resuspended in AmnioMax medium (LTI) and cultured in tissue culture flasks at 37 °C and 10 % CO₂. When cells were growing nicely (approximately one cell division/24 hrs.), the medium was replaced with a 1:1 mixture of AmnioMax complete medium and DMEM low glucose medium (LTI) supplemented with Glutamax I (end concentration 4mM, LTI) and glucose (end concentration 4.5 gr/L, LTI) and 10% FBS (LTI). For transfection ~ 5x10⁵ cells were plated in 10 cm tissue culture dishes. The day after, cells were transfected with 20 µgr of circular pIG270/dish using the CaPO₄ transfection kit (LTI) according to manufacturers instructions and cells were incubated overnight with the DNA precipitate. The following day, cells were washed 4 times with PBS to remove the precipitate and further incubated for over three weeks until foci of transformed cells appeared.

[0261] Once a week the medium was replaced by fresh medium. Other transfection agents like, but not limited to, LipofectAmine (LTI) or PEI (Polyethylenimine, high molecular weight, water-free, Aldrich) were used. Of these three agents PEI reached the best transfection efficiency on primary human amniocytes: ~1% blue cells 48 hrs. following transfection of pAdApt35.LacZ.

[0262] Foci are isolated as follows. The medium is removed and replaced by PBS after which foci are isolated by gently scraping the cells using a 50-200 µl Gilson pipette with a disposable filter tip. Cells contained in 10 µl PBS were brought in a 96 well plate containing 15 µl trypsin/EDTA (LTI) and a single cell suspension was obtained by pipetting up and down and a short incubation at room temperature.

[0263] After addition of 200 µl of the above described 1:1 mixture of AmnioMax complete medium and DMEM with supplements and 10% FBS, cells were further incubated. Clones that continued to grow were expanded and analysed their ability to complement growth of E1-deleted adenoviral vectors of different sub-groups, specifically ones derived from B-group viruses specifically from Ad35 or Ad11.

Generation of new packaging cell lines from human embryonic retinoblasts

[0264] Human retina cells are isolated from the eyes of aborted fetuses and cultured in DMEM medium (LTI) supplemented with 10% FES (LTI). The day before transfection, ~5x10⁵ cells are plated in 6 cm dishes and cultured overnight at 37 °C and 10% CO₂. Transfection is done using the CaPO₄ precipitation kit (LTI) according to the manufacturers instructions. Each dish is transfected with 8-10 µgr pIG270 DNA, either as a circular plasmid or as a purified fragment. To obtain the purified fragment, pIG270 was digested with AvrII and XbaI and the 4 kb fragment corresponding to the Ad35 E1 expression cassette was isolated from gel by agarase treatment (Roche). The following day, the precipitate is washed away carefully by four washes with sterile PBS. Then fresh medium is added and transfected cells are further cultured until foci of transformed cells appear. When large enough (>100 cells) foci are picked and brought into 96-wells as described above. Clones of transformed human embryonic retinoblasts that continue to grow, are expanded and tested for their ability to complement growth of E1-deleted adenoviral vectors of different sub-groups specifically ones derived from B-group viruses specifically from Ad35 or Ad11.

New packaging cell lines derived from PER.C6

[0265] As described in example 8, it is possible to generate and grow Ad35 E1-deleted viruses on PER.C6 cells with cotransfection of an Ad35-E1 expression construct, e.g. pRSV.Ad35.E1. However, large scale production of recombinant adenoviruses using this method is cumbersome because for each amplification step a transfection of the Ad35-E1 construct is needed. In addition, this method increases the risk of non-homologous recombination between the plasmid and the virus genome with high chances of generation of recombinant viruses that incorporate E1 sequences resulting in replication competent viruses. To avoid this, the expression of Ad35-E1 proteins in PER.C6 has to be mediated by integrated copies of the expression plasmid in the genome. Since PER.C6 cells are already transformed and express Ad5-E1 proteins, addition of extra Ad35-E1 expression may be toxic for the cells, however, it is not impossible to stably transfect transformed cells with E1 proteins since Ad5-E1 expressing A549 cells have been generated..

[0266] In an attempt to generate recombinant adenoviruses derived from subgroup B virus Ad7, Abrahamsen *et al.* (1997) were not able to generate E1-deleted viruses on 293 cells without contamination of wt Ad7. Viruses that were picked after plaque purification on 293-ORF6 cells (Brough *et al.*, 1996) were shown to have incorporated Ad7 E1B sequences by non-homologous recombination. Thus, efficient propagation of Ad7 recombinant viruses proved possible only in the presence of Ad7-E1B expression and Ad5-E4-ORF6 expression. The E1B proteins are known to interact with cellular as well as viral proteins (Bridge *et al.*, 1993; White, 1995). Possibly, the complex formed between the E1B 55K protein and E4-ORF6 which is necessary to increase mRNA export of viral proteins and to inhibit export of most cellular mRNAs, is critical and in some way serotype specific. The above experiments suggest that the E1A proteins of Ad5 are capable of complementing an Ad7-E1A deletion and that Ad7-E1B expression in adenovirus packaging cells on itself is not enough to generate a stable complementing cell line. To test whether one or both of the Ad35-E1B proteins is/are the limiting factor in efficient Ad35 vector propagation on PER.C6 cells, we have generated an Ad35 adapter plasmid that does contain the E1B promoter and E1B sequences but lacks the promoter and the coding region for E1A. Hereto, the left end of wtAd35 DNA was amplified using the primers 35F1 and 35R4 (both described in Example 7) with Pwo DNA polymerase (Roche) according to the manufacturers instructions. The 4.6 kb PCR product was purified using the PCR purification kit (LTI) and digested with SnaBI and ApaI enzymes. The resulting 4.2 kb fragment was then purified from gel using the QIAEXII kit (Qiagen).

[0267] Next, pAdApt35IP1 (Example 7) was digested with SnaBI and ApaI and the 2.6 kb vector containing fragment was isolated from gel using the GeneClean kit (BIO 101, Inc). Both isolated fragments were ligated to give pBr/Ad35.leftITR-pIX. Correct amplification during PCR was verified by a functionality test as follows: The DNA was digested with BstBI to liberate the Ad35 insert from vector sequences and 4 µgr of this DNA was cotransfected with 4 µgr of NotI digested pWE/Ad35.pIX-rITR (Example 7) into PER.C6 cells.

[0268] The transfected cells were passaged to T80 flasks at day 2 and again two days later CPE had formed showing that the new pBr/Ad35.leftITR-pIX construct contains functional E1 sequences. The pBr/Ad35.leftITR-pIX construct was then further modified as follows. The DNA was digested with SnaBI and HindIII and the 5' HindIII overhang was filled in using Klenow enzyme. Religation of the digested DNA and transformation into competent cells (LTI) gave construct pBr/Ad35.leftITR-pIXΔE1A. This latter construct contains the left end 4.6 kb of Ad35 except for E1A sequences between bp 450 and 1341 (numbering according to wtAd35, Figure 6) and thus lacks the E1A promoter and most of the E1A coding sequences. pBr/Ad35.leftITR-pIXΔE1A was then digested with BstBI and 2 µgr of this construct was cotransfected with 6 µgr of NotI digested pWE/Ad35.pIX-rITR (Example 7) into PER.C6 cells. One week following transfection full CPE had formed in the transfected flasks.

[0269] This experiment shows that the Ad35-E1A proteins are functionally complemented by Ad5-e1A expression in PER.C6 cells and that at least one of the Ad35-E1B proteins cannot be complemented by Ad5-E1 expression in PER.C6. It further shows that it is possible to make a complementing cell line for Ad35 E1-deleted viruses by expressing Ad35-E1B proteins in PER.C6. Stable expression of Ad35-E1B sequences from integrated copies in the genome of PER.C6 cells may be driven by the E1B promoter and terminated by a heterologous poly-adenylation signal like, but not limited to, the HBVpA.

[0270] The heterologous pA signal is necessary to avoid overlap between the E1B insert and the recombinant vector, since the natural E1B termination is located in the pIX transcription unit which has to be present on the adenoviral vector.

[0271] Alternatively, the E1B sequences may be driven by a heterologous promoter like, but not limited to the human PGK promoter by an inducible promoter like, but not limited to the 7xtetO promoter (Gossen and Bujard, 1992). Also in these cases the transcription termination is mediated by a heterologous pA sequence, e.g. the HBV pA. The Ad35-E1B sequences at least comprise one of the coding regions of the E1B 21K and the E1B 55K proteins located between nucleotides 1611 and 3400 of the wt Ad35 sequence. The insert may also include (part of the) Ad35-E1B sequences between nucleotides 1550 and 1611 of the wt Ad35 sequence.

Example 15

Generation of producer cell lines for the production of recombinant adenoviral vectors deleted in early region 1 and early region 2A

Generation of PER.C6-tTA cells

[0272] Here is described the generation of cell lines for the production of recombinant adenoviral vectors that are deleted in early region 1 (E1) and early region 2A (E2A).

[0273] The producer cell lines complement for the E1 and E2A deletion from recombinant adenoviral vectors *in trans* by constitutive expression of both E1 and E2A genes. The pre-established Ad5-E1 transformed human embryo retinoblast cell line PER.C6 (WO 97/00326) was further equipped with E2A expression cassettes.

[0274] The adenoviral E2A gene encodes a 72 kDa DNA Binding Protein with has a high affinity for single stranded DNA.

[0275] Because of its function, constitutive expression of DBP is toxic for cells. The ts125E2A mutant encodes a DBP which has a Pro→Ser substitution of amino acid 413. Due to this mutation, the ts125E2A encoded DBP is fully active at the permissive temperature of 32°C, but does not bind to ssDNA at the non-permissive temperature of 39°C. This allows the generation of cell lines that constitutively express E2A, which is not functional and is not toxic at the non-permissive temperature of 39°C. Temperature sensitive E2A gradually becomes functional upon temperature decrease and becomes fully functional at a temperature of 32°C, the permissive temperature.

A. Generation of plasmids expressing the wild type E2A- or temperature sensitive ts125E2A gene.

[0276]

pcDNA3wtE2A: The complete wild-type early region 2A (E2A) coding region was amplified from the plasmid pBR/Ad.Bam-rITR (ECACC deposit P97082122) with the primers DBPpcr1 and DBPpcr2 using the Expand™ Long Template PCR system according to the standard protocol of the supplier (Boehringer Mannheim). The PCR was performed on a Biometra Trio Thermoblock, using the following amplification program: 94°C for 2 minutes, 1 cycle; 94°C for 10 seconds + 51°C for 30 seconds + 68°C for 2 minutes, 1 cycle; 94°C for 10 seconds + 58°C for 30 seconds + 68°C for 2 minutes, 10 cycles; 94°C for 10 seconds + 58°C for 30 seconds + 68°C for 2 minutes with 10 seconds extension per cycle, 20 cycles; 68°C for 5 minutes, 1 cycle. The primer DBPpcr1: CGG GAT CCG CCA CCA TGG CCA GTC GGG AAG AGG AG (5' to 3') contains a unique *Bam*HI restriction site (underlined) 5' of the Kozak sequence (italic) and start codon of the E2A coding sequence. The primer DBPpcr2: CGG AAT TCT TAA AAA TCA AAG GGG TTC TGC CGC (5' to 3') contains a unique *Eco*RI restriction site (underlined) 3' of the stop codon of the E2A coding sequence. The bold characters refer to sequences derived from the E2A coding region. The PCR fragment was digested with *Bam*HI/*Eco*RI and cloned into *Bam*HI/*Eco*RI digested pcDNA3 (Invitrogen), giving rise to pcDNA3wtE2A.

pcDNA3tsE2A: The complete ts125E2A-coding region was amplified from DNA isolated from the temperature sensitive adenovirus mutant H5ts125. The PCR amplification procedure was identical to that for the amplification of wtE2A. The PCR fragment was digested with *Bam*HI/*Eco*RI and cloned into *Bam*HI/*Eco*RI digested pcDNA3 (Invitrogen), giving rise to pcDNA3tsE2A. The integrity of the coding sequence of wtE2A and tsE2A was confirmed by sequencing.

B. Growth characteristics of producer cells for the production of recombinant adenoviral vectors cultured at 32-, 37- and 39°C.

[0277] PER.C6 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL) supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL) and 10mM MgCl₂ in a 10% CO₂ atmosphere at either 32°C, 37°C or 39°C. At day 0, a total of 1 x 10⁶ PER.C6 cells were seeded per 25cm² tissue culture flask (Nunc) and the cells were cultured at either 32°C, 37°C or 39°C. At day 1-8, cells were counted. Figure 30 shows that the growth rate and the final cell density of the PER.C6 culture at 39°C are comparable to that at 37°C. The growth rate and final density of the PER.C6 culture at 32°C were slightly reduced as compared to that at 37°C or 39°C. No significant cell death was observed at any of the incubation temperatures. Thus PER.C6 performs very well both at 32°C and 39°C, the permissive and non-permissive temperature for ts125E2A, respectively.

C. Transfection of PER.C6 with E2A expression vectors; colony formation and generation of cell lines

[0278] One day prior to transfection, 2×10^6 PER.C6 cells were seeded per 6 cm tissue culture dish (Greiner) in DMEM, supplemented with 10% FBS and 10mM $MgCl_2$ and incubated at 37°C in a 10% CO_2 atmosphere. The next day, the cells were transfected with 3, 5 or 8 µg of either pcDNA3, pcDNA3wtE2A or pcDNA3tsE2A plasmid DNA per dish, using the LipofectAMINE PLUS™ Reagent Kit according to the standard protocol of the supplier (Gibco BRL), except that the cells were transfected at 39°C in a 10% CO_2 atmosphere. After the transfection, the cells were constantly kept at 39°C, the non-permissive temperature for ts125E2A. Three days later, the cells were put in DMEM supplemented with 10% FBS, 10mM $MgCl_2$ and 0.25mg/ml G418 (Gibco BRL), and the first G418 resistant colonies appeared at 10 days post transfection. As shown in table 1, there was a dramatic difference between the total number of colonies obtained after transfection of pcDNA3 (~200 colonies) or pcDNA3tsE2A (~100 colonies) and pcDNA3wtE2A (only 4 colonies). These results indicate that the toxicity of constitutively expressed E2A can be overcome by using a temperature sensitive mutant of E2A (ts125E2A) and culturing of the cells at the non-permissive temperature of 39°C.

[0279] From each transfection, a number of colonies was picked by scraping the cells from the dish with a pipette. The detached cells were subsequently put into 24 wells tissue culture dishes (Greiner) and cultured further at 39°C in a 10% CO_2 atmosphere in DMEM, supplemented with 10% FBS, 10mM $MgCl_2$ and 0.25mg/ml G418. As shown in table 1, 100% of the pcDNA3 transfected colonies (4/4) and 82% of the pcDNA3tsE2A transfected colonies (37/45) were established to stable cell lines (the remaining 8 pcDNA3tsE2A transfected colonies grew slowly and were discarded). In contrast, only 1 pcDNA3wtE2A-transfected colony could be established. The other 3 died directly after picking.

[0280] Next, the E2A expression levels in the different cell lines were determined by Western blotting. The cell lines were seeded on 6 well tissue culture dishes and sub-confluent cultures were washed twice with PBS (NPBI) and lysed and scraped in RIPA (1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in PBS, supplemented with 1mM phenylmethylsulfonylfluoride and 0.1 mg/ml trypsin inhibitor). After 15 minutes incubation on ice, the lysates were cleared by centrifugation. Protein concentrations were determined by the Bio-Rad protein assay, according to standard procedures of the supplier (BioRad). Equal amounts of whole-cell extract were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes (Millipore) and incubated with the αDBP monoclonal antibody B6. The secondary antibody was a horseradish-peroxidase-conjugated goat anti mouse antibody (BioRad). The Western blotting procedure and incubations were performed according to the protocol provided by Millipore. The complexes were visualized with the ECL detection system according to the manufacturer's protocol (Amersham). Figure 31 shows that all of the cell lines derived from the pcDNA3tsE2A transfection expressed the 72-kDa E2A protein (left panel, lanes 4-14; middle panel, lanes 1-13; right panel, lanes 1-12). In contrast, the only cell line derived from the pcDNAwtE2A transfection did not express the E2A protein (left panel, lane 2). No E2A protein was detected in extract from a cell line derived from the pcDNA3 transfection (left panel, lane 1), which served as a negative control. Extract from PER.C6 cells transiently transfected with pcDNA3ts125 (left panel, lane 3) served as a positive control for the Western blot procedure. These data confirmed that constitutive expression of wtE2A is toxic for cells and that using the ts125 mutant of E2A could circumvent this toxicity.

D. Complementation of E2A deletion in adenoviral vectors on PER.C6 cells constitutively expressing full-length ts125E2A.

[0281] The adenovirus Ad5.dl802 is an Ad 5 derived vector deleted for the major part of the E2A coding region and does not produce functional DBP. Ad5.dl802 was used to test the E2A trans-complementing activity of PER.C6 cells constitutively expressing ts125E2A. Parental PER.C6 cells or PER.C6tsE2A clone 3-9 were cultured in DMEM, supplemented with 10% FBS and 10mM $MgCl_2$ at 39°C and 10% CO_2 in 25 cm² flasks and either mock infected or infected with Ad5.dl802 at an m.o.i. of 5. Subsequently the infected cells were cultured at 32°C and cells were screened for the appearance of a cytopathic effect (CPE) as determined by changes in cell morphology and detachment of the cells from the flask. Full CPE appeared in the Ad5.dl802 infected PER.C6tsE2A clone 3-9 within 2 days.

[0282] No CPE appeared in the Ad5.dl802 infected PER.C6 cells or the mock infected cells. These data showed that PER.C6 cells constitutively expressing ts125E2A complemented in trans for the E2A deletion in the Ad5.dl802 vector at the permissive temperature of 32°C.

E. Serum-free suspension culture of PER.C6tsE2A cell lines.

[0283] Large-scale production of recombinant adenoviral vectors for human gene therapy requires an easy and scalable culturing method for the producer cell line, preferably a suspension culture in medium devoid of any human or animal constituents. To that end, the cell line PER.C6tsE2A c5-9 (designated c5-9) was cultured at 39°C and 10% CO_2 in a 175 cm² tissue culture flask (Nunc) in DMEM, supplemented with 10% FBS and 10mM $MgCl_2$. At sub-confluency (70-80% confluent), the cells were washed with PBS (NPBI) and the medium was replaced by 25 ml serum free

suspension medium Ex-cell™ 525 (JRH) supplemented with 1 x L-Glutamine (Gibco BRL), hereafter designated SFM. Two days later, cells were detached from the flask by flicking and the cells were centrifuged at 1,000 rpm for 5 minutes. The cell pellet was resuspended in 5 ml SFM and 0.5 ml cell suspension was transferred to a 80 cm² tissue culture flask (Nunc), together with 12 ml fresh SFM. After 2 days, cells were harvested (all cells are in suspension) and counted in a
 5 Burker cell counter. Next, cells were seeded in a 125 ml tissue culture erlenmeyer (Corning) at a seeding density of 3 x 10⁵ cells per ml in a total volume of 20 ml SFM. Cells were further cultured at 125 RPM on an orbital shaker (GFL) at 39°C in a 10% CO₂ atmosphere. Cells were counted at day 1-6 in a Burker cell counter. In Figure 4, the mean growth curve from 8 cultures is shown. PER.C6tsE2A c5-9 performed well in serum free suspension culture. The maximum cell density of approximately 2 x 10⁶ cells per ml is reached within 5 days of culture.

10

F. Growth characteristics of PER.C6 and PER.C6/E2A at 37°C and 39°C.

[0284] PER.C6 cells or PER.C6ts125E2A (c8-4) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL) supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL) and 10mM MgCl₂ in a 10% CO₂ atmo-
 15 sphere at either 37°C (PER.C6) or 39°C (PER.C6ts125E2A c8-4). At day 0, a total of 1 x 10⁶ cells were seeded per 25cm² tissue culture flask (Nunc) and the cells were cultured at the respective temperatures. At the indicated time points, cells were counted. The growth of PER.C6 cells at 37°C was comparable to the growth of PER.C6ts125E2A c8-4 at 39°C (Figure 33).

[0285] This shows that constitutive expression of ts125E2A encoded DBP had no adverse effect on the growth of
 20 cells at the non-permissive temperature of 39°C.

G. Stability of PER.C6ts125E2A

[0286] For several passages, the PER.C6ts125E2A cell line clone 8-4 was cultured at 39°C and 10% CO₂ in a 25
 25 cm² tissue culture flask (Nunc) in DMEM, supplemented with 10% FBS and 10 mM MgCl₂ in the absence of selection pressure (G418). At sub-confluency (70-80% confluent), the cells were washed with PBS (NPBI) and lysed and scraped in RIPA (1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in PBS, supplemented with 1mM phenylmethylsulfo-
 30 nylfluoride and 0.1 mg/ml trypsin inhibitor). After 15 minutes incubation on ice, the lysates were cleared by centrifuga-
 35 tion. Protein concentrations were determined by the BioRad protein assay, according to standard procedures of the supplier (BioRad). Equal amounts of whole-cell extract were fractionated by SDS-PAGE in 10% gels. Proteins were transferred onto Immobilon-P membranes (Millipore) and incubated with the αDBP monoclonal antibody B6. The sec-
 40 ondary antibody was a horseradish-peroxidase-conjugated goat anti mouse antibody (BioRad). The Western blotting procedure and incubations were performed according to the protocol provided by Millipore. The complexes were visu-
 45 alized with the ECL detection system according to the manufacturer's protocol (Amersham). The expression of
 50 ts125E2A encoded DBP was stable for at least 16 passages, which is equivalent to approximately 40 cell doublings (Figure 34). No decrease in DBP levels was observed during this culture period, indicating that the expression of
 55 ts125E2A was stable, even in the absence of G418 selection pressure.

Example 16

40

Generation of tTA expressing packaging cell lines

A. Generation of a plasmid from which the tTA gene is expressed.

45 [0287]

pcDNA3.1-tTA: The tTA gene, a fusion of the tetR and VP16 genes, was removed from the plasmid pUHD 15-1 (Gossen and Bujard, 1992) by digestion using the restriction enzymes *Bam*HI and *Eco*RI. First, pUHD15-1 was digested with *Eco*RI.

50 The linearized plasmid was treated with Klenow enzyme in the presence of dNTPs to fill in the *Eco*RI sticky ends. Then, the plasmid was digested with *Bam*HI. The resulting fragment, 1025 bp in length, was purified from agarose. Subsequently, the fragment was used in a ligation reaction with *Bam*HI/*Eco*RV digested pcDNA 3.1 HYGRO (-) (Invitrogen) giving rise to pcDNA3.1-tTA. After transformation into competent *E. Coli* DH5α (Life Techn.) and analysis of ampicillin resistant colonies, one clone was selected that showed a digestion pattern as expected for
 55 pcDNA3.1-tTA.

B. Transfection of PER.C6 and PER.C6/E2A with the tTA expression vector; colony formation and generation of cell lines

[0288] One day prior to transfection, 2×10^6 PER.C6 or PER.C6/E2A cells were seeded per 60 mm tissue culture dish (Greiner) in Dulbecco's modified essential medium (DMEM, Gibco BRL) supplemented with 10% FBS (JRH) and 10 mM $MgCl_2$ and incubated at 37°C in a 10% CO_2 atmosphere. The next day, cells were transfected with 4-8 μg of pcDNA3.1-tTA plasmid DNA using the LipofectAMINE PLUS™ Reagent Kit according to the standard protocol of the supplier (Gibco BRL). The cells were incubated with the LipofectAMINE PLUS™-DNA mixture for four hours at 37°C and 10% CO_2 . Then, 2 ml of DMEM supplemented with 20% FBS and 10 mM $MgCl_2$ was added and cells were further incubated at 37°C and 10% CO_2 . The next day, cells were washed with PBS and incubated in fresh DMEM supplemented with 10% FBS, 10 mM $MgCl_2$ at either 37°C (PER.C6) or 39°C (PER.C6/E2A) in a 10% CO_2 atmosphere for three days. Then, the media were exchanged for selection media; PER.C6 cells were incubated with DMEM supplemented with 10% PBS, 10 mM $MgCl_2$ and 50 $\mu g/ml$ hygromycin B (GIBCO) while PER.C6/E2A cells were maintained in DMEM supplemented with 10% PBS, 10 mM $MgCl_2$ and 100 $\mu g/ml$ hygromycin B.

[0289] Colonies of cells that resisted the selection appeared within three weeks while nonresistant cells died during this period.

[0290] From each transfection, a number of independent, hygromycin resistant cell colonies were picked by scraping the cells from the dish with a pipette and put into 2.5 cm^2 dishes (Greiner) for further growth in DMEM containing 10% FBS, 10 mM $MgCl_2$ and supplemented with 50 $\mu g/ml$ (PER.C6 cells) or 100 $\mu g/ml$ (PER.C6/E2A cells) hygromycin in a 10% CO_2 atmosphere and at 37°C or 39°C, respectively.

[0291] Next, it was determined whether these hygromycin-resistant cell colonies expressed functional tTA protein.

[0292] Therefore, cultures of PER.C6/tTA or PER/E2A/tTA cells were transfected with the plasmid pUHC 13-3 that contains the reporter gene luciferase under the control of the 7xtetO promoter (Gossens and Bujard, 1992). To demonstrate that the expression of luciferase was mediated by tTA, one half of the cultures was maintained in medium without doxycycline.

[0293] The other half was maintained in medium with 8 $\mu g/ml$ doxycycline (Sigma). The latter drug is an analogue of tetracycline and binds to tTA and inhibits its activity. All PER.C6/tTA and PER/E2A/tTA cell lines yielded high levels of luciferase, indicating that all cell lines expressed the tTA protein (Figure 35). In addition, the expression of luciferase was greatly suppressed when the cells were treated with doxycycline. Collectively, the data showed that the isolated and established hygromycin-resistant PER.C6 and PER/E2A cell clones all expressed functional tTA.

Legend to the figures:

[0294]

Figure 1:

Bar graph showing the percentage of serum samples positive for neutralisation for each human wt adenovirus tested (see example 1 for description of the neutralisation assay).

Figure 2:

Graph showing absence of correlation between the VP/CCID50 ratio and the percentage of neutralisation.

Figure 3:

Schematic representation of a partial restriction map of Ad35 (taken from Kang *et al.*, 1989) and the clones generated to make recombinant Ad35-based viruses.

Figure 4: Bar graph presenting the percentage sera samples that show neutralizing activity to a selection of adenovirus serotypes. Sera were derived from healthy volunteers from Belgium and the UK.

Figure 5: Bar graph presenting the percentage sera samples that show neutralizing activity to adenovirus serotypes 5, 11, 26, 34, 35, 48 and 49. Sera were derived from five different locations in Europe and the United States.

Figure 6: Sequence of human adenovirus type 35. As explained in the text the nucleotide sequence of the terminal ends of the virus are not definite resolved.

Figure 7: Map of pAdApt

Figure 8: Map of pIPspAdapt

EP 1 054 064 A1

Figure 9: Map of pIPspAdapt1

Figure 10: Map of pIPspAdapt3

5 Figure 11: Map of pAdApt35IP3

Figure 12: Map of pAdApt35IP1

10 Figure 13: Schematic representation of the steps undertaken to construct pWE.Ad35.pIX-rITR

Figure 14: Map of pWE.Ad35.pIX-rITR

Figure 15: Map of pRSV.Ad35-E1

15 Figure 16: Map of PGKneopA

20 Figure 17: Map of pRSVpNeo Figure 18: Map of pRSVhvbNeo

Figure 19: Flow cytometric analyses on Green fluorescent protein (GFP) expression in human TF-1 cells. Non-transduced TF-1 cells were used to set a background level of 1%. GFP expression in cells transduced with Ad5, Ad5.Fib16, Ad5.Fib17, Ad5.Fib40-L, Ad5.Fib35, and Ad5.Fib51 is shown.

25 Figure 20: Transduction of primary human fibroblast-like stroma. Cells were analysed 48 hours after a two hour exposure to the different chimaeric fiber viruses. Shown is percentage of cells found positive for the transgene: green fluorescent protein (GFP) using a flow cytometer. Non-transduced stroma cells were used to set a background at 1%. Results of different experiments (n=3) are shown \pm standard deviation.

30 Figure 21: Transduction of primary human fibroblast-like stroma, CD34⁺ cells and CD34⁺Lin⁻ cells. Cells were analyzed 5 days after a two hour exposure to the different chimaeric fiber viruses. Shown is percentage of cells found positive for the transgene: green fluorescent protein (GFP) using a flow cytometer. Non-transduced cells were used to set a background at 1%. Also shown is the number of GFP positive events divided by the total number of events analysed (between brackets).

35 Figure 22 A) Flow cytometric analysis of GFP positive cells after transduction of CD34⁺ cells with Ad5.Fib51. All cells gated in R2-R7 are positive for CD34 but differ in their expression of early differentiation markers CD33, CD38, and CD71 (Lin). Cells in R2 are negative for CD333, CD38, CD71 whereas cells in R7 are positive for these markers. To demonstrate specificity of Ad5.Fib51 the percentage of GFP positive cells was determined in R2-R7 which proved to decline from 91% (R2) to 15% (R7). B) Identical experiment as shown under A (X-axes is R2-R7) but for the other Ad fiber chimaeric viruses showing that Ad5.Fib35, and Ad5.Fib16 behave similar as Ad5.Fib51.

40 Figure 23: Alignment of the chimeric fiber proteins of Ad5fib16, Ad5fib35 and Ad5fib51 with the Ad5 fiber sequence.

45 Figure 24: Toxicity of Adenovirus exposure to primitive human Bone marrow cells and Stem cells. Cell cultures were counted just before and 5 days after adenovirus transduction. Shown is the percentage of primitive human bone marrow cells (CD34⁺) and HSCs (CD34⁺Lin⁻) recovered as compared to day 0.

50 Figure 25: Transduction of immature DCs at a virus dose of 100 or 1000 virus particles per cell. Virus tested is Ad5 and Ad5 based vectors carrying the fiber of serotype 12 (Ad5.Fib12), 16 (Ad5.Fib16), 28 (Ad5.Fib28), 32 (Ad5.Fib32), the long fiber of 40 (Ad5.Fib40-L, 49 (Ad5.Fib49), 51 (Ad5.Fib51). Luciferase transgene expression is expressed as relative light units per microgram of protein.

55 Figure 26: Flow cytometric analyses of LacZ expression on immature and mature DCs transduced with 10000 virus particles per cell of Ad5 or the fiber chimaeric vectors Ad5.Fib16, Ad5.Fib40-L, or Ad5.Fib51. Percentages of cells scored positive are shown in upper left corner of each histogram.

Figure 27: Luciferase transgene expression in human immature DCs measured 48 hours after transduction with

EP 1 054 064 A1

1000 or 5000 virus particles per cell. Virus tested were fiber chimaeric viruses carrying the fiber of subgroup B members (serotypes 11, 16, 35, and 51).

Figure 28: Green fluorescent protein (GFP) expression in immature human DCs 48 hours after transduction with 1000 virus particles per cell of Ad5, Ad5.Fib16, and Ad5.Fib35.

Non-transduced cells were used to set a background level of approximately 1% (-).

Figure 29: Transduction of mouse and chimpanzee DCs.

Luciferase transgene expression measured in mouse DCs 48 hours after transduction is expressed as relative light units per microgram of protein. Chimpanzee DCs were measured 48 hours after transduction using a flow cytometer. GFP expression demonstrates the poor transduction of Ad (35) in contrast to Ad5.Fib35 (66%).

Figure 30: Temperature dependent growth of PER.C6.

PER.C6 cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL) and 10mM MgCl₂ in a 10% CO₂ atmosphere at either 32°C, 37°C or 39°C. At day 0, a total of 1 x 10⁶ PER.C6 cells were seeded per 25cm² tissue culture flask (Nunc) and the cells were cultured at either 32°C, 37°C or 39°C. At day 1-8, cells were counted. The growth rate and the final cell density of the PER.C6 culture at 39°C are comparable to that at 37°C.

The growth rate and final density of the PER.C6 culture at 32°C were slightly reduced as compared to that at 37°C or 39°C.

PER.C6 cells were seeded at a density of 1 x 10⁶ cells per 25 cm² tissue culture flask and cultured at either 32-, 37- or 39°C. At the indicated time points, cells were counted in a Burkert cell counter. PER.C6 grows well at both 32-, 37- and 39°C.

Figure 31: DBP levels in PER.C6 cells transfected with pcDNA3, pcDNA3wtE2A or pcDNA3ts125E2A.

Equal amounts of whole-cell extract were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes and DBP protein was visualized using the αDBP monoclonal B6 in an ECL detection system. All of the cell lines derived from the pcDNA3ts125E2A transfection express the 72-kDa E2A-encoded DBP protein (left panel, lanes 4-14; middle panel, lanes 1-13; right panel, lanes 1-12). In contrast, the only cell line derived from the pcDNAwtE2A transfection did not express the DBP protein (left panel, lane 2). No DBP protein was detected in extract from a cell line derived from the pcDNA3 transfection (left panel, lane 1), which serves as a negative control. Extract from PER.C6 cells transiently transfected with pcDNA3ts125 (left panel, lane 3) served as a positive control for the Western blot procedure. These data confirm that constitutive expression of wtE2A is toxic for cells and that using the ts125 mutant of E2A can circumvent this toxicity.

Figure 32: Suspension growth of PER.C6ts125E2A C5-9.

The tsE2A expressing cell line PER.C6tsE2A.c5-9 was cultured in suspension in serum free Ex-cell™. At the indicated time points, cells were counted in a Burkert cell counter. The results of 8 independent cultures are indicated. PER.C6tsE2A grows well in suspension in serum free Ex-cell™ medium.

Figure 33: Growth curve PER.C6 and PER.C6tsE2A.

PER.C6 cells or PER.C6ts125E2A (c8-4) cells were cultured at 37°C or 39°C, respectively. At day 0, a total of 1 x 10⁶ cells was seeded per 25cm² tissue culture flask. At the indicated time points, cells were counted. The growth of PER.C6 cells at 37°C is comparable to the growth of PER.C6ts125E2A c8-4 at 39°C. This shows that constitutive overexpression of ts125E2A has no adverse effect on the growth of cells at the non-permissive temperature of 39°C.

Figure 34: Stability of PER.C6ts125E2A.

For several passages, the PER.C6ts125E2A cell line clone 8-4 was cultured at 39°C in medium without G418. Equal amounts of whole-cell extract from different passage numbers were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes and DBP protein was visualized using the αDBP monoclonal B6 in an ECL detection system. The expression of ts125E2A encoded DBP is stable for at least 16 passages, which is equivalent to approximately 40 cell doublings. No decrease in DBP levels were observed during this culture period, indicating that the expression of ts125E2A is stable, even in the absence of G418 selection pressure.

Figure 35: tTA activity in hygromycin resistant PER.C6/tTA (A) and PER/E2A/tTA (B) cells.

Sixteen independent hygromycin resistant PER.C6/tTA cell colonies and 23 independent hygromycin resistant

EP 1 054 064 A1

PER/E2A/TA cell colonies were grown in 10 cm² wells to sub-confluency and transfected with 2 µg of pUHC 13-3 (a plasmid that contains the reporter gene luciferase under the control of the 7xtetO promoter). One half of the cultures was maintained in medium containing doxycycline to inhibit the activity of tTA. Cells were harvested at 48 hours after transfection and luciferase activity was measured. The luciferase activity is indicated in relative light units (RLU) per µg protein.

Table I:

Serotype	Elution [NaCl] mM	VP/ml	CCID50	log ₁₀ VP/CCID50 ratio
1	597	8.66x10 ¹⁰	5.00x10 ⁷	3.2
2	574	1.04x10 ¹²	3.66x10 ¹¹	0.4
3	131	1.19x10 ¹¹	1.28x10 ⁷	4.0
4	260	4.84x10 ¹¹	2.50x10 ⁸	3.3
5	533	5.40x10 ¹¹	1.12x10 ¹⁰	1.7
6	477	1.05x10 ¹²	2.14x10 ¹⁰	1.7
7	328	1.68x10 ¹²	2.73x10 ⁹	2.4
9	379	4.99x10 ¹¹	3.75x10 ⁷	4.1
10	387	8.32x10 ¹²	1.12x10 ⁹	3.9
12	305	3.64x10 ¹¹	1.46x10 ⁷	4.4
13	231	4.37x10 ¹²	7.31x10 ⁸	3.8
15	443	5.33x10 ¹²	1.25x10 ⁹	3.6
16	312	1.75x10 ¹²	5.59x10 ⁸	3.5
17	478	1.39x10 ¹²	1.45x10 ⁹	3.0
19	430	8.44x10 ¹¹	8.55x10 ⁷	4.0
20	156	1.41x10 ¹¹	1.68x10 ⁷	3.9
21	437	3.21x10 ¹¹	1.12x10 ⁸	3.5
22	383	1.43x10 ¹⁰	3.33x10 ¹⁰	3.1
23	132	2.33x10 ¹¹	1.57x10 ⁷	4.2
24	405	5.12x10 ¹²	4.27x10 ⁸	4.1
25	405	7.24x10 ¹¹	5.59x10 ⁷	4.1
26	356	1.13x10 ¹²	1.12x10 ⁸	4.0
27	342	2.00x10 ¹²	1.28x10 ⁸	4.2
28	347	2.77x10 ¹²	5.00x10 ⁷	4.7
29	386	2.78x10 ¹¹	2.00x10 ⁷	4.1
30	409	1.33x10 ¹²	5.59x10 ⁸	3.4
31	303	8.48x10 ¹⁰	2.19x10 ⁷	3.6
33	302	1.02x10 ¹²	1.12x10 ⁷	5.0
34	425	1.08x10 ¹²	1.63x10 ¹¹	0.8
35	446	3.26x10 ¹²	1.25x10 ¹¹	1.4
36	325	9.26x10 ¹²	3.62x10 ⁹	3.4
37	257	5.86x10 ¹²	2.8x10 ⁹	3.3
38	337	3.61x10 ¹²	5.59x10 ⁷	4.8
39	241	3.34x10 ¹¹	1.17x10 ⁷	4.5
42	370	1.95x10 ¹²	1.12x10 ⁸	4.2

Continued on next page.

Serotype #	Elution [NaCl] mM	VP/ml	CCID50	log ₁₀ VP/CCID50 ratio
43	284	2.42x10 ¹²	1.81x10 ⁸	4.1
44	295	8.45x10 ¹¹	2.00x10 ⁷	4.6
45	283	5.20x10 ¹¹	2.99x10 ⁷	4.2
46	282	9.73x10 ¹²	2.50x10 ⁸	4.6
47	271	5.69x10 ¹¹	3.42x10 ⁷	4.2
48	264	1.68x10 ¹²	9.56x10 ⁸	3.3
49	332	2.20x10 ¹²	8.55x10 ⁷	4.4
50	459	7.38x10 ¹²	2.80x10 ⁹	3.4
51	450	8.41x10 ¹¹	1.88x10 ⁸	3.7

Legend to table I:

[0295] All human adenoviruses used in the neutralisation experiments were produced on PER.C6 cells (ECACC deposit number 96022940) (Fallaux *et al.*, 1998) and purified on CsCl as described in example 1. The NaCl concentration at which the different serotypes eluted from the HPLC column is shown. Virus particles/ml (VP/ml) were calculated from an Ad5 standard. The titer in the experiment (CCID50) was determined on PER.C6 cells (ECACC deposit number 96022940) as described in example 1 by titrations performed in parallel with the neutralisation experiment. The CCID50 is shown for the 44 viruses used in this study and reflects the dilution of the virus needed to obtain CPE in 50% of the wells after 5 days. The ratio of VP/CCID50 is depicted in log₁₀ and is a measurement of the infectivity of the different batches on PER.C6 cells (ECACC deposit number 96022940).

Table II

AdApt35.LacZ viruses escape neutralization by human serum.						
Virus	Human serum dilution					
	no serum	10x	50x	250x	1250x	6250x
AdApt5.LacZ moi: 5 VP/cell	100 %	0 %	0 %	1 %	40 %	80 %
AdApt35.LacZ 250 µl crude lysate	100 %	100 %	100 %	100 %	100 %	100 %

Table III

Percentage of synovial fluid samples containing neutralizing activity (NA) to wt adenoviruses of different serotypes.		
	% of SF samples with NA (all positives)	% of SF samples with NA (positives at ≥64x dilution)
Ad5	72	59
Ad26	66	34
Ad34	45	19
Ad35	4	0
Ad48	42	4

Table IV

The numbers of foci obtained with the different E1 expression constructs in BRK transformation experiments.			
Average # of foci/dish:			
	Construct	1 µgr	5 µgr
Experiment 1	pIG.E1A.E1 B	nd	60
	pIG.E1A.E1 B	nd	35
	pRSVAd35E1	0	3
	pIG.Ad35.E 1	3	7
Experiment 2	pIG.E1A.E1 B	37	nd
	pIG.Ad35.E 1	nd	2
Experiment 3	pIG.E1A.E1 B	nd	140
	pIG.Ad35.E 1	nd	20
	pIG270	nd	30

REFERENCES

[0296]

Abrahamsen, K., Kong, H.-L., Mastrangeli, A., Brough, D., Lizonova, A., Crystal, R. and Falck-Pedersen, E. (1997) Construction of an adenovirus type 7a E1A vector. *J. Virol.* 71, no. 11, p8946-8951.

Athappilly, F.K., Murali, R., Rux, J.J., Cai, Z. and Burnett, R.M. (1994). The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 Å resolution. *J. Mol. Biol.* 242, 430-455.

Basler, C.F., Droguett, G., Horwitz, M.S. (1996). Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35. *Gene* 170:249-54

Bridge, E., Medghalchi, S., Ubol, S., Leesong, M. and Ketner, G. (1993) Adenovirus early region 4 and viral DNA synthesis. *Virology* 193, 794-801.

Brody, S.L. and Crystal, R.G. (1994) Adenovirus mediated in vivo gene transfer. *Ann. N. Y. Acad. Sci.* 716:90-101.

Boshart, M., Weber, F., Jahn, G., Dorsch-Hasler, K., Fleckenstein B. and Schaffner W. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 41, 521-530,

Dijkema, R., Dekker, B.M.M., van der Feltz, M.J.M. and van der Eb, A.J. (1979). Transformation of primary rat kidney cells by DNA fragments of weakly oncogenic adenoviruses. *J. Virol.* 32, No 3, 943-950.

Fallaux, F.J., Bout, A., van der Velde, I., van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., van Ormondt, H., van der Eb, A.J., Valerio, D. and Hoebe, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. *Hum. Gene Ther.* 9, 1909-1917.

Gossen, M., and H. Bujard (1992) Tight control of gene expression in mammalian cells by tetracyclin-responsive promoters. *Proc. Natl. Acad. Sci. USA* 89; 5547-5551.

EP 1 054 064 A1

- Flomenberg, P.R., Chen, M., Munk, G., Horwitz, M.S. (1987). Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. *J. Infect Dis.* 155(6): 1127-34.
- 5 Francki, R.I.B., Fauquet, C.M., Knudson, D.L. and Brown, F. (1991). Classification and nomenclature of viruses. Fifth report of the international Committee on taxonomy of viruses. *Arch. Virol. Suppl.* 2: 140-144.
- Gahery-Segard, H., Farace, F., Godfrin, D., Gaston, J., Lengagne, R., Tursz, P., Boulanger, P. and Guillet, J.-G. (1998). Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralising activity. *J. Virol.* 72, 2388-2397.
- 10 He, T.-C., Zhou, S., Da Costa, L.T., Yu, J., Kinzler, K.W., Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA* 95, 2509-2514.
- Hierholzer, J.C., Wigand, R., Anderson, L.J., Adrian, T., and Gold, J.W.M. (1988) Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). *J. Infect. Dis.* 158, 804-813.
- 15 De Jong, P.J., Valderrama, G., Spigland, I. and Horwitz, M.S. (1983). Adenovirus isolates from urine of patients with acquired immunodeficiency syndrome. *Lancet* 1(8337): 1293-1296.
- 20 Kay, R., Takei, F., and Humphries, R.K. (1990). Expression cloning of a cDNA encoding M1/69. *J. Immunol.* 145, 1952-1959.
- Kang, W.G., Berencsi, G., Takacs, M., Ascher, Z., Fejer, G., Nasz, I. (1989a). Molecular cloning and physical mapping of the DNA of human adenovirus type 35. *Acta Microbiol Hung* 36(1): 67-75.
- 25 Kang, W.G., Berencsi, G., Banrevi, A., Ascher, Z., Fejer, G., Takacs, M., Kiss, A., Nasz, I. (1989b). Relationship of E1 and E3 regions of human adenovirus 35 to those of human adenovirus subgroups A, C and D. *Acta Microbiol Hung* 36(4): 445-57.
- 30 Levrero, M., Barban, V., Manteca, S., Ballay, A., Balsamo, C., Avantiaggiati, M.L., Natoli, G., Skellekens, H., Tiollais, P., and Perricaudet, M. (1991). Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. *Gene* 101, 195-202.
- 35 Li, Q.G., Hambraeus, J. and Wadell, G. (1991). Genetic relationship between thirteen genomes of types of adenovirus 11, 34, and 35 with different tropisms. *Interviol.* 32, 338-350.
- Prince, H.M. (1998). Gene transfer: a review of methods and applications. *Pathology* 30(4), 335-347.
- 40 Robbins, P.D. and Ghivizzani, S.C. (1998). Viral vectors for gene therapy. *Pharmacol Ther.* 80, 35-47.
- Schnurr, D and Dondero, M.E. (1993). Two new candidate adenovirus serotypes. *Interviol.* 36, 79-83.
- Schulick, A.H., Vassalli, G., Dunn, P.F., Dong, G., Rade, J.J., Zamarron, C. and Dichek, D.A. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. *J. Clin. Invest.* 99(2), 209-19.
- 45 Shabram, P.W., Giroux, D.D., Goudreau, A.M., Gregory, R.J., Horn, M.T., Huyghe, B.G., Liu, X., Nunnally, M.H., Sugarman, B.J. and Sutjipto, S. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. *Hum. Gene Ther.* 8(4): 453-465.
- 50 Toogood et al., 1989; *J. Gen Virol.* 70, 3203-3214
- Toogood, C.I., Murali, R., Burnett, R.M., Hay, R.T.(1989). The adenovirus type 40 hexon: sequence, predicted structure and relationship to other adenovirus hexons. *J. Gen. Virol.* 70, 3203-14.
- 55 Valderrama-Leon, G., Flomenberg, P., Horwitz, M.S. (1985). Restriction endonuclease mapping of adenovirus 35, a type isolated from immunocompromised hosts. *J Virol.* 56(2):647-50.

EP 1 054 064 A1

Wadell, G. (1984). Molecular epidemiology of adenoviruses. Curr. Top. Microbiol. Immunol. 110, 191-220.

White, E. (1995) Regulation of p53-dependent apoptosis by E1a and E1b. Curr. Top. Microbiol. Immunol. 199, 34-58

SEQUENCE LISTING

<110> Introgene B.V.

<120> Serotype of Adenovirus and uses Thereof

<130> P49636EP10

<140> 00201738.2

<141> 2000-05-16

<150> EP 99201545.3

<151> 1999-05-17

<160> 88

<170> PatentIn Ver. 2.1

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker
containing a PacI site

<220>

<221> misc_feature

<222> (1)..(23)

<400> 1

aattgtctta attaaccgct taa

23

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligonucleotide

<220>

<221> misc_feature

<222> (1)..(19)

<400> 2

aattgtctta attaaccgc

19

<210> 3

5 <211> 19
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Description of Artificial Sequence: oligonucleotide

 <220>
 <221> misc_feature
 <222> (1)..(19)

15 <400> 3
 aattgcggtt aattaagac 19

20 <210> 4
 <211> 39
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> Description of Artificial Sequence: primer ITR-EPH

 <220>
 <221> misc_feature
 <222> (1)..(39)

30 <400> 4
 cggaattctt aattaagtta acatcatcaa taatatacc 39

35 <210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Description of Artificial Sequence: primer Ad101

 <220>
 <221> misc_feature
 <222> (1)..(20)

45 <400> 5
 tgattcacat cggtcagtgc 20

50 <210> 6
 <211> 23
 <212> DNA
 <213> Artificial Sequence

55

EP 1 054 064 A1

5 <220>
 <223> Description of Artificial Sequence: primer delta E2A.SnaBI

 10 <220>
 <221> misc_feature
 <222> (1)..(23)

 <400> 6
 10 ggcgtacgta gccctgtcga aag 23

 <210> 7
 <211> 35
 15 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer delta E2A.DBP-start
 20
 <220>
 <221> misc_feature
 <222> (1)..(35)
 25 <400> 7
 ccaatgcatt cgaagtactt cctctccta taggc 35

 <210> 8
 30 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer delta E2A.DBP-stop
 35
 <220>
 <221> misc_feature
 <222> (1)..(22)
 40 <400> 8
 ccaatgcata cggcgagac gg 22

 <210> 9
 45 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer delta E2A.BamHI
 50
 <220>
 55

EP 1 054 064 A1

<221> misc_feature

<222> (1)..(21)

5

<400> 9

gaggtggatc ccatggacga g

21

10

<210> 10

<211> 47

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence: primer LTR-1

<220>

<221> misc_feature

20

<222> (1)..(47)

<400> 10

ctgtacgtac cagtgcactg gcttaggcat ggaaaaatac ataactg

47

25

<210> 11

<211> 64

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: primer LTR-2

<220>

<221> misc_feature

35

<222> (1)..(64)

<400> 11

gcggatcctt cgaacatgg taagcttggt accgctagcg ttaaccgggc gactcagtca 60
atcg 64

40

<210> 12

<211> 28

<212> DNA

45

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer HSA1

50

<220>

<221> misc_feature

<222> (1)..(28)

55

EP 1 054 064 A1

5
 <400> 12
 gcgccacccat ggcagagcg atggtggc 28

10
 <210> 13
 <211> 50
 <212> DNA
 <213> Artificial Sequence

15
 <220>
 <223> Description of Artificial Sequence: primer HSA2

20
 <220>
 <221> misc_feature
 <222> (1)..(50)

25
 <400> 13
 gttagatcta agcttgctga catcgatcta ctaacagtag agatgtagaa 50

30
 <210> 14
 <211> 10
 <212> DNA
 <213> Artificial Sequence

35
 <220>
 <223> Description of Artificial Sequence: oligonucleotide

40
 <220>
 <221> misc_feature
 <222> (1)..(10)

45
 <400> 14
 ttaagtcgac 10

50
 <210> 15
 <211> 23
 <212> DNA
 <213> Artificial Sequence

55
 <220>
 <223> Description of Artificial Sequence: linker

60
 <220>
 <221> misc_feature
 <222> (1)..(23)

65
 <400> 15
 aattgtctta attaaccgca att 23

5
 <210> 16
 <211> 67
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: oligonucleotide PLL-1

10
 <220>
 <221> misc_feature
 <222> (1)..(67)

15
 <400> 16
 gccatcccta ggaagcttgg tacgggtgaa ttgctagcg ttaacggatc ctctagacga 60
 gatctgg 67

20
 <210> 17
 <211> 67
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: oligonucleotide PLL-2

30
 <220>
 <221> misc_feature
 <222> (1)..(67)

35
 <400> 17
 ccagatctcg tctagaggat ccgttaacgc tagcgaattc accggtacca agcttcttag 60
 ggatggc 67

40
 <210> 18
 <211> 39
 <212> DNA
 <213> Artificial Sequence

45
 <220>
 <223> Description of Artificial Sequence: primer CMVplus

50
 <220>
 <221> misc_feature
 <222> (1)..(39)

55
 <400> 18
 gatcggatcc actgcagtgg tcaatattgg ccattagcc 39

<210> 19
 <211> 29

EP 1 054 064 A1

5 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer CMVminA
 <220>
 10 <221> misc_feature
 <222> (1)..(29)
 <400> 19
 gatcaagctt ccaatgcacc gttcccggtc 29
 15
 <210> 20
 <211> 32
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> Description of Artificial Sequence: primer
 <220>
 25 <221> misc_feature
 <222> (1)..(32)
 <400> 20
 ggggtggcca gggtagctct aggtttttgc aa 32
 30
 <210> 21
 <211> 29
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer
 <220>
 40 <221> misc_feature
 <222> (1)..(29)
 <400> 21
 45 ggggggatcc ataaacaagt tcagaatcc 29
 <210> 22
 <211> 18
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 55

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

<223> Description of Artificial Sequence: primer delta hex1

<220>
 <221> misc_feature
 <222> (1)..(18)

<400> 22
 cctggtgctg ccaacagc 18

<210> 23
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer delta hex2

<220>
 <221> misc_feature
 <222> (1)..(30)

<400> 23
 ccggtaccac tagtggaaag cgggcgcgcg 30

<210> 24
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer delta hex3

<220>
 <221> misc_feature
 <222> (1)..(35)

<400> 24
 ccggtccaa ttgagaagca agcaacatca acaac 35

<210> 25
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer delta hex4

<220>
 <221> misc_feature

5
 <222> (1)..(19)
 <400> 25
 gagaaggcca tggaggctg 19

10
 <210> 26
 <211> 32
 <212> DNA
 <213> Artificial Sequence

15
 <220>
 <223> Description of Artificial Sequence: primer Hex-up2

20
 <220>
 <221> misc_feature
 <222> (1)..(32)
 <400> 26
 gactagtcaa gatggcyacc cchtgatga tg 32

25
 <210> 27
 <211> 33
 <212> DNA
 <213> Artificial Sequence

30
 <220>
 <223> Description of Artificial Sequence: primer Hex-do2

35
 <220>
 <221> misc_feature
 <222> (1)..(33)
 <400> 27
 gctggccaat tgttatgtkg tkgcgttrcc ggc 33

40
 <210> 28
 <211> 20
 <212> DNA
 <213> Artificial Sequence

45
 <220>
 <223> Description of Artificial Sequence: primer DP5-F

50
 <220>
 <221> misc_feature
 <222> (1)..(20)
 <400> 28
 ctgttgctgc tgctaatagc 20

55

EP 1 054 064 A1

5
<210> 29
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer DP5-R

10
<220>
<221> misc_feature
<222> (1)..(32)

15
<400> 29
cgcggtatcct gtacaactaa ggggaataca ag 32

20
<210> 30
<211> 33
<212> DNA
<213> Artificial Sequence

25
<220>
<223> Description of Artificial Sequence: primer DP3-F

30
<220>
<221> misc_feature
<222> (1)..(33)

35
<400> 30
cgcggtatccc ttaaggcaag catgtccatc ctt 33

40
<210> 31
<211> 27
<212> DNA
<213> Artificial Sequence

45
<220>
<223> Description of Artificial Sequence: primer DP3-3R

50
<220>
<221> misc_feature
<222> (1)..(27)

55
<400> 31
aaaacacgtt ttacgcgtcg acctttc 27

50
<210> 32
<211> 33

EP 1 054 064 A1

5
5
10
15
20
25
30
35
40
45
50
55

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer P3-for

<220>
<221> misc_feature
<222> (1)..(33)

<400> 32
gctcgatgta caatgaggag acgagccgtg cta 33

<210> 33
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer P3-rev

<220>
<221> misc_feature
<222> (1)..(33)

<400> 33
gctcgactta agttagaaag tgcggcttga aag 33

<210> 34
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer P17F

<220>
<221> misc_feature
<222> (1)..(35)

<400> 34
gctcgatgta caatgaggcg tgcgggtgtg tottc 35

<210> 35
<211> 34
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer P17R

<220>

<221> misc_feature

<222> (1)..(34)

<400> 35

gctcgactta agttagaagg tgcgactgga aagc

34

<210> 36

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer NY-up

<220>

<221> misc_feature

<222> (1)..(42)

<400> 36

cgacatatgt agatgcatta gtttgtgta tgtttcaacg tg

42

<210> 37

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer NY-down

<220>

<221> misc_feature

<222> (1)..(18)

<400> 37

ggagaccact gccatgtt

18

<210> 38

<211> 10

<212> DNA

<213> Adenoviridae

<220>

<221> misc_feature

<222> (1)..(10)

<223> /note="Partial sequence of an adenovirus ITR"

5
 <400> 38
 catcatcaat 10

10
 <210> 39
 <211> 14
 <212> DNA
 <213> Adenoviridae

15
 <220>
 <221> misc_feature
 <222> (1)..(14)
 <223> /note="Partial sequence of an adenovirus ITR"

20
 <400> 39
 ccaataatat acct 14

25
 <210> 40
 <211> 21
 <212> DNA
 <213> Adenoviridae

30
 <220>
 <221> misc_feature
 <222> (1)..(21)
 <223> /note="Partial sequence of an adenovirus ITR"

35
 <400> 40
 aggtatatta ttgatgatgg g 21

40
 <210> 41
 <211> 18
 <212> DNA
 <213> Adenoviridae

45
 <220>
 <221> misc_feature
 <222> (1)..(18)
 <223> /note="Partial sequence of an adenovirus ITR"

50
 <400> 41
 catcatcaat aatatacc 18

55
 <210> 42
 <211> 13
 <212> DNA
 <213> Adenoviridae

<220>

EP 1 054 064 A1

<221> misc_feature

<222> (1)..(13)

<223> /note="Partial sequence of an adenovirus ITR"

<400> 42

catcatcaat aat

13

<210> 43

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo ExSalPacF

<220>

<221> misc_feature

<222> (1)..(47)

<400> 43

tcgatggcaa acagctatta tgggtattat gggttcgaat taattaa

47

<210> 44

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo ExSalPacR

<220>

<221> misc_feature

<222> (1)..(47)

<400> 44

tcgattaatt aattcgaacc cataatacc ataatactg ttgcca

47

<210> 45

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer PCLIPMSF

<220>

<221> misc_feature

<222> (1)..(42)

EP 1 054 064 A1

5
10
15
20
25
30
35
40
45
50
55

<400> 45
ccccaattgg tcgaccatca tcaataatat accttatfff gg 42

<210> 46
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer pCLIPBSRGI

<220>
<221> misc_feature
<222> (1)..(22)

<400> 46
gcgaaaattg tcacttctg tg 22

<210> 47
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ecolinker+

<220>
<221> misc_feature
<222> (1)..(37)

<400> 47
aattcggcgc gccgtcgacg atatcgatag cggccgc 37

<210> 48
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ecolinker-

<220>
<221> misc_feature
<222> (1)..(37)

<400> 48
aattcgggcc gctatcgata tcgtcgacgg cgcgcgcg 37

5
 <210> 49
 <211> 49
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: linker HindXba+

10
 <220>
 <221> misc_feature
 <222> (1)..(49)

15
 <400> 49
 agctctagag gatccgttaa cgctagcgaa ttcaccgta ccaagctta 49

<210> 50
 <211> 49
 <212> DNA
 <213> Artificial Sequence

20
 <220>
 <223> Description of Artificial Sequence: linker HindXba-

25
 <220>
 <221> misc_feature
 <222> (1)..(49)

30
 <400> 50
 ctagtaagct tggtagcggt gaattcgcta gcgttaacgg atcctctag 49

35
 <210> 51
 <211> 44
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Description of Artificial Sequence: primer 35F1

45
 <220>
 <221> misc_feature
 <222> (1)..(44)

50
 <400> 51
 cggaattctt aattaatcga catcatcaat aatatacctt atag 44

55
 <210> 52
 <211> 33
 <212> DNA
 <213> Artificial Sequence

EP 1 054 064 A1

5
5
10
15
20
25
30
35
40
45
50
55

<220>
<223> Description of Artificial Sequence: primer 35R2

<220>
<221> misc_feature
<222> (1)..(33)

<400> 52
gggtggtccta ggctgacacc tacgtaaaaa cag 33

<210> 53
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35F3

<220>
<221> misc_feature
<222> (1)..(30)

<400> 53
tggtggagat ctggtgagta ttgggaaaac 30

<210> 54
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35R4

<220>
<221> misc_feature
<222> (1)..(37)

<400> 54
cggaattctt aattaaggga aatgcaaatac tgtgagg 37

<210> 55
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35F5

EP 1 054 064 A1

5
<220>
<221> misc_feature
<222> (1)..(34)

<400> 55
cggaattcgc ggccgcggtg agtattggga aaac 34

10
<210> 56
<211> 22
<212> DNA
<213> Artificial Sequence

15
<220>
<223> Description of Artificial Sequence: primer 35R6

<220>
<221> misc_feature
20 <222> (1)..(22)

<400> 56
cgccagatcg tctacagaac ag 22

25
<210> 57
<211> 23
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Description of Artificial Sequence: primer 35F7

<220>
35 <221> misc_feature
<222> (1)..(23)

<400> 57
gaatgctggc ttcagttgta atc 23

40
<210> 58
<211> 42
<212> DNA
45 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35R8

50
<220>
<221> misc_feature
<222> (1)..(42)

55

EP 1 054 064 A1

5
10
15
20
25
30
35
40
45
50
55

<400> 58
cggaattcgc ggccgcattt aaatcatcat caataatata cc 42

<210> 59
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35F11

<220>
<221> misc_feature
<222> (1)..(33)

<400> 59
ggggtaccga attctcgcta gggtatttat acc 33

<210> 60
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35F10

<220>
<221> misc_feature
<222> (1)..(38)

<400> 60
gctctagacc tgcaggtag tcagtttctt ctccactg 38

<210> 61
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer HBV-F

<220>
<221> misc_feature
<222> (1)..(27)

<400> 61
ggctctagag atccttcgcg ggacgtc 27

EP 1 054 064 A1

5
<210> 62
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer HBV-R

10
<220>
<221> misc_feature
<222> (1)..(26)

<400> 62
15 ggcgattca ctgcctcca ccaagc 26

<210> 63
<211> 12
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide A-P1

25
<220>
<221> misc_feature
<222> (1)..(12)

30
<400> 63
ctggtggtta at 12

<210> 64
35 <211> 14
<212> DNA
<213> Artificial Sequence

<220>
40 <223> Description of Artificial Sequence:
oligonucleotide A-P2

<220>
<221> misc_feature
45 <222> (1)..(14)

<400> 64
taaccaccag acgt 14

50
<210> 65
<211> 20
<212> DNA

55

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-1

<220>

<221> misc_feature

<222> (1)..(20)

<400> 65

cactcaccac ctccaattcc

20

<210> 66

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-2

<220>

<221> misc_feature

<222> (1)..(32)

<400> 66

cgggatcccg tacgggtaga cagggttgaa gg

32

<210> 67

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-3

<220>

<221> misc_feature

<222> (1)..(49)

<400> 67

cgggatccgc tagctgaat aaagttaag tgtttttatt taaaatcac

49

<210> 68

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-4

EP 1 054 064 A1

<220>

<221> misc_feature

<222> (1)..(21)

<400> 68

ccagttgcat tgcttggtg g

21

<210> 69

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: degenerated primer

<220>

<221> misc_feature

<222> (1)..(27)

<400> 69

cckgtatacc cgtacgaaga tgaagc

27

<210> 70

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: degenerated primer

<220>

<221> misc_feature

<222> (1)..(30)

<400> 70

ccggctagct cagtcattt ctctgatata

30

<210> 71

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer 355ITR

<220>

<221> misc_feature

<222> (1)..(31)

5
10
15
20
25
30
35
40
45
50
55

<400> 71
gatccggagc tcacaacgtc atttccac g 31

<210> 72
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 353ITR

<220>
<221> misc_feature
<222> (1)..(25)

<400> 72
cggaattgc ggccgcatTT aaatc 25

<210> 73
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 35DE4

<220>
<221> misc_feature
<222> (1)..(30)

<400> 73
cccaagcttg ctgtgtata tatattgtg 30

<210> 74
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide TATA-plus

<220>
<221> misc_feature
<222> (1)..(45)

<400> 74
agctttctta taaatttca gtgtagact agtaaattgc ttaag 45

5
 <210> 75
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: oligonucleotide TATA-min

10
 <220>
 <221> misc_feature
 <222> (1)..(45)

15
 <400> 75
 agctcttaag caatttacta gtctaact gaaaatttat aagaa 45

20
 <210> 76
 <211> 37
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: primer tet3

30
 <220>
 <221> misc_feature
 <222> (1)..(37)

35
 <400> 76
 ccggagctcc atggcctaac tcgagtttac cactccc 37

40
 <210> 77
 <211> 30
 <212> DNA
 <213> Artificial Sequence

45
 <220>
 <223> Description of Artificial Sequence: primer tet5

50
 <220>
 <221> misc_feature
 <222> (1)..(30)

55
 <400> 77
 cccaagctta gctcgacttt cacttttctc 30

58
 <210> 78
 <211> 17
 <212> DNA

EP 1 054 064 A1

5
10
15
20
25
30
35
40
45
50
55

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligo BB1

<220>
<221> misc_feature
<222> (1)..(17)

<400> 78
gtgcctaggc cacgggg 17

<210> 79
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligo BB2

<220>
<221> misc_feature
<222> (1)..(13)

<400> 79
gtggcctagg cac 13

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 270F

<220>
<221> misc_feature
<222> (1)..(20)

<400> 80
cacctctgcc taatcatctc 20

<210> 81
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 270R

5
 <220>
 <221> misc_feature
 <222> (1)..(27)
 <400> 81
 gctctagaaa ttccactgcc ttccacc 27

10
 <210> 82
 <211> 35
 <212> DNA
 <213> Artificial Sequence

15
 <220>
 <223> Description of Artificial Sequence: primer DBPpcr1

20
 <220>
 <221> misc_feature
 <222> (1)..(35)
 <400> 82
 cgggatccgc caccatggcc agtcgggaag aggag 35

25
 <210> 83
 <211> 33
 <212> DNA
 <213> Artificial Sequence

30
 <220>
 <223> Description of Artificial Sequence: primer DBPpcr2

35
 <220>
 <221> misc_feature
 <222> (1)..(33)
 <400> 83
 cggaattctt aaaaatcaaa ggggttctgc cgc 33

40
 <210> 84
 <211> 34794
 <212> DNA
 <213> Adenoviridae

45
 <220>
 <221> misc_feature
 <222> (1)..(34794)
 <223> /note="Nucleic acid sequence of Ad35"

50
 <400> 84

55

catcatcaat aatatacctt atagatggaa tgggtccaat atgtaaatga ggtgatttta 60
 aaaagtgtgg gccgtgtggt gattggctgt ggggttaacg gtaaaaaggg gccgcgcggc 120
 5 cgtgggaaaa tgacgtttta tgggggtgga gttttttgc aagttgtcgc gggaaatgtt 180
 acgcataaaa aggcctcttt tctcacgga ciacttagtt tloccacggt atttaacagg 240
 aaatgaggta gtttgaccg gatgcaagtg aaaattgctg attttcgcgc gaaaactgaa 300
 tgaggaaagt tttttctgaa taatgtggta tttatggcag ggtggagtat ttgttcaggg 360
 ccaggtagac ttgacccat tacgtggagg tttegtttac cgtgttttt acctgaattt 420
 ccgcgtaccg tgtcaaagtc ttctgttttt acgtagggtg cagctgatcg ctagggtatt 480
 10 tataccicag ggtttgtgtc aagaggccac tcttagtgc cagcgagaag agttttctcc 540
 tctgcgccgg cagtttaata ataaaaaat gagagatttg cgattttctgc ctcaggaaat 600
 aatctctgt gagactggaa atgaatatatt ggagcttgtg gtgcacgcc tgatgggaga 660
 cgatccggag ccacctgtgc agcttttga gcttctacg cttcaggaaac tgatgattt 720
 agaggtagag ggatcggagg attctaata ggaagctgtg aatggctttt ttaccgattc 780
 15 tatgctttta gctgctaata aaggattaga attagatccg ctttggaca ctttcaatac 840
 tccaggggtg attgtggaaa gccgtacagg tgaagaaaa ttacctgatt tgagttccgt 900
 ggactgtgat ttgactgct atgaagacgg gtttctccg agtgatgagg aggaccatga 960
 aaaggagcag tccatgcaga ctgcagcggg tgaggagtg aaggctgcca atgttgggtt 1020
 tcaattggat tgcgggagc ttctgggaca tggctgaag tcttgaat ttacaggaa 1080
 20 aaatactgga gtaaaggaa tgttatgttc gtttggat atgagaacgc actgccactt 1140
 tattacagt aagtgtgttt aagttaaaat ttaaaggaa atgtgtttt tcaatgat 1200
 attgagtgtg agtttgtgc tcttattat aggtcctgtg tctgatgtg atgaatcacc 1260
 atctctgat tctactact cactctctga tattcaagca cctgttctg tggacgtgcg 1320
 caagcccat cctgtgaagc ttaagcctgg gaaacgtcca gcagtggaga aacttgagga 1380
 25 ctgtttacag ggtggggacg gacctttga cttgagtaca cggaaacgtc caagacaata 1440
 agtgttccat atccgtgttt acttaagggt acgtcaatat ttgtgtgaga gtgcaatga 1500
 ataaaaat gttactgtt cactgtttt tattgtttt tggcgggga ctcaggata 1560
 taagtagaag cagacctgtg tggtagctc ataggagctg gctttcatcc atggaggtt 1620
 gggccatttt ggaagacctt aggaagacta ggcaactgtt agagagcgt tggacggag 1680
 30 tctcgggtt ttggagattc tgggtccta gtgaattagc tagggtagt tttaggataa 1740
 aacaggacta taaacaagaa ttgaaaagt tgttggtaga ttgccagga cttttgaag 1800
 ccttaattt gggccatcag gttcacttta aaaaaaagt tttatcagt tttagctttt 1860
 caacccagg tagaactgct gctgctgtg ctttcttac tttatatta gataaatga 1920
 tcccagac tcatttcagc aggggatac ttttgattt catagccaca gcattgtgga 1980
 35 gaacatggaa ggttcgaag atgaggacaa tcttaggtta ctggccagt cagccttgg 2040
 gtgtagcggg aatctgagg catccaccg tcatgccagc ggttctggag gaggaacagc 2100
 aagaggacaa cccgagagcc ggcctggacc ctccagtga ggagcggag tagctgactt 2160
 gtctctgaa ctgcaacggg tgcctactg atctacgtcc actggacggg atagggcgct 2220
 taagaggag agggcatcca gtgtactga tgcctagatc gattggctt taagttaat 2280
 40 gagtgcaga cgtctgaaa ccatttggtg gcattgaggt cagaagagg gaaggatga 2340
 agtttctgta ttgaggaga aatattcact ggaacagggt aaaaatgtt ggttggagcc 2400
 agaggatgat tggcggtg ccattaaaaa ttatgccaag atagctttga ggcctgataa 2460
 acagtataag atcagtagac ggattaatat ccggaatgct tgttaccat ctggaaatgg 2520
 ggtgaggtg gtaatagata ctcaagacaa gacagttatt agatgtgca tgatggatat 2580
 45 gtggcctgga gtatcggtg tggaaagcag cacttttga aatgttaagt ttaggggaga 2640
 tgggtataat ggaatagtgt ttatggcaa taccaaactt atattgcat gtttagctt 2700
 tttgtttc aacaatact gtgtagatgc ctggggacag gttagtgtac ggggtgtag 2760
 tttctatgc ttttgattg ccacagctgg cagaaccaag agtcaattgt cctgaagaa 2820
 atgcatttc caaagatga acctgggcat tctgaatgaa ggcgaagcaa ggtccgtca 2880
 50 ctgccttct acagatactg gatgtttat ttaattaa ggaaatgcca gcgtaaagca 2940
 taacatgatt tgtgtgctt ccgatgagag gccttatcaa atgtcactt gtgtggtg 3000
 gattgtaat atgtgtgta ctgtcatat tgttccat caacgcaaaa aatggcctgt 3060
 tttgatcac aatgtttga ccaagtgcac catgcatga ggtgggagta gaggaatgtt 3120

55

tatgccttac cagtgtaca tgaatcatgt gaaagtgttg ttggaaccag atgccttttc 3180
 cagaatgagc ctaacaggaa tctttgacat gaacacgcaa atctggaaga tcttgaggta 3240
 5 tgaatgacag agatcgaggg tgcgcgcatg cgaatcgga ggcaagcatg ccagggtcca 3300
 gccggtgtgt gtagatgtga ccgaagatct cagaccggat catttggtta ttgccgcac 3360
 tggagcagag ttcggatcca gtggagaaga aactgactaa ggtgagtatt gggaaaactt 3420
 tggggtggga ttticagatg gacagattga gtaaaaattt gtttttctg tcttcagct 3480
 gacatgagt gaaatgcttc ttttaagggg ggagtcttca gcccttatct gacagggcgt 3540
 ctccatctt gggcaggagt tctcagaat gttatggat ctactgtga tggagacc 3600
 10 gttcaaccg ccaattctc aacgtgacc tatctactt taagtcttc accttggac 3660
 gcagctgag ccgctgccg cgctctgtc gccgtaaca ctgtgcttg aatgggttac 3720
 tatggaagca tcttgctaa tccacttcc tctaataacc ctctacact gactcaggac 3780
 aagttacttg tcttttggc ccagctggag gctttgacc aacgtctgg tgaactttc 3840
 cagcaggtgg ccgagtggc agtacaact gagtctgtg tggcagggc aaagtctaaa 3900
 15 taaaaaaaat tccagaatca atgaataaat aaacgagctt gttgtgatt taaaatcaag 3960
 tgtttttatt tcaattttc gcacgggtat gccctggacc accgatctc atcattgaga 4020
 actcgggtga tttttccag aatctatag aggtgggatt gaattttag atacatgggc 4080
 attagccgt ctttgggtg gagatagct cattgaaggg attcatgctc cgggtagtg 4140
 20 ttgtaataca ccagtcata acaaggtgc agtgcattgt gttgcacaat atcttttaga 4200
 agtaggctga ttgccacaga taagcccttg gttaggtgt ttacaaaccg gttgagctgg 4260
 gaggggtgca ttgaggtga aattatgtc attttgatt ggaattttta gttggcaata 4320
 ttgcccaa gatccgtct tgggttcag ttatgaagga ctaccaagac ggtgatccg 4380
 gtacatttag gaaatttat gtgcagctg gatgaaaag cgtgaaaaa tttggagaca 4440
 25 ccttggctc ctccagatt ttcatgcac tcatcatga taatagcaat gggccgtgg 4500
 gcagcggcg gggcaaacac gttccgtgg tctgacacat catagttatg ttctgagtt 4560
 aatcatcat aagccattt atgaatttg gggcggagcg taccagattg gggtatgaat 4620
 gttcttcgg gccccggagc atagtcccc tcacagattt gcatttcca agcttcagt 4680
 tctgaggtg gaatcatgc cactggggg gctatgaaga acaccgttc gggggcggg 4740
 30 gtgattagt gggatgtag caagtcttg agcaattgag atttgcaca tccggtggg 4800
 ccataataa ttccgattac aggttcagg tggtagtta gggaacggca actgccgtct 4860
 tctgaagca agggggccac ctcttcacat atttcccta catcatatt ttccgcacc 4920
 aaatccatta ggagcgctc tctctagt gatagaattt ctgtagtga gaaaagt 4980
 35 ttacgggtt ttgacccgt agcatggc attttgaaa gatttctg caaagtct 5040
 agtctgtcc acagttcag gatgttct atggcatct gatccagcag acctctctg 5100
 ttccgggtt tggacggct ctgagtagg gtatgagacg atggcgctc agcgtgcca 5160
 ggttcggct ctccagggt ctactgtc gactcagggt tgttccgtc acagtgaag 5220
 ggtgtgcgc tcttggggc ctgocaggg tgccttcag actattctg ctggtggaga 5280
 40 acttctgtc ctggcgccc gtatgtcgg ccaagtagca gtttaccatg agttcgtag 5340
 tgagcgctc ggtcgttg ctttggcg ggagcttacc tttggaagt tcttgcata 5400
 ccgggcagta taggcattc agcgcataca gtttggcgc aaggaaaatg gattctggg 5460
 agtatgcat cgcgcgcag gaggcgcaa cagtttaca ttccaccagc caggttaaat 5520
 45 ccggttcatt ggggtcaaaa acaagtttc cccatattt ttgatgcgt ttctacctt 5580
 tggctccat aagtctgt cctcttgag tgacaacag gctgtccga tctccgtaga 5640
 ctgattttac aggcctctc tccagtgag tgcctcgct tcttctgac aggaactctg 5700
 50 accactctga tacaaggcg cgcgtccag ccagcacaag ggaggctatg tgggagggg 5760
 agcatcgtt gtcaaccag ggtccacct ttccaaagt atgcaaacac atgtcacct 5820
 ctcaacac caggaatgtg attggtgtt aggtgtatt cagtgacct ggggtcccc 5880
 ctgggggggt aaaaaagg ggggtctt gctcttctc actgtcttc ggtcgtgt 5940
 ccaggaactg cagctgttg gtaggtatt cctctcgaa ggcggcgatg acctctgac 6000
 55 ttaggtgtc agtttctag aacgaggag atttcatatt gacagtgcg gttgagatc 6060
 ctctatgag gtttctgc atttctcag aaaaacaa tttttattg tcaagtttg 6120
 tggcaaatga tccatacag gcgttgata aaagtttgc aatggatgc atggtttgt 6180
 tctttctt gtccgcgc tcttggcg cgtgttgag ttggacatac tgcgtgcca 6240

5 ggcacttcca ttccgggaag atagtgtta attcatctgg cagcattctc acttgcacc 6300
 ctcgattatg caaggtaatt aaatccacac tgggtgccac ctgcctcga aggggttcat 6360
 tggccaaca gagctacct cctttctag aacagaaagg ggggaagtgg tctagcataa 6420
 gticacggg agggctgca tccatggtaa agattcccgg aagtaatecc ttatcaaat 6480
 agctgatgg agtggggca tctaaggcca ttgccattc tcgagctgcc agtgcgcgt 6540
 catatgggtt aaggggactg cccaggga tgggatgggt gagagcagag gcatacatgc 6600
 cacagatgtc atagacgtag atgggatcct caaagatgcc tatgtagggt gtagtagc 6660
 gccccctct gatacttct cgcacatagt catatagttc atgtgatggc gtagcagcc 6720
 10 ccggacccaa gttgggtcga ttgggtttt ctgtctgta gacgatctgg cgaaagatgg 6780
 cgtgagaatt ggaagagatg gtgggtctt gaaaaatgtt gaaatgggca tgaggtagac 6840
 ctacagagtc tctgacaag tgggcataag attctgaag ctgggttacc agtgcggcg 6900
 tgacaagtac gtcaggcg cagtagtcaa gtgttcttg aatgatgtca taacctgtt 6960
 ggttttctt ttccacagt tcgcggtga gaaggtatc ttccgatcc ttccagtact 7020
 15 ctctagcgg aaacctct tigtctgcac ggaagatcc tagcatgtag aactgattaa 7080
 ctgccttga agggcagcag ccttctcta cggtagaga gtatgctga gcagctttc 7140
 gtagcgaagc gtgagtaagg gcaaagggt ctctgacct gactttgaga aattggtatt 7200
 tgaagtccat gtcgtcacag gctcctgtt cccagagtig gaagtctacc cgttctgt 7260
 agggggggtt gggcaagcg aaagtaacat catgaagag aatcttaccg gctctgggca 7320
 20 taaaatttgc agtgatcgg aaaggctgtg gtacttccg tcgattgtt atcaacctgg 7380
 cagctaggac gattctgc aaacctga tgtgtgtc tacgatgtat aattctatga 7440
 aacgcggcgt gcctctgac tgaggtagct tactgagct atcaaagggt agtctgtg 7500
 ggtcagataa ggcgtagtgt tcgagagccc attcgtcag gtgaggatt gcagttaga 7560
 atgatgacca aagatctacc gccagtgctg ttgtaactg gtccgatac tgacgaaaat 7620
 25 gccggccaat tgccatttt tctgagtgca cacagtagaa ggttctggg tctgttgc 7680
 atcgatecca ctgagtta atggttagat cgtgggcat gtagcaga cgtctctc 7740
 ctgagagttt catgaccagc atgaaggaa ctattgtt gccaaaggat cccatccagg 7800
 tgaagtct cacatcgtag gtcaggaa gcttctgt gcgaggatga gagcgatcg 7860
 ggaagaactg gatttctgc caccagttg aggttggt gttgatgtga tggaagtaga 7920
 30 agttctgc gcgcgcgag cattctgtt tgtcttga cacagcgcc cagtgtgc 7980
 agcgttcac ggttgtatc tctgaatga gctgtacct gcttccctg acgagaaat 8040
 tcagtggaa gccaggcct ggcattgta tctgtctc ttctatatt gctgtatcg 8100
 cctgttcac ttctgttc atggtgtca tctgacgag ccccgcgagg aggaagtc 8160
 agacctggc gcggagggg cgagagtgaa ggacgagag gcgcaggctg gactgtcca 8220
 35 gactctgag acgctcgga ctacgttag taggtaggga cagaagatta acttgcata 8280
 tctttccag ggcgtcgagg aggttcagat ggtactgt ttccacaggt tcttttag 8340
 agacgtcaat ggttgcagg gttcgtgtc cttgggcgc cactaccgta ctttgttt 8400
 ttctttgat cgttgggtg tcttctgt cttgcatgt cagaagcgt gacggggac 8460
 cgcccgggc ggcagcggtt gttccggacc cgggggcat gctgtagtg gcacgtcgc 8520
 40 gccgcgacg ggcaggttct ggtattgcg tctgagaaga cttgcgtgc ccaccacgc 8580
 tcgattgacg tctgtatct gactctctg ggtgaagct accggcccg tgagcttga 8640
 cctgaagaag agttcaacag aatcaatttc ggtatcgta acggcagctt gctcagat 8700
 ttctgtacg tcaccagagt tgtctgga ggcgatctcc gccatgaact gctcagttc 8760
 ttctctga agatctccg gacctctct ttgacgggt gccgcaggt cattggagat 8820
 45 accgcccag agtgggaga atgcattcat gccgcctcg ttccagacg ggtgtaaac 8880
 caggccccc tcggagctc ttgcgcgat caccacctga gcaggttaa gctccagtg 8940
 tctgtgaag accgcatagt tgcataggcg ctgaaaaagg tagttgagt tgggtgcaat 9000
 gtgtcggcg acgaagaat acatgatoca tctctcagc gccatttgc taacatcgc 9060
 cagagcttcc aagcgtcca tggcctcga gaagtcacg gcaaaattaa aaaactgga 9120
 50 gtttcggcg gacacgtca attctctc gagaagacg atgattcgg ctatggtgc 9180
 ccgtacttc gttcgaag ctccgggat ctctctcc tctctatct ctcttccac 9240
 taacatctct tcttctct caggcgggg cggaggggc acgcggcgac gtcagggcg 9300
 cacgggcaaa cgtcgtatga atcgttcaat gacctccg cggcgcgcg gcattgttc 9360

55

agtgacggcg cgccgttct cgcgcggtcg cagagtaaaa acaccgccgc gcattctctt 9420
 aaagtgggta ctgggagggt ctccgtttgg gagggagagg gcgtgatta tacattttat 9480
 taattggccc gtagggactg cgcgcagaga tctgatctg tcaagatcca cgggatctga 9540
 aaaccttctc acgaaagcgt ctaccagtc acagtcacaa ggtaggctga gtacggcttc 9600
 ttgtggcgcg ggggtggtat gtgttcggtc tgggtcttct gtttcttct catctcggga 9660
 aggtgagacg atctgctggt tgatgaaatt aaagtaggca gtictaagac ggcggatggt 9720
 ggcgaggagc accaggtctt tgggtccggc ttgctggata cgcaggcgat tggccattcc 9780
 ccaagcatta tcttgacatc tagcaagatc ttgtagtag tcttgcatga gccgttctac 9840
 gggcacttct tctcaccgc ttctgcatg catacgtgt agtccaaatc cgcgcattgg 9900
 ttgtaccagt gccaaagtcag ctacgactct ttcggcgagg atggcttgcg gtacttgggt 9960
 aagggtggct tgaagtcac caaaatccac aaagcgggtg taagccctg tattaatggt 10020
 gtaagcacag ttggccatga ctgaccagtt aactgtctgg tgaccagggc gcacgagctc 10080
 ggtgtattta aggcgcgaat aggcgcgggt gtcaaatgag taatcgttgc aggtgcgcac 10140
 cagatactgg taccctataa gaaaatgcgg cgggtggtgg cggtagagag gccatcgttc 10200
 ttagctggga gcgcaggagg caggtcttcc caacataagg cggtagatgc cgtagatgta 10260
 cctggacatc caggtgattc ctgcggcggt agtagaagcc caggaaaact cgcgtacgcg 10320
 gttccaatg ttgcgtagcg gcataagta gttcattgta ggcacgggtt gaccagttag 10380
 gcgcgcgagc tcattgatgc tctatagaca cggagaaaat gaaagcgttc agcactcga 10440
 ctccgtagcc tggaggaaac tgaacgggtt ggttcgcggt gtaccccggt tcgagacttg 10500
 tactcgagcc ggcgggagcc ggcgctaacg ttgtattggc actcccgctc cgaccagcc 10560
 tacaaaaatc caggatagcg aatcgagtcg ttttctggt ttcgaatgg cagggaagt 10620
 agtctattt tttttttt tttgcgcgc agatgcacc cgtgctgga cagatgcgc 10680
 cccaacaaca gcccccctcg cagcagcagc agcagcaacc aaaaaaggct gtccctgcaa 10740
 ctactgcaac tgcgcgcgtg agcgggtcgg gacagccgc ctatgatctg gacttggag 10800
 agggcgaagg actggcacgt ctagggtgcg cttgcgccga gcggcatccg cgagtccaac 10860
 tgaanaaaga ttctcgcgag gcgtatgtgc ccaacagaa cctatttaga gacagaagcg 10920
 gcgaggagcc ggaggagatg cgagcttccc gcttaacgc ggttcgtgag ctgcgtcacg 10980
 gtttggaccg aagacgagtg ttgcgagacg aggtattcga agttgatga gtgacaggga 11040
 tcagtctgc caggccacac gtgctgcag ccaacctgt atcgcttac gacgagacag 11100
 taaggaaga gcgttaactc caaaagtctt ttaataatca tgtcgcaacc ctgattgcc 11160
 gcgaagaagt tacccttgg ttgatgcatt ttgtggattt gatggaagct atcattcaga 11220
 accctacag caaacctctg accgccagc tgttctggt ggtgcaacac agcagagaca 11280
 atgaggctt cagagaggcg ctgctgaaca tcaccgaacc cagggggaga tggttgtatg 11340
 atcttatcaa cattctacag agtatcatag tgcaggagcg gacgtgggc ctggccgaga 11400
 aggtagctgc catcaattac tcggttttga gcttgggaaa atattacgt cgcaaatct 11460
 acaagactcc atacgttccc atagacaagg aggtgaagat agatgggttc tacatgcga 11520
 tgacgtcaa ggtcttgacc ctgagcgatg atcttgggt gtatgcgaat gacagaatgc 11580
 atcgcgcggt tagcgcagc aggaggcgcg agttaagca cagggaactg atgcacagt 11640
 tgcaagagc tctgactgga gctggaaccg agggtagaa ttacttcgac atgggagctg 11700
 acttgcagtg gcagcctagt cgcagggtc tgagcgccgc gacggcagga tgtgagcttc 11760
 cttacataga agaggcggt gaaggcgagg aggaagagg cgagtactg gaagactgat 11820
 ggcacaacc gtgtttttg ctatagga cagcaagcac cggatccgc aatgcggcg 11880
 gcgtgcaga gccagccgtc cggcattaac tctcggacg attggacca ggcattgcaa 11940
 cgtatcatg cgttgacgac tcgcaacccc gaagccttta gacagcaacc ccaggccaac 12000
 cgtctatcg ccatcatgga agctgtagt ccttcccgat ctaatccac tcatgagaag 12060
 gtcttgcca tctgaacgc gttggtggag aacaaagcta ttcgtcaga tgaggccgga 12120
 ctggtatata acgctctctt agaacgcgtg gctcgtaca acagtacaa tgtgcaaac 12180
 aattggacc gtatgataac agatgtacgc gaagccgtgt ctcagcgca aaggttcag 12240
 cgtgatcca acctgggtc gctggtggcg ttaaatgctt tcttgatc tcagcctgct 12300
 aatgtccgc gtggtcaaca ggattatact aacttttaa gtgcttgag actgatgga 12360
 tcagaagtac ctcagagcga agtgtatcag tccgctcgt attacttct tcagactagc 12420
 agacagggt tgcagaggt aaatctgagc caagcttta aaaaactta aggtttgtg 12480

ggagtgcatg ccccggtagg agaagagca accgtgtcta gcttgtaac tccgaactcc 12540
 cgctgttat tactgttgg agctccttc accgacagcg gtagcatcga ccgtaattcc 12600
 tatttgggtt acctactaaa cctgtatcgc gaagccatag ggcaaatga ggtggacgag 12660
 cagacctatc aagaattac ccaagtcagt cgcgtttgg gacaggaaga cactggcagt 12720
 ttggaagca ctctgaactt ctgttacc aatcggtctc aaaagatccc tctcaatat 12780
 gctcttactg cggaggagga gaggatcctt agatatgtgc agcagagcgt gggattgtt 12840
 ctgatgcaag agggggcaac tccgactgca gcactggaca tgacagcgcg aaatatggag 12900
 ccagcatgt atccagtaa ccgaccttc attaacaac tctggacta ctgcacaga 12960
 gctgcogeta tgaacttga ttatttacc aatgccatct taaaccgca ctggtgccc 13020
 ccacctgtt tctacacggg cgaatatgac atgcccagc ctatgacgg atttcttgg 13080
 gacgacgtg acagcgatgt ttttaccct cttctgac atcgacgtg gaaaaaggaa 13140
 ggcggtgata gaatgcattc tctgcatcg ctgtccgggg tcatgggtgc taccgcggt 13200
 gagcccgagt ctgaagtc ttttctagt ctaccttt ctctacacag tgtacgtagc 13260
 agcgaagtg gtagaataag tgcoccgagt ttaatggcg aagaggagta cctaaacgat 13320
 tcttgccta gaccggcaag agaaaaaat tccccaaaca atggaataga agtttggg 13380
 gataaaatga gtagatgaa gacttatgct caggatcaca gagacgacc tgggatcatg 13440
 gggactacaa gtagagcgag ccgtagacgc cagcgccatg acagacagag ggtcttctg 13500
 tgggacgatg aggattcgc cgtatagac agcgtgttg acttgggtg gagaggaagg 13560
 ggcaaccgtt ttgtcattt gcgcctcgc ttgggtgta tgttgtaaa aaaaataaaa 13620
 aaaaaaact caccaaggcc atggcgacga gcgtacgttc gttctctt attatctgtg 13680
 tctagtataa tgaggcgagt cgtctagcg ggagcggtg tctatccga ggtctctct 13740
 ccttctagc agagcgtgat gcagcagcg caggcgacgg cgtgatgca atcccactg 13800
 gaggctcct ttgtcctcc gcgatacct gcacctacgg agggcagaaa cagcattcgt 13860
 tactcggaac tggacctca gtacataacc accaggtgt atctgttga caacaagtcg 13920
 gcggacatt ctctctgaa ctatcagaat gaccacagca actcttgac caggtgtgtg 13980
 cagaacaatg actttaccoc tacggaagcc agcaccaga ccattaact tgaagaaga 14040
 tgcgggtggg cgggtcagct aaagaccatc atgcatacta acatgcaaa cgtgaacgag 14100
 tatatgtta gtaacaagt caaagcgct gtgatggtt ccagaaacc tccgacggt 14160
 gctgcagtg gggatactta tgatcacaag caggatattt tgaatatga gtgttcgag 14220
 ttactttgc cagaaggcaa ctttcagtt actatgacta ttgattgat gaacaatgcc 14280
 atcatagata attactgaa agtgggtaga cagaatggag tgcctgaaag tgacattggt 14340
 gttaaagtcg acaccaggaa ctcaagctg ggtatggatc ccgaaccaa gttgatcatg 14400
 cctggagtgt atacgtatga agccttccat cgtgacatt tcttactgcc tggctcgga 14460
 gtggatttta ccgagagtcg ttgagcaac ctcttggtg tcagaaaaaa acagccattt 14520
 caagagggtt ttaagatttt gtatgaagat ttagaagggt gtaattatcc ggccctctg 14580
 gatgtagatg cctatgagaa cagtaagaaa gaacaaaaag ccaaaataga agctgttaca 14640
 gctgctcag aagctaagc aaacatagtt gccagcgact ctacaagggt tgctaacgt 14700
 ggagaggica gaggagacaa ttttgcgca acactgttc cgttcgaca atcattattg 14760
 gccgatgtgt ctgaaggaa gcacgtgaaa ctactattc aaactgtaga aaaagatagt 14820
 aagaatagaa gctataatgt gtggagac aaatcaaca cagctatcg cagttggtat 14880
 ctttctaca attatggcga tccgaaaaa ggagtgcgtt cctggacatt gctcaccacc 14940
 tcagatgca cctgcggagc agagcaggtt tactggtgc ttccagacat gatgaaggat 15000
 cctgtcact tccgtccac tagacaagt agtaactacc ctgtgtggg tgacagctt 15060
 atgcccgtct tctcaagag cttctacaac gaacaagctg tgaactcca gcagctccg 15120
 cagtcacact cgttacgca cgtcttaac cgtttctg agaaccagat ttaatccgt 15180
 ccgcccgcgc ccaccattac caccgtcagt gaaaacgttc ctgctctac agatcacggg 15240
 accctgccgt tgcgacgag tatccgggga gtccaacgtg tgaccgttac tgacgccaga 15300
 cgcgcacct gtccctacgt gtacaaggca ctgggcatag tgcacccgc cgtccttca 15360
 agccgcact tctaaaaaa aaaaatgtcc attcttatct cgcagtaa taacaccgt 15420
 tgggtctgc gcgtccaag caagatgtac ggaggcgac gaaaacgttc taccoacat 15480
 ccgtgctgt ttccgggaca ttttgcgt ccatgggtg cctcaaggc ccgactcgc 15540
 gttcgaacca ccgtgatga tgaatcgt caggtgttg ccgacccc taattatact 15600

cctactgcgc ctacatctac tgtggatgca gttattgaca gtgtagtggc tgacgtcgc 15660
 aactatgctc gacgtaagag cggcggaagg cgcattgcc aacgccaccg agctaccact 15720
 gccatgcgag ccgcaagagc tctgctacga agagctagac gcgtggggcg aagagccatg 15780
 5 cttagggcgcg ccagacgtgc agcttcgggc gccagcgccg gcaggtcccg caggcaagca 15840
 gccgctgtcg cagcgcgacg tattgccgac atggccaat cgcgaagagg caatgtatac 15900
 tgggtgcgtg acgctgccac cgtcaacgt gtacccgtgc gcacccgtcc cctcgcact 15960
 tagaagatac tgagcagctc ccgatgtgt gtccagcggc caggatgtc caagcgcaaa 16020
 10 tacaaggaag aaatgctgca ggttatcgca cctgaagtct acggccaacc gttgaaggat 16080
 gaaaaaaaaa cccgcaaaat caagcgggtt aaaaaggaca aaaaagaaga ggaagatggc 16140
 gatgatgggc tggcggagtt tgtgcgcgag ttgtccacac ggcgacgcgt gcaatggcgt 16200
 gggcgcaaaag ttgcacatgt gttgagacct ggaacttcgg tggctttac acccgcgag 16260
 cgttcaagcg ctactttta gcttccat gatgaggtgt acggggatga tgatattctt 16320
 gagcagggcg ctgaccgatt aggcgagttt gcttatggca agcgtatgag aataacttc 16380
 15 aaggatgaga cagtgtcaat accctggat catggaatc ccacccctag tcttaaacg 16440
 gtcactttgc agcaagtgtt acccgttaact ccgcgaacag gtgttaaacg cgaaggtgaa 16500
 gatttgtatc ccactatgca actgatgta cccaacgcc agaagtggga ggacgtttt 16560
 gagaagataa aagtggatcc agatattcaa cctgaggtta aagtgaagacc cattaagcag 16620
 gtacgcctg gtctgggggt acaaaactga gacattaaga tccactga aagtatggaa 16680
 20 gtgcaaaactg aacccgcaaa gctactgcc accccactg aagtcaaac ggaatccatg 16740
 atgcccacgc ctattacaac tgacgcgcgc ggtccactc gaagatccc acgaaagtac 16800
 ggtccagcaa gtctgtgat gcccaattat gttgtacac catctattat tctactcct 16860
 ggttacgcag gcaactcgta ctatcgagc cgaacagta cctcccgccg tcgcccaag 16920
 25 acacctgcaa atgcagtcg tcgccgtaga cgcacaagca aacgcactc cggcgccctg 16980
 gtgcggcaag tgtacgcgaa tggtagtcg gaaccttga cactgcgcgc tgcgcgttac 17040
 catccgagta tcatcactta atcaatgttg ccgtgcctc cttgcagata tggccctac 17100
 ttgtccctt cgcgttcca tcatgttga ccgaggaaga aactcgccc gtagaagagg 17160
 gatgttggga cgcggaatgc gacgtacag gcgacggcgt gctatccga agcaattgcg 17220
 30 ggtgtgttt ttaccagct taattccaat tatcgtgtc gcaattggcg cgataccagg 17280
 catagcttc gtggcggtc aggcctcgca acgacatga cattgaaaa aaaacgtata 17340
 aataaaaaaa aatacaatgg actctgacac tctgttctt gtactatgt tttcttagag 17400
 atggaagaca tcaattttc atccttggt ccgcgacac gcacgaagcc gtacatgggc 17460
 acctggagcg acatggcac gagccaactg aacggggcg cttcaattg gagcagatc 17520
 35 tggagcgggc ttaaaaattt tggctcaacc ataaaaacat acgggaacaa agcttggaa 17580
 agcagtagac gacagggcgt tagaaataaa cttaaagacc agaacttca aaaaaagta 17640
 gtcatggga tagcttcgg catcaatgga gtgtagatt tggctaaca gctgtgcag 17700
 aaaaagataa acagtcttt ggaccccgcc ccagcaacc caggtaaat gcaagtggag 17760
 gaagaaattc ctccgccaga aaaaagggc gacaagcgc cgcgtccga ttggaagag 17820
 40 acgtgtgta cgcgcgtaga tgaaccgct tcttatgagg aagcaacgaa gcttggaa 17880
 cccaccata gaccgatag ccaatggcc accgggtga tgaaccttc tcagttgcat 17940
 cgacccgtca ccttgattt gcccctccc cctgtgcta ctgtgtacc cgcttcaag 18000
 cctgtcgtg cccgaaacc agtcgcgta gccaggtcac gtccggggg cgctcctct 18060
 ccaaatgcgc actggcaaaa tactctgaac agcatcgtg gtctagggct gcaagtgta 18120
 45 aaacgcgcgc gctgtttta attaaatat gactagcgt taactgct atctgtgtat 18180
 atgtgtcatt acacgcgc acagcagcag aggaaaaaag gaagaggtc tgcgtgcag 18240
 ctgagttact tcaagatgg ccacccatc gatgtgccc caatggcat acatgcacat 18300
 cgccggacag gatgttcgg agtaacctg tccgggtct gtgcagttc cccgcgccac 18360
 agacacctac ttaacttgg gaaataagtt tagaaatccc accgtagcgc cgaccacga 18420
 tgtgaccacc gaccgatgc agcgcctcat gttgcgttc gtgcocgtg accgggagga 18480
 50 caatacatat tcttcaaaag tgggttacac cctggccgtg ggcgacaaca gactgtgga 18540
 tatggccagc agtctttt acattagggc cgtgttgac agaggtcca gtttcaaac 18600
 ctattctgt acgcttaca actcttggc tctaaaggc gctcaaatg catctcaatg 18660
 gattgcaaaa ggcgtacca ctgcagcag cgcaggcaat ggtgaagaag aacatgaac 18720

agaggagaaa actgctactt acacttttgc caatgctcct gtaaaagccg aggcctcaaat 18780
 tacaaaagag ggcttaccaa taggtttgga gatttcagct gaaaacgaat ctaaacccat 18840
 ctatgcagat aaactttatc agccagaacc tcaagtggga gatgaactt ggaactgacct 18900
 5 agacggaaaa accgaagagt atggaggcag ggctctaaag cctactacta acatgaaacc 18960
 ctgttacggg tcctatcgga agcctactaa tttaaaaggt ggtagggcaa aaccgaaaaa 19020
 ctcggaaccc tcgagtgaaa aaattgaata tgatattgac atggaatttt ttgataactc 19080
 atcgcaaaaga acaaaactta gtcttaaaat tgcctatgat gcagaaaatg taggtttgga 19140
 aacgccagac actcatgtag tgtacaaacc tggaaacaga gacacaagt cgaagctaa 19200
 10 ttgggacaa cagtctatgc ccaacagacc caactacatt ggcttcagag ataactttat 19260
 tggactcatg tactataaca gtactggtta catgggggtg ctggctggtc aagcgttca 19320
 gttaaatgca gtggttgact tgcaggacag aaacacagaa ctttcttacc aactcttgc 19380
 tgactctctg ggagacagaa ccagataact tagcatgtgg aatcaggctg tggacagtta 19440
 tgatcctgat gtacgtgtta ttgaaaatca tgggtggaa gatgaactt ccaactattg 19500
 15 ttttccactg gacggcatag gtgttccaac aaccagttac aaatcaatag ttccaaatgg 19560
 agaagataat aataattgga aagaacctga agtaaatgga acaagtgaaga tcggacaggg 19620
 taattgttt gccatggaaa ttaacctta agccaatcta tggcgaagt tctttattc 19680
 caatgtggct ctgtatctcc cagactcgt caaatacacc ccgtccaatg tcaactctcc 19740
 agaaaaacaaa aacacctacg actacatgaa cggcgggggtg gtgcggccat ctctagtga 19800
 20 cactatgtg aacattgggt ccagggtggtc tctggatgcc atggacaatg tcaaccatt 19860
 caaccaccac cgtaacgtg gtttgcgtta ccgatctatg ctctgggta acggacgtta 19920
 tgtcctttc cacatacaag tgcctaaaa atttctcgt gttaaaaacc tctgcttct 19980
 ccaggctcc tacacttatg agtgaactt taggaaggat gtgaacatgg ttctacagag 20040
 ttccctcgt aacgacctg gggtagatgg cgcagcctc agtttcacga gcataaact 20100
 25 ctatgctact ttttccca tggctcaaa caccgttcc accctgaag ccattgctg 20160
 gaatgacacc aatgatcagt catcaacga ctacctatct gcagtaaca tgcctaccc 20220
 catctctcc aatgaacca atattccat ttccattct tctcgcaact gggcggttt 20280
 cagaggctgg tcatttaca gactgaaaac caaanaaact cctctttgg ggtctggatt 20340
 tgacctctac ttgtctatt ctggttctat tccctacctg gatggtacct tctacctga 20400
 30 ccacactttt aagaagggtt ccactcatgt tgactttca gtgagctggc ctggaaatga 20460
 caggttacta tctctaacc aatttgaat aaagcgcact gtggatggcg aaggttaca 20520
 cgtagccaa tgcaaatga ccaagactg gttcttgta cagatgctcg ccaactaca 20580
 ctggctcat cagggttct acattcaga aggatacaaa gatcgcattg attcatttt 20640
 cagaacttc cagccatga gcaggcaggt ggtgatgag gtcaattaca aagacttca 20700
 35 ggccgtgcc atacctacc aacacaacaa ctctggttt gtgggttaca tggctccgac 20760
 catcgccaa ggtcaacct atcccgtaa ctatccat ccactcatt gaacaactgc 20820
 cgtaaatagt gttacgaga aaaagtctt gtgtgacaga accatgtggc gcataccgt 20880
 ctgagcaac ttcattgcta tgggggccc tacagacttg ggacagaata tgcctatgc 20940
 caactcagct catgctcgg acatgacct tgagggtgat ccatggatg agccacct 21000
 40 gctttatct ctctcgaag tttcgactg gtcagagtgc catcagccac acccgggcat 21060
 catcgagga gtctacctgc gtacacggt ctggccggt aacgtacca cgtagaagc 21120
 ttctgttc ttgcaaatag cagctgcaac catggcctgc ggaatccaaa acggctccag 21180
 cgagcaagag ctgagagcca ttgtccaaga cctgggtgc ggacctatt tttgggaac 21240
 ctacgataag cgttcccg ggtcatggc cccgataag ctgctgtg ccattgtaa 21300
 45 tacggccga cgtgagacgg ggggagaga ctggttggt ttcggttga acccagttc 21360
 taacacctgc taccttttg atcttttg attctggat gatcgttca aacagattta 21420
 ccagttgaa tatgagggtc tctgcgcg cagcgtctt gctaccaagg accgtgtat 21480
 tacgtggaa aaacttacc agaccgtga gggcccccgt tctgcgct gggactttt 21540
 ctgctcatg ttcctcacg ctttgtgca ctggcctgac cgtccatgg acggaaccc 21600
 caccatgaaa ttgtaactg gagtccaac caacatgct catttctta aagtccagcc 21660
 50 caccctgtg gacaatcaaa aagcactta ccttttctt aataccatt cgccttatt 21720
 tgcctctat cgtacacaca tcgaaaggc cactgcgtt gaccgtatg atgttcaata 21780
 atgactcatg taaacaactg gttcaataaa catcactta ttttttaca tgtatcaagg 21840

ctctggatta cttatttatt tacaagtcga atgggttctg acgagaatca gaatgacccg 21900
 caggcagtg tacgttgcgg aactgatact tgggttgcca cttgaattcg ggaatcacca 21960
 acttgggaac cggatatcgc ggcaggatgt cactccacag ctttctgtgc agctgcaaa 22020
 ctccaagcag gtcaggagcc gaaatcttga aatcacaatt aggaccagtg ctctgagcgc 22080
 gagagtgcg gtacaccgga ttgcagcact gaaacacat cagcgacgga tgtctcacgc 22140
 ttgccagcac ggtgggatct gcaatcatgc ccacatccag atcttcagca ttggcaatgc 22200
 tgaacggggt catcttcag gtctgcctac ccattggcgg caccatcta ggcttgggt 22260
 tgcaatgcga gtgcaggggg atcagtatca tcttggcctg atoctgtctg attctggat 22320
 acacggctct catgaaagca tcatattgct tgaagcctg ctgggttta ctacctcgg 22380
 tataaaacat ccgcaggac ctgctcgaaa actggttagc tgcacagccg gcatcattca 22440
 cacagcagcg ggcgtcattg ttggctattt gcaccacact tctgcccag cggttttggg 22500
 tgattttgt tgcctcggga ttctccttta aggtccttg tccgttctg ctggccacat 22560
 ccattcgtat aatctgtcc ttctgaatca taatattgcc atgcaggcac ttacgttgc 22620
 cctcataatc attgcagcca tgaggccaca acgcacagcc tgtacattcc caattatggt 22680
 gggcgatctg agaaaaagaa tgtatcattc cctgcagaaa tcttccatc atcgtgtca 22740
 gtgtctgtg actagtgaat gtttaactga tgcctcgtg ctcttcgttt acgtactggt 22800
 gacagatgcg cttgtattgt tctgttgcct caggcattag tttaaacag gttctaagt 22860
 cgttatccag cctgtacttc tccatcagca gacacatcac ttcatgct ttctcccaag 22920
 cagacaccag gggcaagcta atcggattct taacagtga ggcagcagct cctttagcca 22980
 gaggtcatc tttagcgtc ttctaatgc ttcttttgc atcttctca acgatgcga 23040
 cggcggggta gctgaaaccc actgctacaa gttgcgctc ttctctttt tcttctgtg 23100
 cttagctgat gtctgcagc gggatatgtt tggcttctt tggcttctt ttgggggta 23160
 tggaggagg aggactgtc ctccgttccg gagacagga ggaattgac gtttcgtca 23220
 ccattacca ctgactgtc gtagaagaac ctgacccac acggcgacag gttttttct 23280
 tggggggcag aggtggagcg gattgcgaag gctcgggc cgacctgaa ggcggatgac 23340
 tggcagaacc ccttcgcgt tgggggtgt gtcctctg gggctgctt aactgattc 23400
 cttcggcgt ggccattgt ttctctagg cagagaaaca acagacatgg aaactcagc 23460
 attgtgtca acatgccac gagtccatc acatctctc ctacgcagc aggaaaagga 23520
 gcagagctta agcattccac cgcacagtc tgcaccacc tctacctag aagataagga 23580
 ggtcgacga tctcatgca tcagataaa aaaagcgaag gactctgaga cagacatga 23640
 gcaagaccg gctatgtga caccggtgga acacgagga gattgaac gttttaga 23700
 gagagaggat gaaaactgcc caaaacagcg agcagataac tatcacaag atgtggaaa 23760
 tagggatcag aacaccgact acctcatagg gttgacggg gaagacgcgc tcttaana 23820
 tctagcaaga cagtgcctca tagtcaagga tgcattatg gacagaactg aagtcccat 23880
 cagtgtgaa gagctcagct ggcctacga gcttaacct tttcacctc gtactcccc 23940
 caaacgtcag ccaaacggca cctgcagcc aaatctctc ttaactttt atccagctt 24000
 tctgtgcca gaagtactg ctacctatca catcttttt aaaaatcaaa aaattccagt 24060
 ctctgcgcg gctaactga cccgcgcga tgcctactc aatctgggac ctggttcag 24120
 cttacctat atagcttct tgaagaggt tccaaagatc ttcgagggtc tgggcaata 24180
 tgagactcgg gccgcaatg ctctcgaana gggagaaaat ggcattgatg agcatcacg 24240
 cgttctgtg gaattggaag gcgataatgc cagactcga gtactcaagc gaagcgtga 24300
 ggtcacacac ttgcataat ccgtgtcaa cctgcccct aaagtcatga cggcggtcat 24360
 ggaccagta ctcattaaag gcgcaagtcc ctttcagaa gacatgatg accagatgc 24420
 ctgtgatgag ggtaaaccag tggtagtga tgagcagta acccgatggc tgggaccca 24480
 ctctcccggt gatttgaag agcgtcga gcttatgat ggcgtgtgc tggttaccgt 24540
 agaactagag tgtctccgac gttttttac cgattcagaa accttgcga aactgaaga 24600
 gaactgcac tacactttta gacacggctt tgtcggcag gcatgcaaga tatctaact 24660
 ggaactcacc aacctgttt cttacatggg tatttgcag gagaatgcc taggacaaag 24720
 cgtgctcac agcacctta agggggaagc ccgcgtgat tacatccgc attgtgtca 24780
 tcttacctg tgcacacgt ggcaaacgg catgggtga tggcagcaat gtttagaaga 24840
 acagaactg aaagagctt acaagctct acagaaatct cttaggttc tgtggacag 24900
 gttcgacgag cgcaccgtc cttccgact ggcagacct atcttccag agcgtctcag 24960

gggttactttg cgaaacggat tgcctgactt tatgagccag agcatgctta acaattttcg 25020
 ctcttttcac ctggaacgct ccggtatcct gcccgcacc tgcctgctac tgcctccga 25080
 5 ctttgtgct ctacctacc cggagtgc ccgcgccta tggagtact gtaactgtt 25140
 ccgtctggcc aactatctt cctaccactt ggaatgtatc gaggatgtga gcggagacgg 25200
 cttgtctggag tgcactgcc gctgcaatct gtgcacgcc caccggtccc tagcttgcaa 25260
 cccccagttg atgagcgaaa ccagataat aggcaccttt gaattgcaag gcccagcag 25320
 ccaagcgat ggtctcttc ctgggcaag ttaaaactg acccgggac tctggacctc 25380
 cgctacttg cgcaagttg ctccgaaga taccacccc tatgaatca agtctatga 25440
 10 ggaaccaatc cagctccaa agccggaact ttcggttgc gtcacaccc agggggcaat 25500
 tctggccaa ttgcaagcca tcaaaaaatc ccgccaagaa ttctactga aaaagggtaa 25560
 gggggtctac cttgacccc agaccggcga ggaactcaac acaagttcc ctacagatgt 25620
 cccaacgacg agaaaacaag aagtgaagg tgcagccgc gccccagaa gatattggagg 25680
 aagattggga cagtacgga gaggaggcgg agggagacg tctggaggac agtctggagg 25740
 15 aagacagttt ggaggaggaa aacgaggagg cagaggaggt ggaagaagta accgcgaca 25800
 aacagtiate ctgggtgctg gagacaagca acagcgtac catctccgt ccgagtcgag 25860
 gaaccggcg gcgtccagc agtagatggg acgagaccgg acgttccc aaaccaacca 25920
 ggccttcaa gaccgtaag aaggatcgcc agggatacaa gtctggcgg gggcataaga 25980
 atgcacat ctctgcttg catgagtcg ggggcaacat atcttcacg cgcgctact 26040
 20 tctattcca ccatggggg aactttccg gcaatgttt gctactac cgtcacctc 26100
 acagcccta ctatagccag caaatccga cagtctgc agataangac agcggcgcg 26160
 actccaaca gaaaaccagc agcggcagtt agaaaataca caacaagtc agcaacagga 26220
 ggattaaaga ttacagcaa cgagccagc caaaccgag agtaagaaa tcgcatctt 26280
 ccaacctgt atgcatctt ccagcagagt cgggtcaag agcaggaact gaaaataaaa 26340
 25 aaccgatctc tgcgttctc caccagaagt tgtttgtat acaagagcga agatcaact 26400
 cagcgcactc tgcaggacgc caggtcttc tcaacaagt actgcgct gactcttaa 26460
 gaggtagcag cgaccgctt tattcaaaa agcgggaat tacatator tgcacatgag 26520
 taaagaaatt ccacgcctt acatgtggag ttatcaacc caaatgggat tggcagcagg 26580
 cgctccag gactactca ccgcagtaa ttggctcagc gccggcctt ctatgattc 26640
 30 tgcagttat gatatacgc cctaccgaaa ccaatactt ttggaacagt cagctctac 26700
 caaccgccc cgcaacacc ttaatccag aaattggcc gccgctag tgcacagga 26760
 aagtcctgt ccaccactg tattacttc tgcagagcc caggccgag tocaaatgac 26820
 taatgcaggt gcgcagttg ctggcgctc caccatgt cgtcacagg ctgcgcataa 26880
 tataaaacgc ctgatgata gaggccgagg tatccagctc aacgacgagt cggtagctc 26940
 35 tccgttgt ctacgaccag acggaatct ttagattgc ggtcgggga gatcttctt 27000
 caacctgt cagctgttc tgactttga aagttctt tgcacccc gctcggggg 27060
 aatcgggacc gtcaatttg tagaggagt tactcctct gctactta acccttctc 27120
 cggatctct gggcactacc cggacgagt cataccgac ttgcagcga ttagcgagt 27180
 agtgagcgc tagattgat gtctgtgac cggctgagc tatctcggt gcgacatca 27240
 40 gaccactgc gccgtttc ctgcttgc cggaacta ttgattcat ctacttgaa 27300
 ctcccaagg atcaccctca agtccggcc cagcgagtgc ggattacta cgaaggcaa 27360
 atagactct cctgcaacg aattttctc cagcgcccg tctgatcga gcgagaccag 27420
 ggaaacacca cgtttccat ctactgcat tgaatcacc ccgattgca tgaagcctt 27480
 tctgtctta tctgtactga gtttaataa aactgaatta agactctct acggactgc 27540
 45 gcttctcaa ccggatttt acaaccagaa gaacaaact ttctctgct tccaggactc 27600
 tgttaactc accttcta ctacaaact agaagtcga cgaactacc gttttccag 27660
 agcattttc ctactaata ctacttcaa aaccggaggt gagtcacg gttccctac 27720
 agaaaacct tgggtggaag cgggcttgt agtactagga attcttgcg gtgggctgt 27780
 gattattctt tctactat acacacctg ctactttc ctagtgtgt tctgtattg 27840
 50 gtttaaaaa tggggccat actagtctt cttgtttac ttctgtttt ggaaccgggt 27900
 tctgcaatt acgatccat tctagactt gaccagaaa actgcacact tacttttga 27960
 ccgacacaa gccgatctg tggattctt attagtgc gatgggaat caggtccgt 28020
 gaaattacac acaataacaa aacctggaac aatcttat ccaccatg ggagccagga 28080

gtccccgagt ggtacactgt ctctgtccga ggctctgacg gttccatccg cattagtaac 28140
 aacactttca tttttctga aatgtgcgat ctggccatgt tcatgagcaa acagtattct 28200
 ctatggctc ctagcaagga caacatcgt acgtttcca ttgcttattg ctgtgcgt 28260
 5 tgccttcta ctgcttact gtgcgtatgc atacactgc ttgtaaccac tgcacataa 28320
 aacgccaata acaaagaaaa aatgcctta cctctttctg ttacagaca tggcttct 28380
 tacatctc atattgtca gcattgtcac tgcgctcac ggacaacag tegtctctat 28440
 cccactagga cataattaca ctctcatagg accccaatc acttcagagg tcatctggac 28500
 caaactggga agcgttgatt actttgatat aatctgtaac aaaacaaaac caataatagt 28560
 10 aacttgcaac atacaaaatc ttacattgat taatgttagc aaagtattaca gcggttacta 28620
 ttatggttat gacagataca gtatgcaata tagaaattac ttggttcgtg ttaccagtt 28680
 gaaaaccacg aaaatgcca atatggcaaa gattcgatcc gatgacaatt ctctagaac 28740
 tttacatct cccaccacac ccgacgaaaa aaacatocca gattcaatga ttgcaattgt 28800
 tgcagcggg gcagtggtga tggcactaat aataatagc atgttttat atgttctg 28860
 15 ctacaaaaag tttcatccta aaaaacaaga tctctacta aggttaaca ttaatttct 28920
 tttatagag ccatggttc cactaccaca ttcttatgc ttactagtct cgaactctg 28980
 actctgctc gctcacact cactgtaact ataggctcaa actgcacact aaaaggacct 29040
 caagtggtc atgtctttg gtggagaata tatgacaatg gatggttac aaaaccatgt 29100
 gaccaaccig gtatgtttt ctgcaacggc agagacctaa ccattatcaa cgtgacagca 29160
 20 aatgacaaaag gcttctatta tggaaacgac tataaaagta gtttagatta taacattatt 29220
 gtactgcat ctaccactcc agcaccocgc acaactactt tctctagcag cagtctcgt 29280
 aacaatataa ttccaatcc aaccttgcc gcgtttta aacgcactgt gaataattct 29340
 acaacttcac atacaacaat ttccactca acaatcagca tcatcgtgc agtgacaatt 29400
 ggaatatcta ttctgtttt taccataacc tactacgct gctgctatag aaaagacaaa 29460
 25 cataaagggt atccattact tagatttgat atttaattg ttctttttt ttattacag 29520
 tatggtgaac accaatcatg gtacctagaa atttctctt caccatactc atctgtgctt 29580
 ttaattgtt gcgtacttc acagcagtag ccacagcaac cccagactgt ataggagcat 29640
 ttgcttcta tgcactttt gcttttgta ctgcatctg cgtatgtagc atagtctgc 29700
 tggttattaa tttttocaa ctctagact ggtcttctg gcgaattgcc tacctgcgc 29760
 30 accatccga ataccgcaac caaaatatc cggcactct tagactcacc taaaaccatg 29820
 caggctatac taaccaatatt tttgcttcta ttgcttccct acgtgtctc aacccagct 29880
 gcttatagta ctocaccaga acacttaga aaatgcaaat tccaacaacc gtgtcattt 29940
 ctgcttgc atcgagaaaa atcagaaatc ccccaaat taataatgat tcttggaata 30000
 attaatataa tctgttcac cataattca ttttgatat acccttatt tgatttggc 30060
 35 tggaaatgc ccaatgcaca tgatcatcca caagaccag aggaacacat tccccacaa 30120
 aacatgcaac atccaatagc gtaaatagat tacgaaagt aaccacaacc cccactact 30180
 cctgtatta gttacttcaa ctaaccggc ggagatgact gaacactca ccactccaa 30240
 ttccgccgag gatctgctg atatggacgg ccgcttca gaacaacgac ttgccaact 30300
 acgcatccg cagcagcagg aacgcgtgc caaagagctc agagatgca tccaattca 30360
 40 ccaatgcaaa aaaggcatat tctgtttgt aaaacaagcc aagatatct acgagatcac 30420
 cgtactgac catgctct ctacgaact tggccccc aaacaaaaat ttactgcat 30480
 ggtgggaatc aacccatag ttatcacca acaaagtga gatactagg gttgattca 30540
 ctgctctgc gattccatc agtgaccta caccctgtc aagacctat gcggctaag 30600
 agacctgcta ccaatgaatt aaaaaaaat gattaataa aatcaccta ctgaaatca 30660
 45 gcaataagg ctctgttgaa attttctcc agcagacct cacttctc ttccaactc 30720
 tggattcta aacccgttc agcggcatac ttctccata cttaaagg gatgtcaat 30780
 tttagctct ctctgtacc cacaatctc atgttttct tccagatga ccaagagagt 30840
 ccggtcagt gactcttca accctgtc cccatgaa gatgaaagca cctcccaaca 30900
 ccccttata aacccaggt ttatttccc aatggctc acacaaagc cagacggagt 30960
 50 tcttactta aatgtttaa cccactaac aaccacagc ggaactctac agtaaaagt 31020
 gggagggga ctacagtgg atgacatga tggactta caagaaaaca tactgctac 31080
 agcaaccatt actaaaaata atcactctg agaactatc attggaatg gattagaac 31140
 tcaaaacaa aactatgtg ccaattggg aatgggtta aaattaca acggtgacat 31200

ttgtataaag gatagtatta acaccttatg gactggaata aacctccac ctaactgtca 31260
 aattgtgaa aacactaata caaatgatgg caaacttact ttagtattag taaaaaatgg 31320
 5 agggcttgtt aatggctacg tgtctctagt tgggtatca gacactgtga accaaatgtt 31380
 cacacaaaag acagcaaaaca tccaattaag attatatttt gactctctg gaaatctatt 31440
 aactgaggaa tcagacttaa aaatccact taaaaataaa tctctacag cgaccagtga 31500
 aactgtagcc agcagcaaaag cctttatgcc aagtactaca gcttatccct tcaacaccac 31560
 tactagggat agtgaaaact acattcatgg aatatgttac tacatgacta gttatgatag 31620
 10 aagtctattt ccttgaaca ttctataat gctaaacagc cgtatgattt ctccaatgt 31680
 tgccatgcc atacaatttg aatggaatct aaatgcaagt gaatctccag aaagcaacat 31740
 agctacgctg accacatccc ccttttctt ttcttactt acagaagacg acaactaaaa 31800
 taaagtttaa gtgtttttat ttaaaatcac aaaattcgag tagttatttt gctccacct 31860
 tccatttga cagaatacac caatctctcc ccagcacag ctttaaacat tiggatacca 31920
 15 tttagatag acattgtttt agattccaca ttcaaacag tttagagcg agccaatctg 31980
 gggtagtga tagataaaaa tccatcgga tagtctttta aagcgcttc acagccaac 32040
 tctcgcgat ggcactccg agtttgatc acggtcatct ggaagaagaa cgtgggaat 32100
 cataatcga aaacggatc ggacgattgt gtcctatcaa accacaagc agccgctgc 32160
 tgcctgcgc cgtgcgactg ctgtttatgg gatcagggtc cacagttcc tgaagcatga 32220
 20 ttttaatag ccttaacatc aactttctg tgcgatgcgc gcagcaacgc attctgattt 32280
 cactcaaatc ttgcagtag gtacaacaca ttattacaat attgtttaa aaaccataat 32340
 taaaagcgt ccagcaaaa ctcatactg atataatgc cctgcatga ccatcatacc 32400
 aaagttaa ataaattaaa tgacgttccc tcaaaaacac actaccaca tacatgatct 32460
 ctttggcat gtgcataa acaatctgc tgiacctgg acaacgttg ttaatcatgc 32520
 25 aaccaatat aaccttccg aaccacact ccaacaccg tcccagcc atgcattga 32580
 gtgaacctg ctgattacaa tgacaatga gaaccaat ctctgaccg tgaatcactt 32640
 gagaatgaa aatatctata gtggcacaac atagacata atgcatgcat ctctcataa 32700
 ttttaactc ctcaggattt agaacaatat cccaggaat aggaagctct tgcagaacg 32760
 taaagctggc agaacaagga agaccacgaa cacaactac actatgcata gtcatagat 32820
 30 cacaactcg caacagcggt tggcttcag tcatagaagc tgggtttca ttttctcac 32880
 aacgtgttaa ctgggctctg gtgtaagggt gatgtctggc gcagatgct gagcgtgcgc 32940
 gcaacctgt cataatggag ttgcttctg acattctgt attttgtata gcaaacgcg 33000
 gcoctggcg aacacactc tcttgcctt ctactctgc gcttagcgtg ttccgtgtga 33060
 tagttaagt acagccacac tcttaagtg gtcaaaagaa tgcgtgctc agttgtaac 33120
 35 aaaactccat cgcactaat tgtctgagg aaatcatcca cggtagcata tgcaaatccc 33180
 aaccaagcaa tgcaactgga ttgcgttca agcaggagag gagagggag agacggaaga 33240
 accatgttaa tttttatcc aaacgatctc gcagtactc aaattgtaga tgcgcagat 33300
 ggcatctct gccccactg tgttggtgaa aaagcacagc taaatcaaaa gaaatgcgat 33360
 tttaagggt ctcaacggtg gcttcaaca aagctccac gcgcacatcc aagaacaaaa 33420
 40 gaataccaaa agaaggagca ttttctaact cctcaatcat catattacat tctgcacca 33480
 ttccagata attttagct ttccagcctt gaattattcg tgcagttct tgtgttaaat 33540
 ccaatccaca caitacaac agtcccgga gggcgccct caccaccatt cttaaacaca 33600
 cctcataat gacaaaatat ctgtctctg tctacctgt agcgaattga gaatggcaac 33660
 atcaattgac atgccttgg ctctaagttc ttcttaagt tctagttga aaaactctct 33720
 catattatca ccaactgtct tagccagaag cccccggga acaagagcag gggacgctac 33780
 45 agtgcagtac aagcgagac ctcccaatt ggctccagca aaaaacagat tgaataagc 33840
 atattgggaa ccaccagtaa tatcatgaa gttgctggaa atataatcag gcagagtttc 33900
 ttgtagaat tgaataaaag aaaaatttgc caaaaaaca ttcaaacct ctgggatga 33960
 aatgcaatag gttaccgctg tgcgtccaa cattgttagt ttgaattag tctgcaaaaa 34020
 taaaaaaaa acaaggtca tatcatagta gctgacgaa cagggtgata aatcagttt 34080
 50 tccatcaaa gacaagccac agggctcca gctgacct cgtaaaacct gtcactgta 34140
 ttaacaaca gcaccgaaag ttctcgcg tgaccagcat gaataagtct tgatgaagca 34200
 tacaatccag acatgttagc atcagttag gaaaaaac agccaacata gccttgggt 34260
 ataattatgc ttaatcgtaa gtatgcaaa gccacccctc gcggatacaa agtaaaaggc 34320

acaggagaat aaaaaatata attatttctc tgctgctgtt taggcaactg cgccccgggt 34380
 ccctctaaat acacatacaa agcctcatca gccatggctt accagagaaa gtacagcggg 34440
 cacacaaaac acaagctcta aagtcactct ccaacctctc cacaatatat atacacaagc 34500
 cctaaactga cgtaatggga ctaaagtgtg aaaaatcccg ccaaacccaa cacacacccc 34560
 gaaactgct caccagggaa aagtacagtt tcacttcgc aatcccaaca agcgtcactt 34620
 cctctttctc acggtacgtc acatccatt aacttacaac gtcattttcc cagggccgcg 34680
 cgcgcccttt taaccgttaa cccacagcc aatcaccaca cgccccacac tttttaaatt 34740
 cacttcattt acatattggc accattccat ctataaggta tattattgat gatg 34794

<210> 85

<211> 585

<212> PRT

<213> Adenoviridae

<220>

<221> CHAIN

<222> (1)..(585)

<223> /note="Fiber protein of Adenovirus serotype 5"

<400> 85

Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn
 1 5 10 15

Pro Val Tyr Pro Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe
 20 25 30

Leu Thr Pro Pro Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro
 35 40 45

Gly Val Leu Ser Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly
 50 55 60

Met Leu Ala Leu Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly
 65 70 75 80

Asn Leu Thr Ser Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys
 85 90 95

Thr Lys Ser Asn Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr
 100 105 110

Ser Glu Ala Leu Thr Val Ala Ala Ala Ala Pro Leu Met Val Ala Gly
 115 120 125

Asn Thr Leu Thr Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser
 130 135 140

Lys Leu Ser Ile Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys
 145 150 155 160

Leu Ala Leu Gln Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr

EP 1 054 064 A1

	165	170	175
5	Leu Thr Ile Thr Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu		
	180	185	190
	Gly Ile Asp Leu Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly		
	195	200	205
10	Leu Lys Tyr Gly Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu		
	210	215	220
	Thr Val Ala Thr Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln		
15	225	230	235 240
	Thr Lys Val Thr Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln		
	245	250	255
20	Leu Asn Val Ala Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu		
	260	265	270
	Ile Leu Asp Val Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu		
	275	280	285
25	Arg Leu Gly Gln Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp		
	290	295	300
	Ile Asn Tyr Asn Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser		
30	305	310	315 320
	Lys Lys Leu Glu Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp		
	325	330	335
35	Ala Thr Ala Ile Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser		
	340	345	350
	Pro Asn Ala Pro Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly		
	355	360	365
40	Leu Glu Phe Asp Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly		
	370	375	380
	Leu Ser Phe Asp Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn		
	385	390	395 400
45	Asp Lys Leu Thr Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Arg		
	405	410	415
	Leu Asn Ala Glu Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys		
50	420	425	430
	Gly Ser Gln Ile Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser		
	435	440	445

55

EP 1 054 064 A1

Leu Ala Pro Ile Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg
450 455 460

Phe Asp Glu Asn Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu
465 470 475 480

Tyr Trp Asn Phe Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr
485 490 495

Asn Ala Val Gly Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His
500 505 510

Gly Lys Thr Ala Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly
515 520 525

Asp Lys Thr Lys Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln
530 535 540

Glu Thr Gly Asp Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp
545 550 555 560

Asp Trp Ser Gly His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser
565 570 575

Tyr Thr Phe Ser Tyr Ile Ala Gln Glu
580 585

<210> 86
<211> 356
<212> PRT
<213> Adenoviridae

<220>
<221> CHAIN
<222> (1)..(356)
<223> /note="Fiber protein of Adenovirus serotype 16"

<400> 86
Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn
1 5 10 15

Pro Val Tyr Pro Tyr Glu Asp Glu Ser Ser Ser Gln His Pro Phe Ile
20 25 30

Asn Pro Gly Phe Ile Ser Ser Asn Gly Phe Ala Gln Ser Pro Asp Gly
35 40 45

Val Leu Thr Leu Lys Cys Val Asn Pro Leu Thr Thr Ala Ser Gly Pro
50 55 60

EP 1 054 064 A1

5 Leu Gln Leu Lys Val Gly Ser Ser Leu Thr Val Asp Thr Ile Asp Gly
 65 70 75 80
 Ser Leu Glu Glu Asn Ile Thr Ala Ala Ala Pro Leu Thr Lys Thr Asn
 85 90 95
 10 His Ser Ile Gly Leu Leu Ile Gly Ser Gly Leu Gln Thr Lys Asp Asp
 100 105 110
 Lys Leu Cys Leu Ser Leu Glu Asp Gly Leu Val Thr Lys Asp Asp Lys
 115 120 125
 15 Leu Cys Leu Ser Leu Gly Asp Gly Leu Ile Thr Lys Asn Asp Val Leu
 130 135 140
 Cys Ala Lys Leu Gly His Gly Leu Val Phe Asp Ser Ser Asn Xaa Ile
 145 150 155 160
 20 Thr Ile Glu Asn Asn Thr Leu Trp Thr Gly Ala Lys Pro Ser Ala Asn
 165 170 175
 Cys Val Ile Lys Glu Gly Glu Asp Ser Pro Asp Cys Lys Leu Thr Leu
 180 185 190
 25 Val Leu Val Lys Asn Gly Gly Leu Ile Asn Gly Tyr Ile Thr Leu Met
 195 200 205
 30 Gly Ala Ser Glu Tyr Thr Asn Thr Leu Phe Lys Asn Asn Gln Val Thr
 210 215 220
 Ile Asp Val Asn Leu Ala Phe Asp Asn Thr Gly Gln Ile Ile Thr Tyr
 225 230 235 240
 35 Leu Ser Ser Leu Lys Ser Asn Leu Asn Phe Lys Asp Asn Gln Asn Met
 245 250 255
 Ala Thr Gly Thr Ile Thr Ser Ala Lys Gly Phe Met Pro Ser Thr Thr
 260 265 270
 40 Ala Tyr Pro Phe Ile Thr Tyr Ala Thr Glu Thr Leu Asn Glu Asp Tyr
 275 280 285
 45 Ile Tyr Gly Glu Cys Tyr Tyr Lys Ser Thr Asn Gly Thr Leu Phe Pro
 290 295 300
 Leu Lys Val Thr Val Thr Leu Asn Arg Arg Met Leu Ala Ser Gly Met
 305 310 315 320
 50 Ala Tyr Ala Met Asn Phe Ser Trp Ser Leu Asn Ala Glu Glu Ala Pro
 325 330 335
 55

EP 1 054 064 A1

5
10
15
20
25
30
35
40
45
50
55

Glu Thr Thr Glu Val Thr Leu Ile Thr Ser Pro Phe Phe Phe Ser Tyr
340 345 350

Ile Arg Glu Asp
355

<210> 87
<211> 325
<212> PRT
<213> Adenoviridae

<220>
<221> CHAIN
<222> (1)..(325)
<223> /note="Fiber protein of Adenovirus serotype 35"

<400> 87
Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn
1 5 10 15

Pro Val Tyr Pro Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile
20 25 30

Asn Pro Gly Phe Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly
35 40 45

Val Leu Thr Leu Lys Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Ser
50 55 60

Leu Gln Leu Lys Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly
65 70 75 80

Thr Leu Gln Glu Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn
85 90 95

His Ser Val Glu Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn
100 105 110

Lys Leu Cys Ala Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp
115 120 125

Ile Cys Ile Lys Asp Ser Ile Asn Thr Leu Trp Thr Gly Ile Asn Pro
130 135 140

Pro Pro Asn Cys Gln Ile Val Glu Asn Thr Asn Thr Asn Asp Gly Lys
145 150 155 160

Leu Thr Leu Val Leu Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val
165 170 175

EP 1 054 064 A1

5 Ser Leu Val Gly Val Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys
 180 185 190
 Thr Ala Asn Ile Gln Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu
 195 200 205
 10 Leu Thr Glu Glu Ser Asp Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser
 210 215 220
 Thr Ala Thr Ser Glu Thr Val Ala Ser Ser Lys Ala Phe Met Pro Ser
 225 230 235 240
 15 Thr Thr Ala Tyr Pro Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr
 245 250 255
 Ile His Gly Ile Cys Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Phe
 260 265 270
 20 Pro Leu Asn Ile Ser Ile Met Leu Asn Ser Arg Met Ile Ser Ser Asn
 275 280 285
 Val Ala Tyr Ala Ile Gln Phe Glu Trp Asn Leu Asn Ala Ser Glu Ser
 290 295 300
 25 Pro Glu Ser Asn Ile Met Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser
 305 310 315 320
 30 Tyr Ile Thr Glu Asp
 325
 35 <210> 88
 <211> 325
 <212> PRT
 <213> Adenoviridae
 40 <220>
 <221> CHAIN
 <222> (1)..(325)
 <223> /note="Fiber protein of Adenovirus serotype 51"
 45 <400> 88
 Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn
 1 5 10 15
 Pro Val Tyr Pro Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile
 20 25 30
 50 Asn Pro Gly Phe Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly
 35 40 45
 55

EP 1 054 064 A1

Val Leu Thr Leu Asn Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Pro
50 55 60

Leu Gln Leu Lys Val Gly Gly Gly Leu Ile Val Asp Asp Thr Asp Gly
65 70 75 80

Thr Leu Gln Glu Asn Ile Arg Val Thr Ala Pro Ile Thr Lys Asn Asn
85 90 95

His Ser Val Glu Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn
100 105 110

Lys Leu Cys Ala Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp
115 120 125

Ile Cys Ile Lys Asp Ser Ile Asn Thr Leu Trp Thr Gly Ile Lys Pro
130 135 140

Pro Pro Asn Cys Gln Ile Val Glu Asn Thr Asp Thr Asn Asp Gly Lys
145 150 155 160

Leu Thr Leu Val Leu Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val
165 170 175

Ser Leu Val Gly Val Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys
180 185 190

Ser Ala Thr Ile Gln Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu
195 200 205

Leu Thr Asp Glu Ser Asn Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser
210 215 220

Thr Ala Thr Ser Glu Ala Ala Thr Ser Ser Lys Ala Phe Met Pro Ser
225 230 235 240

Thr Thr Ala Tyr Pro Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr
245 250 255

Ile His Gly Ile Cys Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Val
260 265 270

Pro Leu Asn Ile Ser Ile Met Leu Asn Ser Arg Thr Ile Ser Ser Asn
275 280 285

Val Ala Tyr Ala Ile Gln Phe Glu Trp Asn Leu Asn Ala Lys Glu Ser
290 295 300

Pro Glu Ser Asn Ile Ala Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser
305 310 315 320

Tyr Ile Ile Glu Asp

Claims

1. A gene delivery vehicle comprising at least one of the adenovirus serotype 35 elements or a functional equivalent thereof, responsible for avoiding or deminishing neutralising activity against adenoviral elements by the host to which the gene is to be delivered and a gene of interest.
2. Adenovirus serotype 35 or a functional homologue thereof or a chimaeric virus derived therefrom, or a gene delivery vehicle based on said virus its homologue or its chimaera for use as a pharmaceutical.
3. A gene delivery vehicle according to claim 1, whereby said elements comprise adenovirus 35 E3 expression products or the genes encoding them.
4. A gene delivery vehicle according to claim 1 or 3, whereby said elements comprise adenovirus 35 fiber, penton and/or hexon proteins or a gene encoding either.
5. A gene delivery according to any one of claims 1,3, or 4 which is a chimaera of adenovirus 35 with at least one other adenovirus.
6. A gene delivery vehicle according to any one of claims 1,3,4 or 5 which has a different tropism than adenovirus 35.
7. A nucleic acid encoding at least a functional part of a gene delivery vehicle according to any one of claims 1 or 3-6, or a virus, homologue or chimaera thereof according to claim 2.
8. A nucleic acid encoding at least one of the adenovirus serotype 35 elements or a functional equivalent thereof, responsible for avoiding or deminishing neutralising activity against adenoviral elements by the host to which the gene is to be delivered and having a site for introducing a gene of interest therein.
9. A nucleic acid according to claim 7 or 8, further comprising at least one ITR.
10. A nucleic acid according to claim 7, 8 or 9 further comprising a region of nucleotides designed or useable for homologous recombination.
11. At least one set of two nucleic acids comprising a nucleic acid according to any one of claims 7-10, whereby said set of nucleic acids is capable of a single homologous recombination event with each other, which leads to a nucleic acid encoding a functional gene delivery vehicle.
12. A cell comprising a nucleic acid according to any one of claims 7-10 or a set of nucleic acids according to claim 11.
13. A cell according to claim 12 which complements the necessary elements for adenoviral replication which are absent from the nucleic acid according to any one of claims 7-10 or a set of nucleic acids according to claim 11.
14. A cell according to claim 12 or 13, which originates from a PER.C6 cell (ECACC deposit number 96022940).
15. A method for producing a gene delivery vehicle according to claim 1, or 3-6, comprising expressing a nucleic acid according to any one of claims 7-10 in a cell according to claim 12 or 13 and harvesting the resulting gene delivery vehicle.
16. A method for producing a gene delivery vehicle according to claim 1, or 3-6, comprising culturing a cell according to claim 12 or 13 in a suitable culture medium and harvesting the resulting gene delivery vehicle.
17. A gene delivery vehicle obtainable by a method according to claims 15 or 16.
18. A gene delivery vehicle according to any one of claims 1,3-6 or 17, which is derived from a chimaera of an adenovirus and an integrating virus.
19. A gene delivery vehicle according to claim 18, wherein said integrating virus is adeno associated virus.
20. A gene delivery vehicle according to any one of claims 1, 3-6 or 17-19, which has the tropism determining parts of

EP 1 054 064 A1

adenovirus 16 or functional equivalents thereof.

21. A gene delivery vehicle according to anyone of claims 1, 3-6 or 17-20 for use as a pharmaceutical.

5 22. A pharmaceutical formulation comprising a gene delivery vehicle according to any one of claims 1, 3-6 or 17-20 and a suitable excipient.

23. A pharmaceutical formulation comprising an adenovirus, a chimaera thereof, or a functional homologue thereof according to claim 2 and a suitable excipient.

10

15

20

25

30

35

40

45

50

55

Figure 1:
% of human sera with neutralising capacity for human adenovirus (n=100)




Figure 2




Figure 3: Ad35 plasmid-based system for virus generation




Figure 4
Neutralisation in human sera




Figure 5
Neutralisation in human sera from different geographic locations




Figure 6: Total sequence of Ad35.

```

1 CATCATCAAT AATATACCTT ATAGATGGAA TGGTGCCAA ATGTAAATGA GGTGATTTTA AAAAGTGTGG
71 GCCGTGTGGT GATTGGCTGT GGGGTTAACG GTTAAAAGGG GCGGCGCGGC CGTGGGAAAA TGACGTTTTA
141 TGGGGGTGGA GTTTTTTTGC AAGTTGTCGC GGGAAATGTT ACGCATAAAA AGGCTTCTTT TCTCACGGAA
211 CTACTTAGTT TTCCCACGGT ATTTAACAGG AAATGAGGTA GTTTTGACCG GATGCAAGTG AAAATTGCTG
281 ATTTTCGCGC GAAAACTGAA TGAGGAAGTG TTTTCTGAA TAATGTGGTA TTTATGGCAG GGTGGAGTAT
351 TTGTTACGGG CCAGGTAGAC TTTGACCAT TACGTGGAGG TTTGATTAC CGTGTTTTTT ACCTGAAATT
421 CCGCGTACCG TGTCAAAGTC TTCTGTTTTT ACGTAGGTGT CAGCTGATCG CTAGGGTATT TATACCTCAG
491 GGTTTGTGTC AAGAGGCCAC TCTTGAGTGC CAGCGAGAAG AGTTTTCTCC TCTGCGCCGG CAGTTAATA
561 AAAAAAAAT GAGAGATTG CGATTCTGC CTCAGGAAAT AATCTCTGCT GAGACTGGAA ATGAAATATT
631 GGAGCTTGTG GTGCACGCC TGATGGGAGA CGATCCGGAG CCACCTGTGC AGCTTTTGA GCCTCCTACG
701 CTTAGGAAC TGTATGATTT AGAGGTAGAG GGATCGGAGG ATTCTAATGA GGAAGCTGTG AATGGCTTTT
771 TTACCGATTG TATGCTTTTA GCTGCTAATG AAGGATTAGA ATTAGATCCG CCTTGGACA CTTTCAATAC
841 TCCAGGGGTG ATTGTGGAAT GCGGTACAGG TGTAAGAAAA TTACCTGATT TGAGTCCGT GGAGTGTGAT
911 TTGCACTGCT ATGAAGACGG GTTTCCTCCG AGTGATGAGG AGGACCATGA AAAGGAGCAG TCCATGCAGA
981 TCGCAGCGGG TGAGGGAGTG AAGGCTGCCA ATGTTGGTTT TCAGTTGGAT TGCCCGGAGC TTCTGGACA
1051 TGGCTGTAA GCTTGTGAAT TTCACAGGAA AAATACTGGA GTAAAGGAAC TGTATGTTG GCTTGTGTTAT
1121 ATGAGAAGCG ACTGCCACTT TATTTACAGT AAGTGTGTTT AAGTTAAAAT TTAAGGAAT ATGCTGTTTT
1191 TCACATGTAT ATTGAGTGTG AGTTTTGTGC TTCTTATTAT AGGTCTGTG TCTGATGCTG ATGAATCACC
1261 ATCTCCTGAT TCTACTACCT CACCTCCTGA TATCAAGCA CCTGTCTCTG TGGACGTGCG CAAGCCCAT
1331 CCTGTGAAGC TTAAGCCTGG GAAACGTCCA GCAGTGGAGA AACTTGAGGA CTTGTTACAG GGTGGGGACG
1401 GACCTTTGGA CTTGAGTACA CAAAAAGTC CAAGACAATA AGTGTCCAT ATCCGTGTTT ACTTAAGGTG
1471 ACGTCAATAT TGTGTGAGA GTGCAATGTA AAAAAAATG GTTAACTGTT CACTGGTTTT TATGTTTTT
1541 TGGGGCGGGA CTCAGGTATA TAAGTAGAAG CAGACCTGTG TGGTTAGCTC ATAGGAGCTG GCTTTCATCC
1611 ATGGAGGTTT GGGCCATTTT GGAAGACCTT AGGAAGACTA GGCAACTGTT AGAGAGCGCT TCGGACGGAG
1681 TCTCCGTTTT TTGGAGATTG TGTTTCGCTA GTGAATTAGC TAGGGTAGTT TTTAGGATAA AACAGGACTA
1751 TAAACAAGAA TTTGAAAAGT TGTGGTAGA TTGCCAGGA CTTTTGAAG CTCTTAATTT GGGCCATCAG
1821 GTTCACTTTA AAGAAAAAGT TTTATCAGTT TTAGACTTTT CAACCCAGG TAGAAGTCTG GCTGCTGGG
1891 CTTTTCTTAC TTTTATATTA GATAAATGGA TCCCGCAGAC TCATTTTCAG AGGGGATACG TTTTGGATT
1961 CATAGCCACA GCATTGTGGA GAACATGGAA GGTTCGCAAG ATGAGGACAA TCTTAGGTTA CTGGCCAGTG
2031 CAGCCTTTGG GTGTAGCGGG AATCCTGAGG CATCCACCGG TCATGCCAGC GGTCTGGAG GAGGAACAGC
2101 AAGAGGACAA CCGGAGAGCC GGCTGGACC CTCCAGTGGG GAGGCGGAG TAGCTGACTT GTCTCTGAA
2171 CTGCAACGGG TGCTTACTGG ATCTACGTCC ACTGGACGGG ATAGGGGCGT TAAGAGGGAG AGGGCATCCA
2241 GTGGTACTGA TGCTAGATCT GAGTTGGCTT TAAGTTTAAT GAGTCGAGAG CGTCTGAAA CCAATGGTG
2311 GCATAGGTT CAGAAAGAGG GAAGGGATGA AGTTTCTGTA TTGCAAGAGA AATATTCAC TGGAAACAGTG
2381 AAAACATGTT GGTGGAGCC AGAGGATGAT TGGGCGGTGG CCATTAAAAA TTATGCCAAG ATAGCTTTGA
2451 GGCTGATAA AAGTATAAG ATCAGTAGAC GGATTAATAT CCGGAATGCT TGTACATAT CTGGAATGG
2521 GGCTGAGGTG GTAATAGATA CTCAGACAA GACAGTTATT AGATGCTGCA TGATGGATAT GTGGCTGGA
2591 GTAGTGAGTA TGGAGCAGT CACTTTTGTG AATGTTAAGT TTAGGGGAGA TGGTTATAAT GGAATAGTGT
2661 TTATGGCCAA TACCAAACTT ATATTGATG GTTGTAGCTT TTTTGGTTTT AACAATACCT GTGTAGATGC
2731 CTGGGGACAG GTTAGTGTAC GGGGGGTAG TTTCTATGCG TGTGGATTG CCACAGCTGG CAGAACCAG
2801 AGTCAATTGT CTCTGAAGAA ATGCATATT CAAAGATGTA ACCTGGGCAT TCTGAATGAA GCGAAGCAA
2871 GGGTCCGTCA CTGCGCTTCT ACAGATACTG GATGTTTTAT TTTAATTAG GGAATGCCA GCGTAAAGCA
2941 GTAGTGAGTA TGGGTGCTT CCGATGAGAG GCCTTATCAA ATGCTCACTT GTGCTGGTGG GCATTGTAAT
3011 ATGCTGGCTA CTGTGCATAT TGTTTCCCAT CAACGCAAAA AATGGCCTGT TTTTGATCAC AATGTGTTGA
3081 CCAAGTGCAC CATGCATGCA GGTGGGCGTA GAGGAATGTT TATGCCCTAC CAGTGTAAAC TGAATCATGT
3151 GAAAGTGTG TTGGAACCAG ATGCCTTTT CAGAATGAGC CTAACAGGAA TCTTTGACAT GAACACGCAA
3221 ATCTGGAAGA TCTGAGGTA TGATGATACG AGATCGAGGG TGCGCGCATG CGAATGCGGA GGCAAGCATG
3291 CCAGGTTCCA GCCGGTGTGT GTAGATGTGA CCGAAGATCT CAGACCGGAT CATTTGGTTA TTGCCCGCAC
3361 TGGAGCAGAG TTCGGATCCA GTGGAGAAGA AACTGACTAA GGTGAGTATT GGGAAAACCT TGGGGTGGGA
3431 TTTTCAGATG GACAGATTGA GTAAAAATTT GTTTTTCTG TCTTGACAGT GACATGAGTG GAAATCTTCT
3501 TTTAAGGGG GAGTCTTCA GCCCTTATCT GACAGGGCGT CTCCCATCCT GGGCAGGAGT TCGTCAGAA
3571 GTTATGGGAT CTACTGTGGA TGGAAGACCC GTTCAACCGG CCAATCTTCT AACGCTGACC TATGCTACTT
3641 TAAGTCTTCT ACCTTTGGAC GCAGCTGCAG CCGCTGCCCG CGCTCTGTG GCGCTAACA CTGTGCTTGG
3711 AATGGGTTAC TATGGAAGCA TCGTGGCTAA TTCCACTTCC TCTAATAACC CTCTACACT GACTCAGGAC
3781 AAGTTACTTG TCCTTTTGGC CCAGCTGGAG GCTTTGACCC AACGTCTGGG TGAACCTTCT CAGCAGGTGG
3851 CCGAGTTGCG AGTACAACT GAGTCTGCTG TCGGCACGGC AAAGTCTAAA TAAAAAAAT TCCAGAAATCA
3921 ATGAATAAAT AAACGAGCTT GTTGTGATTT TAAAAACAAG TGTTTTTATT TCATTTTTTC GCGACGGTAT
3991 GCCCTGGACC ACCGATCTCG ATCATTGAGA ACTCGGTGGA TTTTTTCCAG AATCCTATAG AGGTGGGATT
4061 GAATGTTTTG ATACATGGGC ATTAGGCCGT CTTTGGGGTG GAGATAGCTC CATTGAAGGG ATTCATGCTC
4131 CCGGGTAGTG TTGTAATCA CCCAGTATA ACAAGGTGCG AGTGCATGTT GTTGACAAAT GTTGAGCTGG GAGGGGTGCA
4201 AGTAGGCTGA TTGCCACAGA TAAGCCCTTG GTGTAGGTGT TTACAAACCG GTTGAGCTGG GAGGGGTGCA
4271 TTCAGGTTGA AATTATGTGC ATTTTGGATT GGATTTTTAA GTTGGCAATA TTGCCGCCAA GATCCCGTCT

```


Figure 6, contd.

4341 TGGGTTTCATG TTATGAAGGA CTACCAAGAC GGTGTATCCG GTACATTTAG GAAATTTATC GTGCAGCTTG
 4411 GATGGAAAAAG CGTGGAAAAA TTTGGAGACA CCCTTGTGTC CTCCGAGATT TTCCATGCAC TCATCCATGA
 4481 TAATAGCAAT GGGGCCGTGG GCAGCGCGCG GGGCAAAACAC GTTCCGTGGG TCTGACACAT CATAGTTATG
 4551 TTCTTGAGTT AAATCATCAT AAGCCATTTT AATGAATTTG GGGCGGAGCG TACCAGATTG GGGTATGAAT
 4621 GTTCTTCCGG GCGCCGGAGC ATAGTTCCCC TCACAGATTT GCATTTCCCA AGCTTTCACT TCTGAGGGTG
 4691 GAATCATGTC CACCTGGGGG GCTATGAAGA ACACCGTTTC GGGGGCGGGG GTGATTAGTT GGGATGATAG
 4761 CAAGTTTCTG AGCAATTTGAG ATTTGCCACA TCCGGTGGGG CCATAAATAA TTCCGATTAC AGGTTGCAGG
 4831 TGGTAGTTTA GGGAAACGCC ACTGCCGTCT TCTCSAAGCA AGGGGGCCAC CTCGTTTCATC ATTTCCCTTA
 4901 CATGCATATT TTCCCGCACC AAATCCATTA GGAGGCGCTC TCCTCTAGT GATAGAAGTT CTTGTAGTGA
 4971 GGAAGAGTTT TTCAGCGGTT TTAGACCGTC AGCCATGGGC ATTTTGGAAA GAGTTTGTCT CAAAGTTCT
 5041 AGTCTGTTC ACAGTTCACT GATGTGTTCT ATGGCATCTC GATCCAGCAG ACCTCCTCGT TTCCGCGGTT
 5111 TGGACGGCTC CTGGAGTAGG GTATGAGACG ATGGCGTCC AGCGCTGCCA GGGTTCCGTC CTTCCAGGGT
 5181 CTCAGTGTTC GAGTCAGGGT TGTTCGCTC ACAGTGAAGG GGTGTGCGCC TGCTTGGGCG CTTGCCAGGG
 5251 TGGCTTTCAG ACTCATTCTG CTGGTGGAGA ACTTCTGTCG CTTGGCGCCC GAGGCTTACC TTGGAAGTT
 5321 GTTTACCATG AGTTCGTAGT TGAGCGCTC GGCTGCGTGG CCTTGGCGC GAGGAAATG GATTCTGGGG
 5391 TTCTTGCTA CCGGGCAGTA TAGGCATTTT CAGTCATACA GCTTGGCGC AAGGAAATG GATTCTGGGG
 5461 AGTATGCATC CGCGCCGCGC GAGGCGCAAA CAGTTTACA TTCCACCAGC CAGGTTAAAT CCGGTTCAAT
 5531 GGGGTCAAAA ACAAGTTTTC GCCATATTTT TTGTATGCGT TTCTTACCTT TGGTCTCCAT AAGTTCTGTT
 5601 CCTCGTTGAG TGACAAACAG GCTGTCCGTA TCTCCGTAGA CTGATTTTAC AGGCTCTTTC TCCAGTGGAG
 5671 TGCTCTGCTC TTCTTCGTAC AGGAACCTG ACCACTCTGA TACAAAGGCG CGCGTCCAGG CCAGCACAAA
 5741 GGAGGCTATG TGGGAGGGGT AGCGATCGTT GTCAACCAAG GGTCCACCT TTTCCAAAGT ATGCAACAC
 5811 ATGTACCCCT CTTCACATC CAGGAATGTG ATTTGGCTTT AGGTGTATT CACGTGACCT GGGTCCCGG
 5881 CTGGGGGGGT ATAAAGGGG GCGGTTCTTT GCTCTTCTTC ACTGTCTTCC GGATCGCTGT CCAGGAACGT
 5951 CAGCTGTTCG GGTAGGTAAT CCTCTGCAAA GCGGCGCATG ACCTCTGAC TCAGGTTGTC AGTTCTAAG
 6021 AACGAGGAGG ATTTGATATT GACAGTGCCG GTTGAGATGC CTTTCATGAG GTTTTCGTCC ATTTGGTCA
 6091 AAAACACAAT TTTTATTG TCAAGTTTGG TGGCAAAATGA TCCATACAGG GCGTTGGATA AAAAGTTGGC
 6161 AATGGATCGC ATGGTTTGGT TCTTTTCTTT GTCCGCGCGC TCTTTGGCGG CGATGTTGAG TTGGACATAC
 6231 TCGCGTGCCA GGCACCTCCA TTCGGGGAAG ATAGTTGTTA ATTCATCTGG CACGATTCTC ACTTCCACC
 6301 CTCGATTATG CAAGGTAATT AAATCCACAC TGGTGGCCAC CTCGCTCGA AGGGGTTTCA TTGTCCAAAC
 6371 GAGCTTACCT CTTTTCTAG AACAGAAAGG GGAAGTGGG TCTAGCATAA GTTCATCGGG AGGGTCTGCA
 6441 TCCATGATAA AGATTCCCGG AAGTAAATCC TTATCAAAAT AGCTGATGGG AGTGGGGTCA TCTAAGGCCA
 6511 TTTGCCATTC TCGAGCTGCC AGTCCGCGCT CATATGGGTT AAGGGGACTG CCCCAGGGCA TGGGATGGG
 6581 GAGAGCAGAG GCATACATGC CACAGATGTC ATAGACGTAG ATGGGATCCT CAAAGATGCC TATGTAGGTT
 6651 GGATAGCATC GCGCCCTCTC GATACTTGCT CGCACATAGT CATATAGTTC ATGTGATGGC GCTAGCAGCC
 6721 CCGGACCCAA GTTGGTGCGA TTGGGTTTTT CTGTTCTGTA GACGATCTGG CGAAAGATGG CGTGAGAAAT
 6791 GGAAGAGATG GTGGGCTTTT GAAAAATGTT GAAATGGGCA TGAGGTAGAC CTACAGAGTC TCTACAAAG
 6861 TGGGCATAAG ATTCTTGAAG CTTGGTTACC AGTTCGCGCG TGACAAGTAC GTCTAGGGCG CAGTAGTCAA
 6931 GTGTTTCTTG AATGATGTCA TAACCTGGTT GGTTTTTCTT TTCCACAGT TCGCGGTTGA GAAGGTATC
 7001 TTCGGCATCC TTCCAGTACT CTTCTAGCGG AAACCCGCTT TTGTCTGCAC GGTAAAGATCC TAGCATGTAG
 7071 AACTGATTA TGCCTTGTA AGGGCAGCAG CCCTTCTCTA CCGGTAGAGA GTATGCTTGA GCAGCTTTTC
 7141 GTAGCGAAGC GTGAGTAAGG GCAAAGGTGT CTCTGACCAT GACTTTGAGA AATTGGTATT TGAAGTCCAT
 7211 GTCGTACAG GCTCCCTGTT CCCAGAGTTG GAAGTCTACC CGTTTCTTGT AGGCGGGGTT GGGCAAGCG
 7281 AAAGTAACAT CATGAAGAG AATCTTACC GCTCTGGGCA TAAATTTGCG AGTGATGCGG AAAGGCTGTG
 7351 GTACTTCCGC TCGATTGTTG ATCACC7GGG CAGCTAGGAC GATTTCTGTC AAACCGTTGA TGTGTGTCTC
 7421 TACGATGTAT AATTCTATGA AACGCGGCGT GCCTCTGACG TGAGGTAGCT TACTGAGCTC ATCAAAGGTT
 7491 AGGTCTGTGG GGTGAGATAA GGCGTAGTGT TCGAGAGCCC ATTCGTGACG GTGAGGATTG GCATGTAGGA
 7561 ATGATGACCA AAGATCTACC GCGAGTGTG TTTGTAACG GTCCCGATAC TGACGAAATG CCGCGGCAAT
 7631 TGCCATTTTT TCTGGAGTGA CACAGTAGAA GGTCTGCGG TCTTGTGCG ATCGATCCCA CTTGAGTTA
 7701 ATGGCTAGAT CGTGGGCCAT GTTGACGAGA CGCTCTTCTC CTGAGAGTTT CATGACCAGC ATGAAAGGAA
 7771 CTAGTTGTTT GCCAAAGGAT CCAATCCAGG TGTAAGTTTC CACATCTGAG GTGAGGAGA GTCTTTCTGT
 7841 GCGAGGATGA GAGCCGATCG GGAAGAACTG GATTCTCTGC CACCAGTTGG AGGATTGGCT GTTGATGTA
 7911 TGGAGTGAAG AGTTTCTGCG GCGCGCCGAG CATTCGTGTT TGTGCTTGT CAGACGCGCG CAGTAGTCGC
 7981 AGCGTTGCAC GGGTTGTATC TCGTGAATGA GCTGTACCTG GCTTCCCTTG ACAGAGAAAT TCAGTGGGAA
 8051 GCGGAGGCGT GCGGATTGTA TCTCGTGTCT TTCTATATTC GCTGTATCGG CCTGTTTCATC TTCTGTTTCG
 8121 ATGGTGGTCA TGCTGACGAG CCCCCGCGGG AGGCAAGTCC AGACCTCGGC GCGGGAGGGG CCGAGCTGAA
 8191 GGACGAGAGC GCGCAGGCTG GAGCTGTCCA GAGTCTGAG ACCTGCGGA CTCAGGTTAG TAGGTAGGGA
 8261 CAGAAGATTA ACTTGATGA TCTTTTCCAG GCGCTGCGGG AGGTTCAAT GGTACTTGAT TTCCACAGG
 8331 TCGTTTGTAG AGACGTCAAT GGCCTGCAAG GTTCCGTGTC CTTTGGGCGC CACTACCGTA CCTTGTGTTT
 8401 TTCTTTTGTAG CCGTGGTGGC TCTTGTGCTT CTTGATGCT CAGAAGCGGT GACGGGGACG CGCGCCGGG
 8471 GCGAGCGGTT TTTCCGAGC CCGGGGCGATG GCTGGTAGTG GCACGTGCGG GCGCGCACG GCGAGGTTCT
 8541 GGTATTGCGC GTTGAGAGA CTTGCGTGG CCACACGCG TCGATTGACG TCTTGTATCT GACGTCTCTG
 8611 GGTGAAAGCT ACCGCCCCG TGAGCTTGAA CCTGAAAGAG AGTTCAACAG AATCAATTTT GGTATCGTTA
 8681 ACGGCAGCTT GCTCAGTAT TTCTTGTACG TCACCAAGT TGTCTGTA GCGGATCTCC GCGATGAAT
 8751 GCTCGATTTC TTCTCTCTGA AGATCTCCCG GACCCGCTCT TTGCACGGTG GCGCGAGGTT CATTGGAGAT

Figure 6, contd.

```

8821 ACGGCCCATG AGTTGGGAGA ATGCATTAT GCGCGCTCG TTCCAGACGC GGCTGTAAAC CACGGCCCCC
8891 TCGGAGTCTC TTGCGCGCAT CACCACCTGA GCGAGGTTAA GCTCCACGTG TCTGGTGAAG ACCGCATAGT
8961 TGCATAGGCG CTGAAAAAGG TAGTTGAGTG TGGTGGCAAT GTGTTCCGCG ACGAAGAAAT ACATGATCCA
9031 TCGTCTCAGC GGCATTTTCG TAACATCGCC CAGAGCTTCC AAGCGCTCCA TGGCCTCGTA GAAGTCCACG
9101 GCAAAATTAA AAAACTGGGA GTTTCGCGCG GACACGGTCA ATTCTCTCTC GAGAAGACGG ATGAGTTCCG
9171 CTATGGTGGC CCGTACTTCG CGTTCGAAGG CTCCCGGGAT CTCTTCTTCC TCTTCTATCT CTTCTTCCAC
9241 TAACATCTCT TCTTCGTCTT CAGGCGGGGG CCGAGGGGGC ACGCGGCGAC GTCGACGGCG CACGGGCAAA
9311 CCGTCGATGA ATCGTTCAAT GACCTCTCCG CGCGCGCGGC GCATGGTTTC AGTGACGGCG CGGCCGTTCT
9381 CGCGCGGTG CAGAGTAAAA ACACCGCGCG GCATCTCTCT AAAGTGGTGA CTGGGAGGTT CTCCGTTTGG
9451 GAGGGAGAGG GCGCTGATTA TACATTTTAT TAATTGGCCC GTAGGGACTG CCGCGCAGAG TCTGATCGTG
9521 TCAAGATCCA CCGGATCTGA AAACCTTTTC ACGAAAGCGT CTAACCACTC ACAGTCACAA GGTAGGCTGA
9591 GTACGGCTTC TTGTGGGCGG GGGTGGTTAT GTGTTCCGTC TGGGTCTTCT GTTCTTCTCT CATCTCGGGA
9661 AGGTGAGACG ATGCTGCTGG TGATGAAATT AAAGTAGGCA GTTCTAAGAC GCGCGATGGT GGCAGGAGCG
9731 ACCAGGTCTT TGGGTCCGGC TTGCTGGATA CCGAGGCGAT TGGCCATTCC CCAAGCATTG TCCTGACATC
9801 TAGCAAGATC TTTGTAGTAG TCTTGATGA GCGGTTCTAC GGGCACTTCT TCCTCACCCT TTCTGCCATG
9871 CATACGTGTG AGTCCAAATC CCGCGATTGG TTGTACCAGT GCCAAGTCAG CTACGACTCT TTCGGCGAGG
9941 ATGGCTTGCT GTACTTGGGT AAGGGTGGCT TGAAGTTCAT CAAAATCCAC AAAGCGGTGG TAAGCCCTCG
10011 TATTAAATGGT GTAAGCACAG TTGGCCATGA CTGACCAAGT AACTGTCTGG TGACCAAGGC GCACGAGCTC
10081 GGTGTATTTA AGGCGCGAAT AGGCGGGGT GTCAAAGATG TAATCGTTGC AGGTGCGCAC CAGATACTGG
10151 TACCTATATA GAAATGCGG CGGTGGTTGG CGGTAGAGAG GCCATCGTTC TGTAGCTGGA GCGCCAGGGG
10221 CGAGGTCTTC CAACATAAGG CCGTGATAGC CGTAGATGTA CCTGGACATC CAGGTGATTG CTGCGGCGGT
10291 AGTAGAAGCC CGAGGAAACT CCGGTACCGG GTTCCAAATG TTGCGTAGCG GCATGAAGTA GTTCATTGTA
10361 GGCACGGTTT GACCAGTGAG GCGCGCGCAG TCATTGATGC TCTATAGACA CCGAGAAAAT GAAAGCGTTC
10431 AGCAGCTGGA CTCCGAGCC TGGAGGAGG TACAGGCTT GGTTCGCGGT GTACCCCGT CGACCCAGCC TACAAAAATC
10501 TACTCGAGCG GCGCGGAGCC GCGGCTAACG TGGTATTGGC ACTCCCGTCT CGACCCAGCC TACAAAAATC
10571 CAGGATACGG AATCGAGTCC TTTTGTGGT TTCCGAATGG CAGGGAAGTG AGTCTATT TTCTTTTTTT
10641 TTTGCCGCTC AGATGCATCC CGTGCTGCGA CAGATGCGCC CCAACAACA GCGCCCTCG CAGCAGCAGC
10711 AGCAGCAACC ACAAAGGCT GTCCCTGCAA CTACTGCAAC TGCCCGCGTG AGCGGTGCGG GACAGCCCGC
10781 CTATGATCTG GACTTGAAG AGGGCGAAGC ACTGGCACGT CTAGGTGCGC CTTCCGCCCA CGGCATCCG
10851 CGAGTTCAAC TGA AAAAAGA TTCTCGCGAG GCGTATGTGC CCAACAGAA CCTATTTAGA GACAGAAAGC
10921 GCGAGGAGCC GGAGGAGATG CGAGCTTCCC GCTTAAACG GGGTCTGAG CTGCGTACG GTTGGACCG
10991 AAGACGAGTG TTGCGAGACG AGGATTTGGA AGTTGATGAA GTGACAGGGA TCAGTCTGTC CAGGGCACAC
11061 GTGGCTGCGA CCAACCTTGT ATCGGCTTAC GAGCAGACAG TAAAGGAAGA GCGTAACCTC CAAAAGTCTT
11131 TTAATAATCA TTGCGAACC CTGATTGCC GCGAAGAAGT TACCCTTGGT TTGATGCATT TTGGGATTTT
11201 GATGGAAGCT ATCATTGAGA ACCCTACTAG CAAACCTCTG ACCGCCAGC TGTTTCTGGT GGTGCAACAC
11271 AGCAGAGACA ATGAGGCTTT CAGAGAGCGC GTCTGAACA TACCGAACC CGAGGGGAGA TGGTTGTATG
11341 ATCTTATCAA CATTCTACAG AGTATCATAG TGCAGGAGCG GAGCCTGGGC CTGCCGAGA AGGTAGCTGC
11411 CATCAATTAC TCGGTTTTGA GCTTGGGAAA ATATTACGCT CGCAAAATCT ACAAGACTCC ATACGTTCCC
11481 ATAGACAAGG AGGTGAAGAT AGATGGGTTT TACATCGCA TGACGCTCAA TGACGCTGAC GGTCTTGACC CTGAGCGATG
11551 ATCTTGGGGT GTATCGCAAT GACAGAATGC ATCGCGCGGT TAGCGCCAGC AGGAGGCGCG AGTTAAGCGA
11621 CAGGGAAGCT ATGCAAGATT TGCAAGAGC TCTGACTGGA GCTGGAACCG AGGGTGAGAA TTACTTCGAC
11691 ATGGGAGCTG ACTTGCAGTG GCAGCCTAGT CCGAGGGGCT TGAGCGCCGC GACGGCAGGA TGTGAGCTTC
11761 CTTACATAGA AGAGGCGGAT GAAGGCGAGG AGGAAGAGGG CGAGTACTTG GAAGACTGAT GGCACAACCC
11831 GTGTTTTTTG CTAGATGGAA CAGCAAGCAC CCGATCCCG AATGCGGGCG GCGCTGCAGA GCCAGCCGTC
11901 CCGCATTAAC TCCTCGGACG ATTTGAGCCA GGCCATGCAA CGTATCATGG CGTTGACGAC TCGCAACCCC
11971 GAAGCCTTTA GACAGCAACC CAGGCCAAC CGTCTATCGG CCATCATGGA AGCTGTAGTG CTTTCCCGAT
12041 CTAATCCCA TCATGAGAAG GTCTTGCCA TCGTGAACGC GTTGGTGGAG AACAAAGCTA TTCTCCAGA
12111 TGAGGCCGGA CTGGTATACA ACGCTCTCTT AGAACGCGTG GCTCGCTACA ACAGTAGCAA TGTGCAAAAC
12181 AATTGGACC GTATGATAAC AGATGTACGC GAAGCCGTGT CTCAGCGCGA AAGGTTCCAG CGTGATGCCA
12251 ACCTGGGTT GCTGGTGGCG TTAATGCTT TCTTGAGTAC TCAGCTGCT AATGTGCCG GTGGTCAACA
12321 GGATTAACT AACTTTTTAA GTGCTTTGAG ACTGATGGTA TCAGAAGTAC CTCAGAGCGA AGTGTATCAG
12391 TCCGGTCTG ATTACTTCTT TCAGACTAGC AGACAGGGCT TGCAGACGGT AAATCTGAGC CAAGCTTTTA
12461 AAAACCTTAA AGGTTTGTGG GGAGTGCA TG CCGCGTAGG AGAAAGASCA ACCGTGTCTA GCTTGTAAAC
12531 TCCGAACCTC CGCCTGTTAT TACTGTTGGT AGCTCCTTTC ACCGACAGCG GTAGCATCGA CCGTAATTCC
12601 TATTGGGTT ACCTACTAAA CCTGTATCGG GAAGCCATAG GGCAAGTCA GGTGGACGAG CAGACCTATC
12671 AAGAAATTAC CCAAGTCAGT CGCGCTTTGG GACAGGAAGA CACTGGCAGT TTGGAAGCCA CTCTGAACCT
12741 CTGTCTTACC AATCGGTCTC AAAAGATCCC TCCTCAATAT GCTCTTACTG CCGAGGAGGA GAGGATCCTT
12811 AGATATGTGC AGCAGAGCGT GGGATTGTTT CTGATGCAAG AGGGGCGAAC TCCGACTGCA GCATGACACA
12881 TGACAGCGCG AATATGAGG CCCAGCATGT ATGCCAGTAA CCGACCTTTC ATTAACAAAC TGCTGGACTA
12951 CTTGACAGA GCTGCCGCTA TGAACCTGTA TTATTTACC AATGCCATCT TAAACCCGCA CTGGCTGCC
13021 CCACCTGGT TCTACACGGG CGAATATGAC ATGCCGAGC CTAATGACGG ATTTCTGTGG GAGCAGCTGG
13091 ACAGCGATGT TTTTTCACCT CTTTCTGATC ATCGCAGCTG GAAAAGGAA GCGCGTGATA GAATGCAATC
13161 TTTCTGATCG TGTCCGGGG TCATGGGTGC TACCGCGGCT GAGCCCGAGT CTGCAAGTCC TTTTCTTAGT
13231 CTACCCTTTT CTCTACACAG TGTACGTAGC AGCGAAGTGG GTAGAATAAG TCGCCCGAGT TTAATGGGCG

```


Figure 6, contd.

```

13301 AAGAGGAGTA CCTAAACGAT TCCTTGCTCA GACCGGCAAG AGAAAAAAT TTCCCAAACA ATGGAATAGA
13371 AAGTTTGGTG GATAAAATGA GTAGATGGAA GACTTATGCT CAGGATCACA GAGACGAGCC TGGGATCATG
13441 GGGACTACAA GTAGAGCGAG CCGTAGACGC CAGCGCCATG ACAGACAGAG GGGTCTTGTG TGGGACGATG
13511 AGGATTCCGGC CGATGATAGC AGCGTGTGGG ACTTGGGTGG GAGAGGAAGG GGCAACCCGT TTGCTCATTT
13581 GCGCCCTCGC TTGGGTGGTA TGTGTGAAAA AAAAATAAAA AAGAAAAACT CACCAAGGCC ATGGCGACGA
13651 GCGTACGTTT GTTCTTCTTT ATTATCTGTG TCTAGTATAA TGAGGCGAGT CGTGCTAGGC GGAGCGGTGG
13721 TGTATCCGGA GGGTCTCTCT CTTTCGTACG AGAGCGTGAT GCAGCAGCAG CAGGCGACGG CGGTGATGCA
13791 ATCCCCACTG GAGGCTCCCT TTGTGCCTCC GCGATACCTG GCACCTACGG AGGGCAGAAA CAGCATTCGT
13861 TACTCGGAAC TGGCACCTCA GTACGATACC ACCAGGTTGT ATCTGGTGGA CAACAAGTCG GCGGACATTG
13931 CTTCTCTGAA CTATCAGAAT GACCACAGCA ACTTCTTGAC CACGGTGGTG CAGAACAATG ACTTTACCCC
14001 TACGGAAGCC AGCACCCAGA CCATTAACCT TGATGAACGA TCGCGGTGGG GCGGTCAGCT AAAGACCATC
14071 ATGCATACTA ACATGCCAAA CGTGAACGAG TATATGTTTA GTAACAAGTT CAAAGCGCGT GTGATGGTGT
14141 CCAGAAAACC TCCCAGCGGT GCTGCAGTTG GGGATACCTA TGATCACAAG CAGGATATTT TGGAAATAGA
14211 TGGGTTTCGAG TTTACTTTGC CAGAAGGCCAA CTTTTCAGTT ACTATGACTA TTGATTTGAT GAACAATGCC
14281 ATCATAGATA ATTACTTGAA AGTGGGTAGA CAGAATGGAG TGCTTGAAAG TGACATTGGT GTTAAGTTCC
14351 ACACCAAGAA TTTCAAGCTG GGTGGGATC CCGAAACCAA GTTGATCATG CCTGGAGTGT ATACGTATGC
14421 AGCCTTCCAT CCTGACATTG TCTTACTGCC TGGCTGCGGA GTGGATTTTA CCGAGAGTCG TTTGAGCAAC
14491 CTCTTGGTA TCAGAAAAAA ACAGCCATTT CAAGAGGGTT TTAAGATTTT GTATGAAGAT TTAGAAGGTG
14561 GTAATATTCC GCGCCTCTTG GATGTAGATG CCTATGAGAA CAGTAAGAAA GAACAAAAAG CCAAATAGA
14631 AGCTGCTACA GCTGCTGCAG AAGCTAAGGC AAACATAGTT GCCAGCGACT CTACAAGGGT TGTAACGCT
14701 GGAGAGGTCA GAGGAGACAA TTTTGCGCCA AACCTGTTC GACTGCAGA ATCATTATTG GCCGATGTGT
14771 CTGAAGGAAC GGACGTGAAA CTCACTATTC AACCTGTAGA AAAAGATAGT AAGAATAGAA GCTATAATGT
14841 GTTGGGAAGC AAAATCAACA CAGCCTATCG CAGTTGGTAT CTTTCGTACA ATTATGGCGA TCCCGAAAAA
14911 GAGGTCGCTT CTTGACATTT GCTGACATTT TCCGCTCCAC TAGACAAGTC AGTAACTACC CTGTGGTGGG
14981 TTCCAGACAT GATGAAGGAT CCTGTCACTT TCCGCTCCAC TAGACAAGTC AGTAACTACC CTGTGGTGGG
15051 TGCAGAGCTT ATGCCCGTCT TCTCAAAGAG CTCTTACAAC GAACAAGCTG TGACTTCCCA GCAGCTCCGC
15121 CAGTCCACCT CGCTTACGCA CGCTTCAAC CGCTTTCCTG AGAACCAGAT TTTAATCCGT CCGCCGGCGC
15191 CCACCATTA CACCGTCACT GAAACCGTTC GTGCTCTCAC AGATCACGGG ACCCTGCCGT TGCGCAGCAG
15261 TATCCGGGGA GTCCAACGTG TGACCGTTAC TGACGCCAGA CGCCGCACTT GTCCCTACGT GTCCTAAGCA
15331 CTGGGCATAG TCGCACCGCG CGTCTTTTCA AGCCGCACTT TCTAAAAAAA AAAAATGTCC ATTTCTTATC
15401 CGCCCAAGTA TAACACCGGT TGGGTCCTGC GCGCTCCAAG CAAGATGTAC GGAGGCGCAC GCAACAGTTC
15471 TACCCAACTA CCGGTGCGTG TTCGCGGACA TTTTCCGCTT CCAATGGGGTG CCGTCAAGGG CCGCACTCGC
15541 GTTCCGAACA CCGTCGATGA TGTAACTGAT CAGGTGGTTG CCGACGCCCC TAATTATATC CTTACTGCGC
15611 CTACATCTAC TGTGGATGCA GTTATTGACA GTGTAGTGGC TGACGCTCGC AACTATGCTC GACGTAAGAG
15681 CCGGGCAAGG CGCATTTGCA GACGCCACCG AGCTACCACT GCCATGCGAG CCGCAAGAGC TCTGCTACGA
15751 AGCAAGTGTT ACCCGTAACT CCGCGAACAG GTGTTAAACG CGAAGGTGAA GATTTGTATC CCACATGCA
15821 GCAGGTCCCG CAGGCAAGCA GCGCTGTGCG CAGCGCGCAC TATTGCGGAC ATGGCCCAAT CGCGAAGAGT
15891 TAATGTATAC TGGGTGCGTG ACGTGGCAC CGGTCAACGT GTACCGTGC GCACCCGTCC CCGTCCGAG
15961 CAGAAGATAC TGAGCAGTCT CCGATGTTGT GTCCAGCGG CGAGGATGTC CAAGCGCAA TACAAGGAAG
16031 AAATGCTGCA GGTATTCGCA CCTGAAGTCT ACGGCCAAC GGTGAAGGAT GAAAAAAAC CCGCAAAAT
16101 CAAGCGGGTT AAAAAGGACA AAAAAGAAGA GGAAGATGGC GATGATGGGC TGGCGGAGTT TGTGCGCGAG
16171 TTTGCCCCAC GGGCAGCGCT GCAATGGCGT GGGCGCAAG TTCGACATGT GTTGAGACCT GGAACCTTCG
16241 TGGTCTTTAC ACCCGGCGAG CGTTCAAGCG CTTACTTTTA GCGTTCTTAT GATGAGGTGT ACGGGATGA
16311 TGATATTCTT GAGCAGGCGG CTGACCGATT AGCGGAGTTT GCTTATGGCA AGCGTAGTAG AATAACTTCC
16381 AAGGATGAGA CAGTGTCAT ACCTTTGGAT CATGGAATC CCACCCCTAG TCTTAAACCG GTCACTTTGC
16451 AGCAAGTGTT ACCCGTAACT CCGCGAACAG GTGTTAAACG CGAAGGTGAA GATTTGTATC CCACATGCA
16521 ACTGATGGTA CCAAAACGCC AGAAGTTGGA GGACGTTTTG GAGAAAGTAA AAGTGGATCC AGATATTCAA
16591 CCTGAGGTTA AAGTGAGACC CATTAGCAG GTACGCTCTG GTCTGGGGT ACAAAGTGA GACATTAAGA
16661 TTCCCACTGA AAGTATGGAA GTGCAAACTG AACCCGCAAA GCCTACTGCC ACCTCCACTG AAGTGCAAA
16731 GGATCCATGG ATGCCCATGC CTATTACAAC TGACGCCGCC GGTCCCACTC GAAGATCCCG ACGAAAGTAC
16801 GGTCCAGCAA GTCTGTTGAT GCCCAATTAT GTTGACACAC CATCTATTAT TCCTACTCCT GGTTACCGAG
16871 GCACTCGCTA CTATCGCAGC CGAAACAGTA CCTCCCGCGG TCGCCGCAAG ACACCTGCAA ATCGCAGTGC
16941 TCGCCGTAGA CGCACAAGCA AACCGACTCC CGGCGCCCTG GTGCGGCAAG TGTACCGCAA TGTAGTGGC
17011 GAACCTTTGA CACTGCCGCG TGCGCGTTAC CATCCGAGTA TCATCACTTA ATCAATGTTG CCGTGCCTC
17081 CTTGCAGATA TGGCCCTCAC TTGTGCGCTT CGCGTTCCTA TCACTGGTTA CCGAGGAAGA AACTCGCGCC
17151 GTAGAAGAGG GATGTTGGGA CGCGGAATGC GACGCTACAG GCGACGCGCT GCTATCCGCA AGCAATTGCG
17221 GGGTGGTTTT TTACCAGCCT TAATTCCAAT TATCGCTGCT GCAATTGGCG CGATACCAGG CATAGCTTCC
17291 GTGGCGGTTT AGGCCTCGCA ACGACATTGA CATTGAAAAA AAAACGTATA AATAAAAAAA AATACAATGG
17361 ACTCTGACAC TCCTGGTCTT GTGACTATGT TTTCTTAGAG ATGGAAGACA TCAATTTTTC ATCCTTGGT
17431 CCGCGACACG GCACGAAGCC GTACATGGGC ACCTGGAGCG ACATCGGCAC GAGCCAACCT AACGGGGGCG
17501 CCTTCAATTG GAGCAGTATC TGGAGCGGGC TAAAAAATTT TGGCTCAACC ATAAAAACAT ACGGGAACAA
17571 AGCTTGAAC AGCAGTACAG GACAGCGCCT TAGAAATAAA CTTAAAGACC AGAACTTCCA ACAAAGTA
17641 GTCGATGGGA TAGCTTCCGG CATCAATGGA GTGGTAGATT TGGCTAACCA GGTGTGCAG AAAAAGATA
17711 ACAGTCGTTT GGACCCGCGG CCAGCAACCC CAGGTGAAAT GCAAGTGGAG GAAGAAATTC CTCGCGCAGA

```


Figure 6, contd.

```

17781 AAAACGAGGC GACAAGCGTC CGCGTCCCGA TTTGGAAGAG ACGCTGGTGA CGCGCGTAGA TGAACCGCCT
17851 TCTTATGAGG AAGCAACGAA GCTTGGAAATG CCCACCACTA GACCGATAGC CCCAATGGCC ACCGGGGTGA
17921 TGAAACCTTC TCAGTTGCAT CGACCCGTCA CCTTGGATTG GCCCCTCCCC CCTGCTGCTA CTGCTGTACC
17991 CGCTTCTAAG CCTGTGCTG CCCCAGAACCC AGTCGCCGTA GCCAGGTCAC GTCCCGGGGG CGCTCCTCGT
18061 CCAAAATGCGC ACTGGCAAAA TACTCTGAAC AGCATCGTGG GTCTAGGCGT GCAAAGTGTA AAACGCCGTC
18131 GCTGCTTTTA ATTAATATG GAGTAGCGCT TAACTTGCCT ATCTGTGTAT ATGTGTCTAT ACACGCCGTC
18201 ACAGCAGCAG AGGAAAAAAG GAAGAGGTCTG TCCGTGACAG CTGAGTTACT TTCAAGATGG CCACCCCATC
18271 GATGCTGCCC CAATGGGCAT ACATGCACAT CGCCGGACAG GATGCTTCGG AGTACCTGAG TCCGGGTCTG
18341 GTGCAGTTTC CCGCGCCAC AGACACCTAC TTCAATCTGG GAAATAAGTT TAGAAATCCC ACCGTAGCGC
18411 CGACCCACGA TGTGACCACC GACCGTAGCC AGCGGCTCAT GTTGGCGTTC GTGCCGTTG ACCGGGAGGA
18481 CAATACATAC TCTTACAAAG TGGGTACAC CCTGGCCGTG GCGGACAACA GAGTGCTGGA TATGGCCAGC
18551 ACGTTCTTTG ACATTAGGGG CGTGTGGAC AGAGGTCCCA GTTTCAAACC CTATCTGGT ACGGCTTACA
18621 ACTCTCTGGC TCCTAAAGGC GCTCCAAATG CATCTCAATG GATTGCAAAA GCGGTACCAA CTGCAGCAGC
18691 CGCAGGCAAT TGTAAGGAG AACATGAAAC AGAGGAGAAA ACTGCTACTT ACACTTTTCG CAATGCTCCT
18761 GTAAAGCCCG AGGCTCAAAT TACAAAAGAG GGCTTACCAA TAGGTTTGGG GATTTTCAGT GAAAACGAAT
18831 CTAAACCCAT CTATGCAGAT AAACCTTATC AGCCAGAAC TCAAGTGGGA GATGAAACTT GGACTGACCT
18901 AGACCGAAAA ACCGAAGAGT ATGGAGGCG AGGCTCTAAG CCTACTACTA ACATGAAACC CTGTACGGG
18971 TCCTATGCGA AGCCTACTAA TTTAAAGGT GGTGAGGCAA AACCGAAAAA CTCGGAACCG TCGAGTGAAA
19041 AAATTGAATA TGATATTGAC ATGGAATTTT TTGATAACTC ATCGCAAAGA ACAAACCTCA GTCTAAAAAT
19111 TGTCATGTAT GCAGAAAATG TAGGTTTGGG AACGCCAGAC ACTCATGTAG TGTACAAACC TGAACAGAAA
19181 GACACAAGTT CCGAAGCTAA TTTGGGACAA CAGTCTATGC CCAACAGACC CAACTACATT GGCCTCAGAG
19251 ATAACCTTAT TGGACTCATG TACTATAACA GTACTGGTAA CATGGGGGTG CTGGCTGGTC AAGCGTCTCA
19321 GTTAAATGCA GTGGTTGACT TGCAGGACAG AAACACAGAA CTCTCTTACC AACTCTTGCT TGACTCTCTG
19391 GCGGACGAAA CAGATATCTT TACATCTGCG AATCAGGCTG TGGACGTTA TGAATCTGAT GTACCTGTAT
19461 TTGAAAATCA TGGTGTGGAA GATGAACCTC CCAACTATTG TTTTCCACTG GACGGCATAG GTGTTCCAAC
19531 AACCCAGTTAC AAATCAATAG TTCCAAATGG AGAAGATAAT AATAATTGGA AAGAACCCTGA AGTAAATGGA
19601 ACAAGTGAGA TCGGACAGGG TAATTTGTTT GCCATGGAAA TTAACCTTCA AGCCAATCTA TGGCGAAGTT
19671 TCCTTTATTC CAATGTGGCT CTGTATCTCC CAGACTCGTA CAAATACACC CCGTCCAATG TCACTCTTCC
19741 AGAAACAAAA AACACCTACG ACTACATGAA CCGGCGGGTG GTGCCGCCAT CTCTAGTAGA CACCTATGTG
19811 AACATTGGTG CCAGGTGGTC TCTGGATGCC ATGGACAATG TCAACCCATT CAACCAACCAC CGTAACCGTG
19881 GCTTGCCTTA CGATCTATG TTTCTGGGTA AGCGACGTTA TGTGCCCTTC CACATACAAG TGCCCTCAAAA
19951 ATTCTTCGCT GTTAAAAACC TGCTGCTTCT CCCAGGCTCC TACACTTATG AGTGGAACTT TAGGAAGGAT
20021 GTGAACATGG TTCTACAGAG TTCCCTCGGT AACGACCTGC GGGTAGATGG CGCCAGCATC AGTTTCACGA
20091 GCATCAACCT CTATGCTACT TTTTCCCCA TGGCTCACAA CACCGCTTCC ACCCTTGAAG CCATGCTGCG
20161 GAATGACACC AATGATCAGT CATTCACGTA CTACCTATCT GCAGCTAACA TGCTTACCC CATTCCTGCC
20231 AATGCAACCA ATATTCCCAT TTCCATTCCT TCTGCAACT GGGCGGCTTT CAGAGGCTGG TCATTTACCA
20301 GACTGAAACAA CAAAGAAACT CCCTCTTTGG GGTCTGGATT TGACCCCTAC TTTGTCTATT CTGGTTCTAT
20371 TCCCTACCTG TATGGTACCT TCTACCTGAA CCACACTTTT AAGAAGGTTT CCATCATGTT TGACTCTTCA
20441 GTGAGCTGGC CTGGAATGA CAGGTTACTA TCTCCTAACG AATTTGAAAT AAAGCGCACT GTGGATGGCG
20511 AAGGCTACAA CGTAGCCCAA TGCAACATGA CCAAAGACTG GTTCTTGGTA CAGATGCTCG CCAACTACAA
20581 CATCGGCTAT CAGGGCTTCT ACATTCCAGA AGGATACAAA GATCGCATGT ATTCAATTTT CAGAAACTTC
20651 CAGCCCATGA GCAGGCAGGT GGTGTATGAG GTCAATTACA AAGACTTCAA GGCCTGCGCC ATACCCCTACC
20721 AACACAACAA CTCTGGCTTT GTGGGTTACA TGGCTCCGAC CATGCGCCAA GGTCAACCC ATCCCGCTAA
20791 CTATCCCTAT CCACTCATTG GAACAACCTGC CGTAAATAGT GTTACGCAGA AAAAGTTCTT GTGTGACAGA
20861 ACCATGTGGC GCATACCGTT CTCGAGCAAC TCTATGTCTA TGGGGGCCCT TACAGACTTG GGACAGAATA
20931 TGCTCTATGC CAACTCAGCT CATGCTCTGG ACATGACCTT TGAGGTGGAT CCCATGGATG AGCCCACTTC
21001 GCTTTATCTT CTCTTCGAAG TTTTCGACGT GGTGAGAGTG CATCAGCCAC ACCGCGGCAT CATCGAGGCA
21071 GTCTACCTGC GTACACCGTT CTCGGCCGGT AACGCTACCA CGTAAGAAGC TTCTTGCTTC TTGCAAAATG
21141 CAGCTGCAAC CATGGCCTGC GGATCCCAAA ACGGCTCCAG CGAGCAAGAG CTCAGAGCCA TTGTCCAAGA
21211 CCTGGGTTGC GGACCTATT TTTTGGGAAC CTACGATAAG CGCTTCCCGG GGTTCATGGC CCCCATAAG
21281 CTCGCCCTG GCAATGTAAA TACGGCCGGA CGTGAGACGG GGGGAGAGCA CTGGTTGGCT TTCGGTTGGA
21351 ACCCAGCTTC TAACACCTGC TACCTTTTTG ATCCTTTTGG ATTTCTGGAT GATCGTCTCA AACAGATTTA
21421 CCAGTTTGA TATGAGGGTC TCCTGCGCCG CAGCGCTCTT GCTACCAAGG ACCGCTGTAT TACGCTGGAA
21491 AAATCTACCC AGACCGTGCA GGGCCCCCGT TCTGCCGCTT CGGCACTTTT CTGCTGCATG TTCCTCACC
21561 CCTTTGTGCA CTGGCTGAC CGTCCCATGG ACGGAAACCC CACCATGAAA TTGCTAACTG GAGTGCCAAA
21631 CAACATGCTT CATTCTCCTA AAGTCCAGCC CACCTGTGTG GACAATCAAA AAGCACTCTA CCATTTTCTT
21701 AATACCCATT CGCCTTATT TCGCTCTCAT CGTACACACA TCGAAAGGGC CACTGCGTTC GACCGTATGG
21771 ATGTTCAATA ATGACTCATG TAAACAACGT GTTCAATAAA CATCACTTTA TTTTTTTACA TGTATCAAGG
21841 CTCTGGATTA CTTATTTATT TACAAGTCGA ATGGGTTCTG ACGAGAATCA GAATGACCCG CAGGCAGTGA
21911 TACGTTGCGG AACGTACTG TGGGTTGCCA CTGGAATTCG GGAATCACCA ACTTGGGAAC CGGTATATCG
21981 GGCAGGATGT CACTCCACAG CTTTCTGGTC AGCTGCAAA GCTCCAAGCAG GTCAGGAGCC GAAATCTTGA
22051 AATCACAATT AGGACCACTG CTCTGAGCGC GAGAGTTGCG GTACACCGGA TTGCGAGCAT TACGAGCATC
22121 CAGCGACGGA TGTCTACGC TGTCCAGCAG GGTGGGATCT GCAATCATGC CCACATCCAG ATCTTCAGCA
22191 TTGGCAATGC TGAACGGGGT CATCTTGCA GTCCTGCTAC CCATGGCGGG CACCAATTA GGCCTGTGGT

```


Figure 6, contd.

22261 TGCAATCGCA GTGCAGGGGG ATCAGTATCA TCTTGGCTG ATCTGTCTG ATTCTGGAT ACACGGCTCT
 22331 CATGAAAGCA TCATATTGCT TGAAGGCTG CTGGGCTTTA CTACCTCGG TATAAACAT CCCGCAGGAC
 22401 CTGCTCGAAA ACTGGTTAGC TGCACAGCCG GCATCATTTA CACAGCAGCG GGCGTCATTG TTGGCTATTT
 22471 GCACCACTACT TCTGCCCCAG CGGTTTTGGG TGATTTTGGT TCGCTCGGGA TTCTCCTTTA AGGCTCGTTG
 22541 TCCGTTCTCG CTGGCCACAT CCATCTCGAT AATCTGCTCC TTCTGAATCA TAATATTGCC ATGCAGGCAC
 22611 TTCAGCTTGC CCTCATAATC ATTGCAGCCA TGAGGCCACA ACGCACAGCC TGTACATTCC CAATTATGGT
 22681 GGGCGATCTG AGAAAAAGAA TGTATCATTC CCTGCAGAAA TCTTCCCATC ATCGTGCTCA GTGTCTTGTG
 22751 ACTAGTGAAG GTTAACTGGA TGCTCGGTG CTCTTCGTTT ACGTACTGGT GACAGATCGG CTTGTATTGT
 22821 TCGTGTGGCT CAGGCATTAG TTTAAACAG GTTCTAAGTT CGTTATCCAG CTGTACTTTC TCCATCAGCA
 22891 GACACATCAC TTCCATGCCT TTCTCCCAAG CAGACACCAG GGGCAAGCTA ATCGGATTCT TAACAGTGCA
 22961 GGCAGCAGCT CCTTTAGCCA GAGGTCATC TTTAGCGATC TTCTCAATGC TTCTTTTGCC ATCTTCTCA
 23031 ACGATGCGCA CGGGCGGGTA GCTGAAACCC ACTGCTACAA GTTGCCTGTC TTCTTTTCT TCTTCGCTGT
 23101 CTTGACTGAT GTCTTGCAAT GGGATATGTT TGGTCTTCTT TGGCTTCTTT TTGGGGGGTA TCGGAGGAGG
 23171 AGGACTGTGC CTCCGTTCCG GAGACAGGGA GGATTTGTAC GTTTCGCTCA CCATTACCAA CTGACTGTCT
 23241 GTAGAGAAGC CTGACCCACG ACGGCGACAG GTGTTTTTCT TCGGGGGCAG AGGTGGAGGC GATTGCGAAG
 23311 GGTGCGGGTC CGACCTGGA GGGGATGAC TGGCAGAAC CCTTCCGCGT TCGGGGGTGT GCTCCCTGTG
 23381 GCGGTGCGCT AACTGATTTT CTTGCGGCT GGCATTGTG TTCTCCTAGG CAGAGAAACA ACAGACATGG
 23451 AAACCTACGC ATTGTGTGCA ACATCGCCAC GAGTGCCATC ACATCTCGTC CTCAGCGACG AGGAAAGGGA
 23521 GCAGAGCTTA AGCATTCAC CGCCACGTC TCTACCTAG AAGATAAGGA GGTCGACGCA
 23591 TCTCATGACA TGCAGATAA AAAAGCGAAA GAGTCTGAGA CAGACATCGA GCAAGACCCG GGCATATGTA
 23661 ACCCGGTGGA ACACGAGGAA GAGTTGAAAC GTTTCTAGA GAGAGAGGAT GAAACTGCC CAAAACACCG
 23731 AGCAGATAAC TATCACAAG ATGCTGGAAA TAGGATCAG AACACCGACT ACCTCATAGG GCTTGACGGG
 23801 GAAGACGCGC TCCTTAAACA TCTAGCAAGA CAGTCGCTCA TAGTCAAGGA TGCATTATTG GACAGAACTG
 23911 AAGTGCCTT CAGTGTGGA GAGTCTGCT GCGCTTACGA GCTTAACTT TTTCACCTC CTACTCCCTC
 23941 CAAACGTCAG CCAACCGGCA CCTGCGAGCC AAATCCTCGC TTAACCTTTT ATCCAGCTTT TGCTGTGCCA
 24011 GAAGTACTGG CTACCTATCA CATCTTTTTT AAAAATCAAA AAATTCAGT CTCTGCGCGC GCTAATCGCA
 24081 CCCGCGCCGA TGCCCTACTC AATCTGGGAC CTGGTTCACG CTTACCTGAT ATAGCTTCTT TGAAGAGGT
 24151 TCCAAGATC TCGAGGGTC TGGCAATAA TGAGACTCGG GCGCAAAATG CTCTGCAAAA GGGAGAAAAA
 24221 GGCATGGATG AGCATCACAG CGTCTGGTG GAATTTGAAG GCGATAATGC CAGACTCGCA GTACTCAAGC
 24291 GAAGCGTCGA GGTACACAC TTGCGATATC CCGCTGTCAA CCTGCCCTCT AAAGTCATGA CCGCGGTCTA
 24361 GGACCAAGTTA CTCATTAAAG CGGCAAGTCC CTTTTCAGAA GACATGCTAT ACCCAGATGC CTGTGTAGAG
 24431 GGTAAACGAG TGGTCAGTGA TGAGCAGCTA ACCCGATGGC TGGGCACCGA CTCTCCCCGG GATTGTGAAG
 24501 AGCGTCGCAA GCTTATGATG GCGGTGGTGC TGGTTACCGT AGAAGTACAG TGTCTCCGAC GTTCTTTTAC
 24571 CGATTGAGAA ACCTTGCGCA AACTCGAAGA GAATCTGCAC TACACTTTTA CACACGGCTT TGTGCGCAG
 24641 GCATGCAAGA TATCTAACGT GGAACCTACC AACCTGGTTT CCTACATGGG TATTCTGCAAT GAGAACTCGC
 24711 TAGGACAAAG CGTGTGCAC AGCACCTTTA AGGGGGAAGC CCGCGGTGAT TACATCCGCG ATTGTGTCTA
 24781 TTCTTACCTG TGCCACACGT GGCAAACCGG CATGGGTGTA TGGCAGCAAT GTTTAGAAGA ACAGAACTTG
 24851 AAAGAGCTTG ACAAGCTCTT ACAGAAATCT CTTAAGGTTT TGTGGACAGG GTTCGACGAG CCGACCGTCT
 24921 CTTCCGACCT GGCAGACCTC ATCTTCCGAG AGCGTCTCAG GGTACTTTTG CGAAACGGAT TGCCTGACTT
 24991 TATGAGCCAG AGCATGCTTA ACAATTTTCG CTCTTTTATC CTGGAACGCT CCGGTATCCT GCCCGCCACC
 25061 TGCTGCGCAC TGCCCTCCGA CTTTGTGCTT CTACCTTACC CTACCTTACC GCGAGTGCCC CCGCGCGCTA TGGATCACT
 25131 GCTACCTGTT CCGTCTGGCC AACTATCTCT CTTACCACTC GGTATGTATC GAGGATGTGA GCGGAGACGG
 25201 CTTGCTGGAG TGCCACTGCC GCTGCAATCT GTGCACGCCC CACCGGTCCC TAGCTTGCAA CCCCAGTTG
 25271 ATGAGCGAAA CCCAGATAAT AGGCACCTTT GAATTGCAAG GCGCCAGCAG CCAAGGCGAT GGGTCTTCTC
 25341 CTGGGCAAG TTTAAACTG ACCCGGGAC TGTGGACCTC CGCCTACTTG CGCAAGTTTG CTCCGGAAGA
 25411 TTACCACCCC TATGAAATCA AGTTCTATGA GGACCAATCA CAGCCTCCAA AGGCCGAATC TTGCGCTTGC
 25481 GTCATCACCC AGGGGGCAAT TCTGGCCCAA TTGCAAGCCA TCCAAAAATC CCGCCAAAGAA TTCTACTGTA
 25551 AAAAGGGTAA GGGGGTCTAC CTTGACCCCC AGACCGGCGA GGAACCTAAC ACAAGGTTCC CTCAGGATGT
 25621 CCCAACGACG AGAAACAAG AAGTTGAAGG TGCAGCGCC GCGCCAGAA GATATGGAGG AAGATTGGGA
 25691 CAGTCAGGCA GAGGAGGCG AGGAGGACAG TCTGGAGGAC AGTCTGGAGG AAGACAGTTT GAGAGAGGAA
 25761 AACGAGGAGG CAGAGGAGGT GGAAGAAGTA ACCGCCGACA AACAGTTATC CTCGGCTGCG GAGACAAGCA
 25831 ACAGCGCTAC CATCTCCGCT CCGAGTGCAG GAACCCGGCG GCGTCCCAGC AGTAGATGGG ACGAGACCGG
 25901 ACGCTTCCCG AACCCAACCA GCGCTTCCAA GACCGGTAAG AAGGATCGGC AGGGATACAA GTCTTGGCGG
 25971 GGGCATAAGA ATGCCATCAT CTCCTGCTTG CATGAGTGGG GGGGCAACAT ATCCTTACCG CCGCGCTACT
 26041 TGCTATTCCA CCATGGGGTG AACTTTCCG GCAATGTTTT GCATTACTAC CGTCACCTCC ACAGCCCTTA
 26111 CTATAGCCAG CAAATCCCGA CAGTCTCGAC AGATAAAGAC AGCGGCGGCG ACCTCCAACA GAAAACACAG
 26181 AGCGGCGAGT AGAAAAACA CAACAAGTGC AGCAACAGGA GGAATTAAGA TTACAGCCAA CGAGCCAGCG
 26251 CAAACCCGAG AGTTAAGAAA TCGGATCTTT CCAACCTGT ATGCCATCTT CCAGCAGAGT CCGGGTCAAG
 26321 AGCAGGAAGT GAAAAATAAA ACCGATCTCT TCGTTCGCT CACCAAGAGT TGTTTGTATC ACAAGAGCGA
 26391 AGATCAACTT CAGCGCACTC TCGAGGACGC CAGGCTCTCT TTCAACAAGT ACTGCGCGCT GACTCTTAA
 26461 GAGTAGGCG CAGCCGCGCT TATTCAAAAA AGCGGGGAAT TACATCATCC TCGACATGAG TAAAGAAATT
 26531 CCCACGCTT ACATGTGGAG TTATCAACCC CAAATGGGAT TGGCAGCAGG CCGCTCCGAG GACTACTCCA
 26601 CCCGCTGAA TTGGCTCAGC GCGGGGCTT CTATGATTTT TCGAGTTAAT GATATACGCG CTAACCGAAA
 26671 CCAAACTACT TTGGAACAGT CAGCTCTTAC CACCACGCCC GCGCAACACC TTAATCCAG AAATTGGCCC

Figure 6, contd.

26741 GCCGCCCTAG TGTACCAGGA AAGTCCCGCT CCCACCACTG TATTACTTCC TCGAGACGCC CAGGCCGAAG
 26811 TCCAAATGAC TAATGCAGGT GCGCAGTTAG CTGGCGGCTC CACCCTATGT CGTCACAGGC CTCGGCATAA
 26881 TATAAAACGC CTGATGATCA GAGGCCGAGG TATCCAGCTC AACGACGAGT CGGTGAGCTC TCCGCTTGGT
 26951 CTACGACCAG ACGGAATCTT TCAGATTGCC GGCTGCGGGA GATCTTCCCT CACCCCTCGT CAGGCTGTTC
 27021 TGACTTTGGA AAGTTCGTCT TCGCAACCCC GCTCGGGCGG AATCGGGACC GTTCAATTTG TAGAGGAGTT
 27091 TACTCCCTCT GTCTACTTCA ACCCTTCTC CGGATCTCCT GGGCACTACC CGGACGAGTT CATACCGAAC
 27161 TTCGACGCGA TTAGCGAGTC AGTGGACGGC TACGATTGAT GTCTGGTGAC GCGGCTGAGC TATCTCGGCT
 27231 GCGACATCTA GACCACTGCC GCCGCTTTCG CTGCTTTGCC CGGGAACCTTA TTGAGTTTAT CTACTTCGAA
 27301 CTCCCCAAGG ATCACCCTCA AGGTCCGGCC CACGGAGTGC GGATTACTAT CGAAGGCAAA ATAGACTCTC
 27371 GCCTGCAACG AATTTTCTCC CAGCGGCCCG TGCTGATCGA GCGAGACCAG GGAACACCA CGGTTTCCAT
 27441 CTACTGCAIT TGTAAATCACC CCGGATTGCA TGAAGCCCTT TGCTGTCTTA TGTGTACTGA GTTTAATAAA
 27511 AACTGAATTA AGACTCTCCT ACGGACTGCC TGTAACTTC ACCTTTCCTA CTCACAACT AGAAGCTCAA CGACTACACC
 27581 TTTCTGTGCG TCCAGGACTC TGTTAACTTC ACCTTTCCTA CTCACAACT AGAAGCTCAA CGACTACACC
 27651 GCTTTTCCAG AAGCATTTTC CCTACTAATA CTACTTTCAA AACCGGAGGT GAGCTCCACG GTCTCCCTAC
 27721 AGAAAACCTT TGGGTGGAAG CCGGCTTGT AGTACTAGGA ATTCTTGGCG GTGGCTTGT GATTATTCTT
 27791 TGCTACCTAT ACACACCTTG CTTCACITTC TAGTGGTGT TGTGGTATTG GTTTAAAAAA TGGGGCCCAT
 27861 ACTAGTCTTG CTGTGTTTAC TTTGCTTTT GGAACCGGGT TCTGCCAATT ACGATCCATT TCTAGACTTT
 27931 GACCCAGAAA ACTGCACACT TACTTTTGCA CCCGACACAA GCCGCATCTG TGGAGTTCTT ATTAAGTGGC
 28001 GATGGGAATG CAGGTCCGTT GAAATTACAC ACAATAACAA AACCTGGAAC AATACCTTAT CCACCACATG
 28071 GGAGCCAGGA GTTCCCGAGT GGTACACTGT CTCTGTCCGA GGTCTGACG GTTCCATCCG CATTAGTAAC
 28141 AACACTTTCA TTTTCTGTA AATGTGCGAT CTGGCCATGT TCATGAGCAA ACAGTATTCT CTATGGCCTC
 28211 CTAGCAAGGA CAACATCGTA ACGTTCCTCA TTGCTTATTG CTGTGCGCT TGCCTTCTTA CTGCTTTACT
 28281 GTGCGTATGC ATACACCTGC TTGTAACCAC TCGCATCAAA AACGCCAATA ACAAGAAAAA AATGCCTTAA
 28351 GCTCTTCTAT TCGTCTCTAT CCCACTAGGA CATAATTACA CTCTCATAGG ACCCCCAATC ACTTCAGAGG
 28421 GGACAAACAG TCGTCTCTAT CCCACTAGGA CATAATTACA CTCTCATAGG ACCCCCAATC ACTTCAGAGG
 28491 TCATCTGGAC CAAACTGGGA AGCGTTGATT ACTTTGATAT AATCTGTAAC AAAACAAAAC CAATAATAGT
 28561 AACTTGCAAC ATACAAAATC TTACATTGAT TAATGTTAGC AAAGTTTACA GCGGTTACTA TTATGTTTAT
 28631 GACAGATACA GTAGTCAATA TAGAAATTAC TTGGTTCTGT TTACCCAGTT GAAAACACAG AAAATGCCAA
 28701 ATATGGCAAA GATTGATCC GATGACAATT CTCTAGAAAC TTTTACATCT CCCACCACAC CCGACGAAAA
 28771 AAACATCCCA GATTCAATGA TTGCAATTGT TGCAGCGGTG GCAGTGGTGA TGGCACTAAT AATAATATGC
 28841 ATGCTTTTAT ATGCTTGTG CTACAAAAAG TTTTATCCCTA AAAACAAGA TCTCTACTA AGGCTTAACA
 28911 TTTAATTCTT TTTTATACAG CCATGGTTTC CACTACCACA TTCCTTATGC TTACTAGTCT CGCAACTCTG
 28981 ACTTCTGCTC GCTCACACCT CACTGTAAC ATAGGCTCAA ACTGCACACT AAAAGGACCT CAAGGTGGTG
 29051 ATGCTTTTGT GTGGAGAATA TATGACAATG GATGGTTTAC AAAACCATGT GACCAACCTG GTAGATTTT
 29121 CTGCAACGGC AGAGACCTAA CCATTATCAA CGTGACAGCA AATGACAAAG GCTTCTATTA TGGAAACCGC
 29191 TATAAAAGTA GTTTAGATTA TAACATTATT CTACTGCCAT CTACCCTCC AGCACCCCGC ACAACTACTT
 29261 TCTCTAGCAG CAGTGTGCTT AACCAATACAA TTTCCAATCC AACCTTTGCC GCGCTTTTAA AACGCACTGT
 29331 GAATAATTCT ACAACTTCAC ATACAACAAT TTCACCTTCA ACAATCAGCA TCATCGTGTC AGTGACAATT
 29401 GGAATATCTA TTCTTGTITT TACCATAACC TACTACGCTT GCTGCTATAG AAAAGACAAA CATAAAGGTG
 29471 ATCCATTACT TAGATTGAT ATTTAATTTG TTTCTTTTCT TTATTATACG TATGGTGAAC ACCAATCATG
 29541 GTACCTAGAA ATTTCTTCTT CACCATACTC ATCTGTGCTT TTAATGTTTG CGCTACTTTC ACAGCAGTAG
 29611 CCACAGCAAC CCCAGACTGT ATAGGAGCAT TTGCTTCTTA TGCATTTTTT GCTTTTGTTA CTTGCACTG
 29681 CGTATGTAGC ATAGTCTGCC TGGTTATTAA TTTTTCCTAA CTCTAGACT GGATCCTTGT GCGAATTGCC
 29751 TACCTGCGCC ACCATCCCGA ATACCGCAAC CAAAATATCG CCGCACTTCT TAGACTCATC TAAACCATG
 29821 CAGGCTATAC TACCAATATT TTTGCTTCTA TTGCTTCCCT ACGCTGTCTC AACCCAGCT GCCTATAGTA
 29891 CTCCACCAGA ACACCTTAGA AAATGCAAA TCCAAACAAC GTGGTCATT CTGTCTTGTCT ATCGAGAAAA
 29961 ATCAGAAATC CCCCCAATTT TAATAATGAT TGCTGGAATA ATTAATATAA TCTGTTGCAC CATAATTTCA
 30031 TTTTGTATAT ACCCCCTATT TGATTTTGGC TGGAATGCTC CCAATGCACA TGATCATCCA CAAGACCCAG
 30101 AGGAACACAT TCCCCACAAA AACATGCAAC ATCCAATAGC GCTAATAGAT TACGAAAGTG AACCACAACC
 30171 CCCACTACTC CCGTCTATTA GTTACTTCAA CCTAACCGGC GGAGATGACT GAAACACTCA CCACCTCCAA
 30241 TCCGCGGAG GATCTGCTCG ATATGGACGG CCGGCTCTCA GAACAACGAC TTGCCCAACT ACGCATCCCG
 30311 CAGCAGCAGG AACCGCTGGC CAAAGAGCTC AGAGATGTCA TCCAAATTCA CCAATGCAAA AAAGGCATAT
 30381 TCTGTTTGGT AAAACAAGCC AAGATATCCT ACGAGATCAC CGCTACTGAC CATCGCTCT CTTACGAACT
 30451 TGGCCCCCAA CGACAAAAAT TTACCTGCAT GGTGGGAATC AACCCCATAG TTATACCCA ACAAGTGGA
 30521 GATACTAAGG GTTGCAATCA CTGCTCCTGC GATTCCATCG AGTGACCTA CACCTGTCTG AAGACCTAT
 30591 GCGGCTAAG AGACCTGCTA CCAATGAATT AAAAAAAAT GATTAATAAA AAATCACTTA CTTGAAATCA
 30661 GCAATAAGGT CTCTGTTGAA ATTTCTCCCA CTTTAAAGGG GATGTCAAAT TTTAGTCTCT CTTCTGTACC
 30731 AACCCCGTTC AGCGGCATAC TTTCTCCATA CTTTAAAGGG GATGTCAAAT TTTAGTCTCT CTTCTGTACC
 30801 CACAATCTTC ATGTCTTTCT TCCCAGATGA CCAAGAGAGT CCGGCTCAGT GACTCCTTCA ACCCTGTCTA
 30871 CCCCTATGAA GATGAAAGCA CCTCCCAACA CCCCTTTATA AACCCAGGGT TTATTTCCTC AAATGGCTTC
 30941 ACACAAAGCC CAGACGGAGT TCTTACTTTA AAATGTTTAA CCCCACTAAC AACCCAGGGT TTATTTCCTC AAATGGCTTC
 31011 AGCTAAAGAT GGGAGGGGGA CTTACAGTGG ATGACACTGA TGGTACCTTA CAAGAAAAAC TACGTGCTAC
 31081 AGCCCAATT ACTAAAAATA ATCACTCTGT AGAAGTATCC ATTGGAATG GATTAGAAAC TCAAAACAA
 31151 AAACATATGT CCAAAATGGG AAATGGGTTA AAATTAACA ACGGTGACAT TTGTATAAG GATAGTATTA

Figure 6, contd.

```

31221 ACACCTTATG GACTGGAATA AACCTCCAC CTAACGTGCA AATTGTGGAA AACACTAATA CAAATGATGG
31291 CAAACTTACT TTAGTATTAG TAAAAAATGG AGGGCTTGT AATGGCTACG TGTCTCTAGT TGGTGTATCA
31361 GACACTGTGA ACCAAATGTT CACACAAAAG ACAGCAAAACA TCCAATTAAG ATTATATTTT GACTCTTCTG
31431 GAAATCTATT AACTGAGGAA TCAGACTTAA AAATTCACCT TAAAAATAAA TCTTCTACAG CGACCAAGTGA
31501 AACTGTAGCC AGCAGCAAAAG CCTTTATGCC AAGTACTACA GCTTATCCCT TCAACACCAC TACTAGGGAT
31571 AGTGAAAACCT ACATTCATGG AATATGTTAC TACATGACTA GTTATGATAG AAGTCTATTT CCCTTGAACA
31641 TTTCTATAAT GCTAAACAGC CGTATGATTT CTTCCTATGT TGCCTATGCC ATACAATTTG AATGGAATCT
31711 AAATGCAAGT GAATCTCCAG AAAGCAACAT AGCTACGCTG ACCACATCCC CCTTTTCTT TTCTTACATT
31781 ACAGAAGACG ACAACTAAAA TAAAGTTTAA GTGTTTTTAT TTAATAACAC AAAATTCGAG TAGTTATTTT
31851 GCCTCCACCT TCCCATTTGA CAGAATACAC CAATCTCTCC CCACGCACAG CTTTAAACAT TTGGATACCA
31921 TTAGAGATAG ACATTTGTTT AGATTCCACA TTCCAACAG TTTCCAGAGC AGCCAATCTG GGGTCAGTGA
31991 TAGATAAAAA TCCATCGCGA TAGTCTTTTA AAGCGCTTTC ACAGTCCAAC TGC TCGCGGAT GCGACTCCGG
32061 AGTTTGGATC ACGGTCATCT GGAAGAAGAA CGATGGGAAT CATAATCCGA AAACGGTATC GGACGATTGT
32131 GTCTCATCAA ACCCACAAGC AGCCGCTGTC TCGCTCGCTC CGTGGCAGTG CTGTTTATGG GATCAGGGTG
32201 CACAGTTTCC TGAAGCATGA TTTTAATAGC CCTTAACATC AACTTTCTGG TGCATGCGC GCAGCAACGC
32271 ATTCTGATTT CACTCAAAATC TTTGCAGTAG GTACAACACA TTATTACAAT ATTGTTTAAAT AAACCATAAT
32341 TAAAGCGCT CCAGCCAAAA CTCATATCTG ATATAATCGC CCCTGCATGA CCATCATACC AAAGTTTAAAT
32411 ATAAATTAAT TGACGTTCCC TCAAAAACAC ACTACCCACA TACATGATCT CTTTGGCAT GTGCATATTA
32481 ACAATCTGTC TGTACCATGG ACAACGTTGG TTAATCATGC AACCCAATAT AACCTTCCGG AACCCACTG
32551 CCAACACCGC TCCCCAGCC ATGCATTGAA GTGAACCTG CTGATTACAA TGACAATGAA GAACCCAATT
32621 CTCTCGACCG TGAATCACTT GAGAATGAAA AATATCTATA GTGGCACAAC ATAGACATAA ATGCATGCAT
32691 CTCTCATAAA TTTTAACTC CTCAGGATTT AGAAACATAT CCCAGGGAAT AGGAAGCTCT TGCAGAACAG
32761 TAAAGCTGGC AGAACAAGGA AGACCACGAA CACAACCTAC ACTATGCATA GTCATAGTAT CACAATCTGG
32831 CACAGCGGCT TGTCTTCAAG TCAATGAGC TCCGCTTCA TTTCTTAC CACCTGCTAT CTGCTCTG
32901 GTGTAAGGGT GATGCTGGC GCATGATGTC GAGCGTGGC GCAACCTTGT CATAATGGAG TTGCTTCTG
32971 ACATTCTCGT ATTTGTATA GCAAAACCGC GCCCTGGCAG AACACACTCT TCTTCGCTT CTATCCTGCC
33041 GCTTAGCGTG TCCGTTGTA TAGTTCAAGT ACAGCCACAC TCTTAAGTTG GTCAAAAGAA TGTGGCTTC
33111 AGTTGTAATC AAAACTCCAT CGCATCTAAT TGTCTGAGG AAATCATCCA CGGTAGCATA TGCAAAATCCC
33181 AACCAAGCAA TGCAACTGGA TTGCGTTTCA AGCAGGAGAG GAGAGGGAAG AGACGGAAGA ACCATGTTAA
33251 TTTTATTCC AAACGATCTC GCAGTACTTC AAATTGTAGA TCGCGCAGAT GGCATCTCTC GCCCCACTG
33321 TGTGGTGAA AAAGCACAGC TAAATCAAAA GAAATGCGAT TTTCAAGGTG CTCAACGGTG GCTTCCAACA
33391 AAGCTCCAC GCGCACATCC AAGAACAATA GAATACCAAA AGAAGGAGCA TTTTCTAAT CCTCAATCAT
33461 CATATTACAT TCCTGCACCA TTCCAGATA ATTTTCAGCT TTCCAGCCTT GAATTATTCG TGTCACTTCT
33531 TGTGGTAAAT CCAATCCACA CATTACAAAC AGGTCCCGGA GGGCGCCCTC CACCACCAT CTTAACACA
33601 CCCTCATAAT GACAAAATAT CTTGCTCTCT GTCTACCTGT AGCGAATTGA GAATGGCAAC ATCAATTGAC
33671 ATGCCCTTGG CTCTAAGTTC TTTCTTAAAT TCTAGTTGTA AAAACTCTCT CATATTATCA CCAAACTGCT
33741 TAGCCAGAAG CCCCCCGGGA ACAAGAGCAG GGGACGCTAC AGTGCAGTAC AAGCGCAGAC CTCCCAATT
33811 GGTCCAGCA AAAACAAGAT TGGAAATAGC ATATTGGGAA CCACCAGTAA TATCATCGAA GTTGCTGGAA
33881 ATATAATCAG GCAGAGTTTC TTGTAGAAAT TGAATAAAG AAAAATTGTC CAAAAAACA TTCAAAACCT
33951 CTGGGATGCA AATGCAATAG GTTACCGCGC TCGCTCCAA CATTGTTAGT TTTGAATTAG TCTGCAAAA
34021 TAAAAAATAA ACAAGCGTCA TATCATAGTA GCCTGACGAA CAGGTGGATA AATCAGTCTT TCCATCACA
34091 GACAAGCCAC AGGGTCTCCA GCTCGACCTT CGTAAAACT GTCATCGTGA TTAACAACA GCACCGAAAG
34161 TTCTCGCGG TGACCAGCAT GAATAAGTCT TGATGAAGCA TACAATCCAG ACATGTTAGC ATCAGTTAAG
34231 GAGAAAAAAC AGCCAACATA GCCTTTGGGT ATAATTATGC TTAATCGTAA GTATAGCAAA GCCACCCCTC
34301 GCGGATACAA AGTAAAGGC ACAGGAGAAT AAAAAATATA ATTATTTCTC TGTGCTGTT TAGGCAACGT
34371 CGCCCCCGGT CCTCTAAAT ACACATACAA AGCCTCATCA GCCATGGCTT ACCAGAGAAA GTACAGCGGG
34441 CACACAAACC ACAAGCTCTA AAGTCACTCT CCAACCTSTC CACAATATAT ATACACAAGC CTAAGCTGA
34511 CGTAATGGGA CTAAGTGTAA AAAAAATCCC CCAACCCCAA CACACACCCC GAAACTGCGT CACCAAGGAA
34581 AAGTACAGTT TCATTTCCGC AATCCCAACA AGCGTCACTT CTTCTTTCTC ACGGTACGTC ACATCCCAT
34651 AACTTACAAC GTCATTTTCC CACGGCCGCG CCGCCCTTTT TAACGGTTAA CCCCACAGCC AATCACCACA
34721 CGGCCACAC TTTTAAAT CACCTCATTT ACATATTGGC ACCATTCCAT CTATAAGGTA TATTATTGAT
34791 GATG

```


Figure 7





Figure 8



143

Figure 9




Figure 10




Figure 11




Figure 12




Figure 13

Construction of cosmid vector pWE.Ad:5.pIX-rITR




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22a




Figure 22b





FIGURE 23

1 MLLQMKRRARPS EDTFNPVYPYD TETGPPTVPF LTPPFVSP Fib 5 protein
 1 MLLQMKRRARPS EDTFNPVYPYD E[SSSQH] PFINP[GF]S[SS] Fib 16 protein
 1 MLLQMKRRARPS EDTFNPVYPYD E[STSQH] PFINP[GF]S[SS] Fib 35 protein
 1 MLLQMKRRARPS EDTFNPVYPYD E[STSQH] PFINP[GF]S[SS] Fib 51 protein
 41 NGFQESPPGVL S LRLSEPLVTSNGMLALRMGNGLSLDEAG Fib 5 protein
 40 NGFQESPPGVL T LKCVNPLTTTASGFLQLKVGSSLTVDITD Fib 16 protein
 40 NGFTQSPGVL T LKCLTPLTTTGGSLQLKVGGLTVDDTD Fib 35 protein
 40 NGFTQSPGVL T LKCLTPLTTTGGSLQLKVGGLTVDDTD Fib 51 protein
 81 NLTSONVTTVSPPLKKT KSNINLEISAPLTVTSEALTVA Fib 5 protein
 80 GSLEENIT-AAA PLTKTNHSHIGLI[GSGL]QT- Fib 16 protein
 80 GTLQENIR-ATA PITKNNHSHVLSIGNGLET- Fib 35 protein
 80 GTLQENIR-VTA PITKNNHSHVLSIGNGLET- Fib 51 protein
 121 AAPLMVAGNTLT MOSQAPLTVHDSKLSIATOGPLTVSEK Fib 5 protein
 110 GSLEENIT-AAA PLTKTNHSHIGLI[GSGL]QT- Fib 16 protein
 110 QNNKLC- Fib 35 protein
 110 QNNKLC- Fib 51 protein
 161 LALQTSGLPLTTTDSSTLTITASPLTTATGSLGIDLKEPI Fib 5 protein
 129 LALQTSGLPLTTTDSSTLTITASPLTTATGSLGIDLKEPI Fib 16 protein
 116 LALQTSGLPLTTTDSSTLTITASPLTTATGSLGIDLKEPI Fib 35 protein
 116 LALQTSGLPLTTTDSSTLTITASPLTTATGSLGIDLKEPI Fib 51 protein
 201 YTONGKLG LKYGAPLHVTD DDLNTLT VATGPGVTINNTSLQ Fib 5 protein
 132 YTONGKLG LKYGAPLHVTD DDLNTLT VATGPGVTINNTSLQ Fib 16 protein
 116 YTONGKLG LKYGAPLHVTD DDLNTLT VATGPGVTINNTSLQ Fib 35 protein
 116 YTONGKLG LKYGAPLHVTD DDLNTLT VATGPGVTINNTSLQ Fib 51 protein
 241 TKVTGALGFDSQGNHQLNVAGGLRIDSONRRLLLDVSYPF Fib 5 protein
 132 TKVTGALGFDSQGNHQLNVAGGLRIDSONRRLLLDVSYPF Fib 16 protein
 116 TKVTGALGFDSQGNHQLNVAGGLRIDSONRRLLLDVSYPF Fib 35 protein
 116 TKVTGALGFDSQGNHQLNVAGGLRIDSONRRLLLDVSYPF Fib 51 protein
 281 DAONQLNLR LGGGLPINSAHNLDINYNKGLYLPTASNNS Fib 5 protein
 132 DAONQLNLR LGGGLPINSAHNLDINYNKGLYLPTASNNS Fib 16 protein
 116 DAONQLNLR LGGGLPINSAHNLDINYNKGLYLPTASNNS Fib 35 protein
 116 DAONQLNLR LGGGLPINSAHNLDINYNKGLYLPTASNNS Fib 51 protein
 321 KKLEVNLS TAKGLMFDATAIAINAGDGLFGSPNAPNTNP Fib 5 protein
 137 KKLEVNLS TAKGLMFDATAIAINAGDGLFGSPNAPNTNP Fib 16 protein
 116 KKLEVNLS TAKGLMFDATAIAINAGDGLFGSPNAPNTNP Fib 35 protein
 116 KKLEVNLS TAKGLMFDATAIAINAGDGLFGSPNAPNTNP Fib 51 protein
 361 LKTKIGHGLEFDSNKAMVFKLGTGLSPDSTGAITVGNKNN Fib 5 protein
 137 LKTKIGHGLEFDSNKAMVFKLGTGLSPDSTGAITVGNKNN Fib 16 protein
 116 LKTKIGHGLEFDSNKAMVFKLGTGLSPDSTGAITVGNKNN Fib 35 protein
 116 LKTKIGHGLEFDSNKAMVFKLGTGLSPDSTGAITVGNKNN Fib 51 protein
 401 DKLT LWTTTAPSPNCRL-NAEKDAKLT LVLT KCGSQIL Fib 5 protein
 166 DKLT LWTTTAPSPNCRL-NAEKDAKLT LVLT KCGSQIL Fib 16 protein
 137 DKLT LWTTTAPSPNCRL-NAEKDAKLT LVLT KCGSQIL Fib 35 protein
 137 DKLT LWTTTAPSPNCRL-NAEKDAKLT LVLT KCGSQIL Fib 51 protein
 438 ATVSVLAVKGS LAPISGTVQSAHLIIRFDENG VLLNNSF Fib 5 protein
 203 GYITLMGASEYTNLTFKNNQVTIDYNLAFDNTGQIITYLS Fib 16 protein
 174 GYVSLVGVS DTVNOMFTOKTANIQLRLYFDSSGNLLTEES Fib 35 protein
 174 GYVSLVGVS DTVNOMFTOKTANIQLRLYFDSSGNLLTEES Fib 51 protein
 477 LDPEYWNFRNGDLTEGTAYTNAVGFMPNLSAYPKSHGKTA Fib 5 protein
 243 SLKSNLNF KDNQNMATGTITSA[AGF]MFPSTTAYPFI--TY Fib 16 protein
 214 DLKIP LKNKSSA-TSETVASSKAFMFPSTTAYFPN--TT Fib 35 protein
 214 NLKIP LKNKSSA-TSETVASSKAFMFPSTTAYFPN--TT Fib 51 protein
 517 KSNIVSQVYLNGLD--KTK-----PVTLLTITLNGTOETG Fib 5 protein
 280 ATETLNEGYIYGECYXKST-NGTLFP LKVTITLNRRLAS Fib 16 protein
 250 TRDS--ENYIHGICYMTSYDRSLFPLNISIMLNSRMIS Fib 35 protein
 250 TRDS--ENYIHGICYMTSYDRSLFPLNISIMLNSRMIS Fib 51 protein
 548 DTFPSAYSMSFSWDWSGHNYINE--IFATSSYTPSYIAO Fib 5 protein
 319 GM--AYAMNFSWSLNAEAPETTEVTLITSPPFFSYIRE Fib 16 protein
 288 NV--AYAIQFENNLNASESPESNIMTLTSPFFFSYITE Fib 35 protein
 288 NV--AYAIQFENNLNASESPESNIMTLTSPFFFSYITE Fib 51 protein
 585 E. Fib 5 protein
 356 D. Fib 16 protein
 325 D. Fib 35 protein
 325 D. Fib 51 protein

Figure 24






Figure 26




Figure 27




Figure 28




Figure 29




Figure 30 Temperature dependent growth of
PER.C6




Figure 31 DBP levels in PER.C6 cells transfected with pcDNA3, pcDNA3wtE2A or pcDNA3 Δ 125E2A




Figure 32 Suspension growth of PE3.C6ts125E2A C5-9




Figure 33 Growth curve PER.C6 and PER.C6tsE2A




Figure 34 Stability of PE R.C6ts125E2A






Figure 35A tTA activity in Per.C6 tTA clones







European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 00 20 1738

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	BASLER C. F. ET AL.: "Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35" GENE, vol. 170, no. 2, 8 May 1996 (1996-05-08), page 249-254 XP004042835 ISSN: 0378-1119	8,9	C12N15/86 C12N15/34 C12N5/10 A61K48/00
Y	* the whole document *	1-3,5-7, 10-19, 21,22	
X	WO 96 12030 A (RHONE-POULENC RORER SA ; LEE MARTIN (FR); PERRICAUDET MICHEL (FR)) 25 April 1996 (1996-04-25)	23	
Y	* the whole document *	1-3,5-7, 10-19, 21,22	
Y	FALLAUX F. J. ET AL.: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses" HUMAN GENE THERAPY, vol. 9, no. 13, 1 September 1998 (1998-09-01), pages 1909-1917, XP002111678 ISSN: 1043-0342	14	
	* the whole document *		TECHNICAL FIELDS SEARCHED (Int.Cl.7) C12N A61K
Y	WO 96 13598 A (UNIV PENNSYLVANIA ; WILSON JAMES M (US); KELLEY WILLIAM M (US); FIS) 9 May 1996 (1996-05-09)	18,19	
	* the whole document *		
-/--			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 7 September 2000	Examiner Mandl, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1603 03.92 (P0401)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 20 1738

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	FLOMENBERG P. R. ET AL.: "Sequence and genetic organization of Adenovirus Type 35 early region 3." JOURNAL OF VIROLOGY, vol. 62, no. 11, 1988, pages 4431-4437, XP002119500 * the whole document *	8,9	
X	BASLER C.F. ET AL.: "Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses." VIROLOGY, vol. 215, 1996, pages 165-177, XP002119501 * the whole document *	8,9	
A	LEE M. G. ET AL.: "THE CONSTITUTIVE EXPRESSION OF THE IMMUNOMODULATORY GP 19K PROTEIN IN E1-, E3- ADENOVIRAL VECTORS STRONGLY REDUCES THE HOST CYTOTOXIC T CELL RESPONSE AGAINST THE VECTOR" GENE THERAPY, vol. 2, no. 4, 1 June 1995 (1995-06-01), pages 256-262, XP000561548 ISSN: 0969-7128 * the whole document *	1-23	
A	WO 97 12986 A (CORNELL RES FOUNDATION INC) 10 April 1997 (1997-04-10) * page 11, line 3 - line 35 * * page 13, line 1 - line 30 *	1-23	
A	WO 98 22609 A (ARMENTANO DONNA E ; GREGORY RICHARD J (US); GENZYME CORP (US); SMIT) 28 May 1998 (1998-05-28) * the whole document *	1-23	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search THE HAGUE		Date of completion of the search 7 September 2000	Examiner Mandl, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P04001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 20 1738

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	GALL J. ET AL.: "ADENOVIRUS TYPE 5 AND 7 CAPSID CHIMERA: FIBER REPLACEMENT ALTERS RECEPTOR TROPISM WITHOUT AFFECTING PRIMARY IMMUNE NEUTRALIZATION EPITOPES" JOURNAL OF VIROLOGY, vol. 70, no. 4, 1 April 1996 (1996-04-01), pages 2116-2123, XP002050655 ISSN: 0022-538X * the whole document *	1-23
P, X	SHAYAKHMETOV D. M. ET AL.: "Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector." JOURNAL OF VIROLOGY, vol. 74, no. 6, March 2000 (2000-03), pages 2567-2583, XP000938716 ISSN: 0022-538X * the whole document *	1,2,4-9, 12,13, 15-17, 20-23
The present search report has been drawn up for all claims		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search THE HAGUE	Date of completion of the search 7 September 2000	Examiner Mandl, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>		

EPO FORM 1503 (03.02.97) (P4/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 20 1738

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-09-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9612030 A	25-04-1996	FR 2725726 A	19-04-1996
		AU 712243 B	04-11-1999
		AU 3658495 A	06-05-1996
		CA 2201399 A	25-04-1996
		EP 0787198 A	06-08-1997
		FI 971613 A	16-04-1997
		JP 10507079 T	14-07-1998
		NO 971590 A	07-04-1997
WO 9613598 A	09-05-1996	ZA 9508686 A	22-05-1996
		US 5856152 A	05-01-1999
		AU 695811 B	20-08-1998
		AU 4405596 A	23-05-1996
		CA 2203808 A	09-05-1996
		EP 0797678 A	01-10-1997
		JP 10507928 T	04-08-1998
		US 5871982 A	16-02-1999
WO 9712986 A	10-04-1997	US 5837511 A	17-11-1998
		EP 0866873 A	30-09-1998
		JP 11514866 T	21-12-1999
WO 9822609 A	28-05-1998	US 5877011 A	02-03-1999
		AU 5455298 A	10-06-1998
		EP 0946742 A	06-10-1999

EPO FORM P4459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.